0001193125-20-288507.txt : 20201109 0001193125-20-288507.hdr.sgml : 20201109 20201109074552 ACCESSION NUMBER: 0001193125-20-288507 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 59 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201109 DATE AS OF CHANGE: 20201109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Intra-Cellular Therapies, Inc. CENTRAL INDEX KEY: 0001567514 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 364742850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36274 FILM NUMBER: 201296133 BUSINESS ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 212-923-3344 MAIL ADDRESS: STREET 1: 430 EAST 29TH STREET CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: Oneida Resources Corp. DATE OF NAME CHANGE: 20130122 10-Q 1 d18633d10q.htm 10-Q 10-Q
false2020Q3P3Y0001567514--12-31Intra-Cellular Therapies, Inc. 0001567514 2020-01-01 2020-09-30 0001567514 2020-07-01 2020-09-30 0001567514 2019-07-01 2019-09-30 0001567514 2019-01-01 2019-09-30 0001567514 2019-12-31 0001567514 2020-09-30 0001567514 2020-01-10 2020-01-10 0001567514 2020-09-15 2020-09-15 0001567514 2020-09-15 0001567514 2020-01-10 0001567514 2019-01-01 2019-12-31 0001567514 2019-12-20 2019-12-31 0001567514 2020-11-06 0001567514 2019-09-30 0001567514 2020-09-10 2020-09-10 0001567514 2020-09-10 0001567514 2019-06-30 0001567514 2018-12-31 0001567514 2020-06-30 0001567514 us-gaap:CertificatesOfDepositMember 2020-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001567514 us-gaap:CommercialPaperMember 2020-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2020-09-30 0001567514 itci:InducementAwardPlanMember 2020-09-30 0001567514 itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember 2020-09-30 0001567514 us-gaap:ComputerEquipmentMember 2020-09-30 0001567514 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001567514 us-gaap:EquipmentMember 2020-09-30 0001567514 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001567514 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 itci:MilestoneRestrictedStockUnitsMember 2020-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001567514 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-09-30 0001567514 itci:RealEstatesLeaseMember 2020-09-30 0001567514 itci:VehicleFleetLeaseMember 2020-09-30 0001567514 us-gaap:FinancialStandbyLetterOfCreditMember itci:VehicleFleetLeaseMember 2020-09-30 0001567514 itci:ItciInducementAwardPlanMember 2020-09-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2019-12-31 0001567514 us-gaap:CommercialPaperMember 2019-12-31 0001567514 us-gaap:CertificatesOfDepositMember 2019-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001567514 itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember 2019-12-31 0001567514 us-gaap:ComputerEquipmentMember 2019-12-31 0001567514 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001567514 us-gaap:EquipmentMember 2019-12-31 0001567514 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001567514 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:CommercialPaperMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:CommercialPaperMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001567514 us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001567514 itci:ItciInducementAwardPlanMember srt:MaximumMember 2019-12-31 0001567514 us-gaap:CommercialPaperMember 2019-12-31 0001567514 itci:InventoriableCostsMember 2020-07-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001567514 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001567514 us-gaap:ProductMember 2020-07-01 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001567514 us-gaap:AccountsReceivableMember itci:CustomerOneMember 2020-07-01 2020-09-30 0001567514 us-gaap:AccountsReceivableMember itci:CustomerTwoMember 2020-07-01 2020-09-30 0001567514 us-gaap:AccountsReceivableMember itci:CustomerThreeMember 2020-07-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001567514 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001567514 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001567514 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001567514 itci:InventoriableCostsMember 2020-01-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001567514 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember srt:MaximumMember 2020-01-01 2020-09-30 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001567514 itci:InducementAwardPlanMember 2020-01-01 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember srt:MinimumMember 2020-01-01 2020-09-30 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember srt:MaximumMember 2020-01-01 2020-09-30 0001567514 us-gaap:GrantMember 2020-01-01 2020-09-30 0001567514 us-gaap:ProductMember 2020-01-01 2020-09-30 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2020-01-01 2020-09-30 0001567514 srt:MaximumMember 2020-01-01 2020-09-30 0001567514 srt:MinimumMember 2020-01-01 2020-09-30 0001567514 itci:VehicleFleetLeaseMember 2020-01-01 2020-09-30 0001567514 itci:VehicleFleetLeaseMember 2020-01-01 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember itci:ITCINationalDemocraticAllianceMemberMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccountsReceivableMember itci:CustomerOneMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccountsReceivableMember itci:CustomerTwoMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccountsReceivableMember itci:CustomerThreeMember 2020-01-01 2020-09-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001567514 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2019-01-01 2019-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001567514 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001567514 itci:RealEstateLeaseMember 2019-01-01 2019-09-30 0001567514 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001567514 us-gaap:IPOMember 2020-01-10 2020-01-10 0001567514 srt:MaximumMember us-gaap:CommonStockMember 2019-09-12 0001567514 srt:MaximumMember 2019-09-12 0001567514 itci:AmtTaxCreditMember 2020-03-27 0001567514 itci:PerformanceBasedRestrictedStockUnitsMember 2020-03-31 2020-03-31 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2018-06-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2020-05-31 0001567514 stpr:NY 2018-09-30 0001567514 stpr:MD 2019-02-28 0001567514 stpr:NY us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 stpr:MD us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2019-01-01 2019-12-31 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2017-01-01 2017-03-31 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-03-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 2005-05-31 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2013-12-01 2013-12-31 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2014-12-01 2014-12-31 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember 2019-01-31 0001567514 us-gaap:ProductMember itci:BristolMyersSquibbCompanyMember itci:NationalDemocraticAllianceMember 2019-12-23 2019-12-23 0001567514 us-gaap:IPOMember 2020-09-15 2020-09-15 0001567514 srt:MaximumMember 2019-09-12 2019-09-12 0001567514 us-gaap:CommonStockMember 2020-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001567514 us-gaap:RetainedEarningsMember 2020-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001567514 us-gaap:CommonStockMember 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001567514 us-gaap:CommonStockMember 2019-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001567514 us-gaap:RetainedEarningsMember 2019-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001567514 us-gaap:CommonStockMember 2019-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001567514 us-gaap:RetainedEarningsMember 2019-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2019-12-31 0001567514 us-gaap:CommonStockMember 2019-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001567514 us-gaap:RetainedEarningsMember 2019-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2020-09-30 0001567514 itci:InducementAwardPlanMember 2019-12-31 0001567514 us-gaap:CommonStockMember 2018-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001567514 us-gaap:RetainedEarningsMember 2018-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 iso4217:USD xbrli:shares xbrli:pure utr:Month utr:Year iso4217:USD xbrli:shares itci:Segment itci:Customers
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
or
 
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
    
        
    
    
to
    
        
    
    
Commission File Number:
001-36274
 
 
INTRA-CELLULAR THERAPIES, INC.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
  
36-4742850
(State or other jurisdiction of
incorporation or organization)
  
(I.R.S. Employer
Identification No.)
430 East 29th Street
New York, New York
  
10016
(Address of principal executive offices)
  
(Zip Code)
(646)
440-9333
(Registrant’s telephone number, including area code)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading
Symbol(s)
  
Name of each exchange
on which registered
Common Stock
  
ITCI
  
The Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in
Rule 12b-2
of the Exchange Act.
 
Large accelerated filer   ☒    Accelerated filer   ☐
Non-accelerated
filer		   ☐    Smaller reporting company   ☐
     Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    Yes  ☐    No  ☒
As of November 
6
, 2020, the registrant had 80,157,554 shares of common stock outstanding.
 
 
 
 
Intra-Cellular Therapies, Inc.
Index to Form
10-Q
 
     1  
Item 1.
        1  
       1  
       2  
       3  
       4  
       5  
       6  
Item 2.
        22  
Item 3.
        33  
Item 4.
        33  
     34  
Item 1.
        34  
Item 1A.
        34  
Item 2.
        35  
Item 3.
        35  
Item 4.
        35  
Item 5.
        35  
Item 6.
        36  
     37  
In this Quarterly Report on Form
10-Q,
the terms “we,” “us,” “our,” and the “Company” mean Intra-Cellular Therapies, Inc. and our subsidiaries. “ITI” refers to our wholly-owned subsidiary ITI, Inc. and “ITI Limited” refers to our wholly-owned subsidiary ITI Limited.
 
i
PART I: FINANCIAL INFORMATION
 
Item 1.
FINANCIAL STATEMENTS
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
 
    
September 30,
2020
    
December 31,
2019
  
    
(Unaudited)
        
Assets
     
Current assets:
     
Cash and cash equivalents
   
$
300,988,981
 
   $ 107,636,849  
Investment securities,
available-for-sale
   
 
420,958,509
 
     116,373,335  
Restricted cash
   
 
1,400,000
 
     —    
Accounts receivable, net
   
 
7,480,604
 
     —    
Inventory
   
 
2,947,138
 
     —    
Prepaid expenses and other current assets
   
 
11,090,774
 
     6,313,785  
  
 
 
    
 
 
  
Total current assets
   
 
744,866,006
 
     230,323,969  
Property and equipment, net
   
 
2,049,552
 
     2,259,740  
Right of use assets, net
   
 
24,292,167
 
     18,252,074  
Deferred tax asset, net
   
 
—  
 
     264,609  
Other assets
   
 
86,084
 
     86,084  
  
 
 
    
 
 
  
Total assets
   
$
771,293,809
 
   $ 251,186,476  
  
 
 
    
 
 
  
Liabilities and stockholders’ equity
     
Current liabilities:
     
Accounts payable
   
$
8,569,148
 
   $ 7,425,024  
Accrued and other current liabilities
   
 
12,186,380
 
     16,138,909  
Lease liabilities, short-term
   
 
5,267,258
 
     3,187,435  
Accrued employee benefits
   
 
12,005,931
 
     9,472,651  
  
 
 
    
 
 
  
Total current liabilities
   
 
38,028,717
 
     36,224,019  
Lease liabilities
   
 
23,869,557
 
     19,955,186  
  
 
 
    
 
 
  
Total liabilities
   
 
61,898,274
 
     56,179,205  
Stockholders’ equity:
     
Common stock, $0.0001 par value: 100,000,000 shares authorized; 80,142,797 and 55,507,497 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively
   
 
8,014
 
     5,551  
Additional
paid-in
capital
   
 
1,585,023,637
 
     904,971,772  
Accumulated deficit
   
 
(876,404,854
) 
     (710,098,369 ) 
Accumulated comprehensive income
   
 
768,738
 
     128,317  
  
 
 
    
 
 
  
Total stockholders’ equity
   
 
709,395,535
 
     195,007,271  
  
 
 
    
 
 
  
Total liabilities and stockholders’ equity
   
$
771,293,809
 
   $ 251,186,476  
  
 
 
    
 
 
  
See accompanying notes to these condensed consolidated financial statements.
 
1
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations (Unaudited)
 
    
Three Months Ended September 30,
    
Nine Months Ended September 30,
  
    
2020
     2019    
2020
     2019  
Revenues
         
Product sales, net
   
$
7,368,594
 
   $ —    
$
10,126,999
 
   $ —  
Grant revenue
      —         —      
 
231,710
 
     —    
  
 
 
    
 
 
    
 
 
    
 
 
  
Total revenues
, net
   
 
7,368,594
 
     —      
 
10,358,709
 
     —    
Operating expenses:
     
Cost of product sales
   
 
556,107
 
     —      
 
753,957
 
     —    
Research and development
   
 
10,275,368
 
     21,339,792    
 
51,483,551
 
     70,059,113  
Selling, general and administrative
   
 
52,473,573
 
     15,036,444    
 
128,015,496
 
     42,184,078  
  
 
 
    
 
 
    
 
 
    
 
 
  
Total operating expenses
   
 
63,305,048
 
     36,376,236    
 
180,253,004
 
     112,243,191  
  
 
 
    
 
 
    
 
 
    
 
 
  
Loss from operations
   
 
(55,936,454
) 
     (36,376,236 )   
 
(169,894,295
) 
     (112,243,191 ) 
Interest income
   
 
752,829
 
     1,513,837      
3,591,091
 
     5,105,464  
  
 
 
    
 
 
    
 
 
    
 
 
  
Loss before provision for income taxes
   
 
(55,183,625
) 
     (34,862,399 )   
 
(166,303,204
) 
     (107,137,727 ) 
Income tax expense
      —         —        
3,281
       1,600  
  
 
 
    
 
 
    
 
 
    
 
 
  
Net loss
   
$
(55,183,625
) 
   $ (34,862,399 )   
$
(166,306,485
) 
   $ (107,139,327 ) 
  
 
 
    
 
 
    
 
 
    
 
 
  
Net loss per common share:
     
Basic & Diluted
   
$
(0.79
) 
   $ (0.63 )   
$
(2.48
) 
   $ (1.94 ) 
Weighted average number of common shares:
     
Basic & Diluted
     
69,530,039
       55,207,400      
67,030,991
       55,155,854  
See accompanying notes to these condensed consolidated financial statements.
 
2
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive Loss (Unaudited)
 
    
Three Months Ended September 30,
    
Nine Months Ended September 30,
  
    
2020
     2019    
2020
     2019  
Net loss
   
$
(55,183,625
) 
   $ (34,862,399 )   
$
(166,306,485
) 
   $ (107,139,327 ) 
Other comprehensive income
 (loss)
:
         
Unrealized gain
(
loss
)
on investment securities
   
 
(399,361
) 
     (33,396 )   
 
640,421
 
     866,805  
  
 
 
    
 
 
    
 
 
    
 
 
  
Comprehensive loss
   
$
(55,582,986
) 
   $ (34,895,795 )   
$
(165,666,064
) 
   $ (106,272,522 ) 
  
 
 
    
 
 
    
 
 
    
 
 
  
See accompanying notes to these condensed consolidated financial statements.
 
3
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders’ Equity (Unaudited)
 
    
Common Stock
     
Additional

Paid-in

Capital
     
Accumulated

Deficit
    
Accumulated

Comprehensive

(Loss) Income
    
Total

Stockholders’

Equity
  
    
Shares
     
Amount
  
Balance at June 30, 2019
      55,186,745      $ 5,519      $
 
 
 
 891,183,518      $ (634,653,119 )    $ 232,444     $ 256,768,362  
Exercise of stock options and issuances of restricted stock
      54,332        6        152,373        —         —         152,379  
Stock issued for services
      6,502        —          48,571        —         —         48,571  
Share-based compensation
      —          —          4,806,768        —         —         4,806,768  
Net loss
      —          —          —          (34,862,399 )      —         (34,862,399 ) 
Other comprehensive
loss
      —          —          —          —         (33,396 )      (33,396 ) 
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
Balance at September 30, 2019
      55,247,579      $ 5,525      $ 896,191,230      $ (669,515,518 )    $ 199,048     $ 226,880,285  
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
    
Common Stock
     
Additional

Paid-in

Capital
     
Accumulated

Deficit
    
Accumulated

Comprehensive

(Loss) Income
    
Total

Stockholders’

Equity
  
    
Shares
     
Amount
  
Balance at December 31, 2018
      54,895,295      $ 5,490      $ 880,753,339      $ (562,376,191 )    $ (667,757 )    $ 317,714,881  
Exercise of stock options and issuances of restricted stock
      338,054        34        442,792        —         —         442,826  
Stock issued for services
      14,230        1        145,690        —         —         145,691  
Share-based compensation
      —          —          14,849,409        —         —         14,849,409  
Net loss
      —          —          —          (107,139,327 )      —         (107,139,327 ) 
Other comprehensive gain
      —          —          —          —         866,805       866,805  
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
Balance at September 30, 2019
      55,247,579      $ 5,525      $
 
 
 
 896,191,230      $ (669,515,518 )    $ 199,048     $ 226,880,285  
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
    
Common Stock
     
Additional

Paid-in

Capital
     
Accumulated

Deficit
    
Accumulated

Comprehensive

(Loss) Income
    
Total

Stockholders’

Equity
  
    
Shares
     
Amount
  
Balance at June 3
0
, 2020
   
 
66,777,737
 
   
$
6,678
 
   
$
1,199,576,320
 
   
$
(821,221,229
) 
  
$
1,168,099
 
  
$
379,529,868
 
Common shares issued
   
 
13,179,458
 
   
 
1,318
 
   
 
370,137,298
 
   
 
—  
 
  
 
—  
 
  
 
370,138,616
 
Common shares
 
receivable
 coll
ected
   
 
—  
 
   
 
—  
 
   
 
5,705,186
 
   
 
—  
 
  
 
—  
 
  
 
5,705,186
 
Exercise of stock options and issuances of restricted stock
   
 
183,516
 
   
 
18
 
   
 
2,650,587
 
   
 
—  
 
  
 
—  
 
  
 
2,650,605
 
Stock issued for services
   
 
2,086
 
   
 
—  
 
   
 
53,527
 
   
 
—  
 
  
 
—  
 
  
 
53,527
 
Share-based compensation
   
 
—  
 
   
 
—  
 
   
 
6,900,719
 
   
 
—  
 
  
 
—  
 
  
 
6,900,719
 
Net loss
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
(55,183,625
) 
  
 
—  
 
  
 
(55,183,625
) 
Other comprehensive 
loss
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
—  
 
  
 
(399,361
) 
    
(399,361
)
 
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
Balance at September 30, 2020
   
 
80,142,797
 
   
$
8,014
 
   
$
1,585,023,637
 
   
$
(876,404,854
) 
  
$
768,738
 
  
$
709,395,535
 
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
    
 
 
  
    
Common Stock
     
Additional

Paid-in

Capital
     
Accumulated

Deficit
    
Accumulated

Comprehensive

(Loss) Income
    
Total

Stockholders’

Equity
  
    
Shares
     
Amount
  
Balance at December 31, 2019
   
 
55,507,497
 
   
$
5,551
 
   
$
904,971,772
 
   
$
(710,098,369
) 
  
$
128,317
 
   
$
195,007,271
 
Common shares issued
   
 
23,409,458
 
   
 
2,341
 
   
 
652,709,670
 
   
 
—  
 
  
 
—  
 
     
652,712,011
 
Exercise of stock options and issuances of restricted stock
   
 
1,218,188
 
   
 
121
 
   
 
7,829,463
 
   
 
—  
 
  
 
—  
 
     
7,829,584
  
Stock issued for services
   
 
7,654
 
   
 
1
 
   
 
160,582
 
   
 
—  
 
  
 
—  
 
     
160,583
  
Share-based compensation
   
 
—  
 
   
 
—  
 
   
 
19,352,150
 
   
 
—  
 
  
 
—  
 
     
19,352,150
 
Net loss
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
(166,306,485
) 
  
 
—  
 
   
 
(166,306,485
) 
Other comprehensive gain
   
 
—  
 
   
 
—  
 
   
 
—  
 
   
 
—  
 
  
 
640,421
 
   
 
640,421
 
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
     
 
 
  
Balance at September 30, 2020
   
 
80,142,797
 
   
$
8,014
 
   
$
1,585,023,637
 
   
$
(876,404,854
) 
  
$
768,738
 
   
$
709,395,535
 
  
 
 
     
 
 
     
 
 
     
 
 
    
 
 
     
 
 
  
See accompanying notes to these condensed consolidated financial statements.
 
4
Intra-Cellular Therapies, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows (Unaudited)
 
    
Nine Months Ended September 30,
  
    
2020
    
2019
  
Cash flows used in operating activities
     
Net loss
   
$
(166,306,485
) 
   $ (107,139,327 ) 
Adjustments to reconcile net loss to net cash used in operating activities:
     
Depreciation
   
 
402,146
 
     335,461  
Share-based compensation
   
 
19,352,150
 
     14,849,409  
Stock issued for services
   
 
160,583
 
     145,691  
Amortization of premiums and discounts on investment securities, net
   
 
(177,374
) 
     (871,412 ) 
Changes in operating assets and liabilities:
     
Accounts receivable, net
   
 
(7,480,604
) 
     —    
Inventory
   
 
(2,947,138
) 
     —    
Prepaid expenses and other assets
   
 
(4,776,989
) 
     4,020,430  
Long term deferred tax asset, net
   
 
264,609
 
     —    
Accounts payable
   
 
1,144,124
 
     (7,730,137 ) 
Accrued liabilities and other
   
 
(1,419,249
) 
     3,462,560  
Lease liabilities, net
   
 
(45,899
) 
     —    
  
 
 
    
 
 
  
Net cash used in operating activities
   
 
(161,830,126
) 
     (92,927,325 ) 
Cash flows (used in) provided by investing activities
     
Purchases of investments
   
 
(488,524,539
) 
     (58,332,886 ) 
Maturities of investments
   
 
184,757,160
 
     199,383,553  
Purchases of property and equipment
   
 
(191,958
) 
     (1,350,688 ) 
  
 
 
    
 
 
  
Net cash (used in) provided by investing activities
   
 
(303,959,337
) 
     139,699,979  
Cash flows provided by financing activities
     
Proceeds from exercise of stock options 
   
 
7,829,584
 
     442,826  
Proceeds of public offerings, net
   
 
652,712,011
 
     —    
  
 
 
    
 
 
  
Net cash provided by financing activities
   
 
660,541,595
 
     442,826  
  
 
 
    
 
 
  
Net increase in cash, cash equivalents, and restricted cash
   
 
194,752,132
 
     47,215,480  
Cash, cash equivalents, and restricted cash at beginning of period
   
 
107,636,849
 
     54,947,502  
  
 
 
    
 
 
  
Cash, cash equivalents, and restricted cash at end of period
   
$
302,388,981
 
   $ 102,162,982  
  
 
 
    
 
 
  
Non-cash
investing and financing activities
     
Right of use assets under operating vehicle fleet leases
   
$
7,750,959
 
   $ —  
Right of use assets under operating real estate leases
 
$
 
—
 
 
$
 
219,703
 
  
 
 
    
 
 
  
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported
within
the condensed consolidated balance sheets that sum to the total of the same such amounts shown in the condensed consolidated statements of cash flows:
 
    
September 30,
  
    
2020
      2019  
Cash and cash equivalents
   
$
300,988,981
 
  
 
 
 		 $ 102,162,982
 
 
Restricted cash
     
1,400,000
        —    
  
 
 
     
 
 
  
Total cash, cash equivalents and restricted cash
   
$
302,388,981
 
    $ 102,162,982  
  
 
 
     
 
 
  
See accompanying notes to these condensed consolidated financial statements.
 
5
Intra-Cellular Therapies, Inc.
Notes to Condensed Consolidated Financial Statements (Unaudited)
September 30, 2020
1. Organization
Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiaries, ITI, Inc. (“ITI”) and ITI Limited, is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In December 2019, the Company announced that CAPLYTA
TM
(lumateperone) had been approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA in late March 2020. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia. Lumateperone is in Phase 3 clinical development as a novel treatment for bipolar depression.
On January 10, 2020, the Company completed a public offering of common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $29.50 per share for aggregate gross proceeds of $295.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $277.0 million.
 
On September 15, 2020
,
the Company completed a public offering of common stock in which the Company sold 12,666,667 shares of common stock at an offering price of $30.00 per share for aggregate gross proceeds of $380.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8 million.
In order to further its commercial activities and research projects and support its collaborations, the Company will require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s product candidates and technology and, to a lesser extent, grant funding. On August 30, 2019, the Company filed a universal shelf registration statement on Form
S-3,
which was declared effective by the SEC on September 12, 2019, on which the Company registered for sale up to $350 million of any combination of its common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that the Company may determine, which includes up to $75 million of common stock that the Company may issue and sell from time to time, through SVB Leerink LLC acting as its sales agent, pursuant to the sale agreement that the Company entered into with SVB Leerink on August 29, 2019 for the Company’s
“at-the-market”
equity program. On September 10, 2020, the Company terminated the
“at-the-market”
equity program sales agreement with SVB Leerink LLC. Through the date of the termination of the sales agreement on September 10, 2020, the Company had issued an aggregate 742,791 shares of common stock under the Company’s
“at-the-market”
equity program which resulted in the Company receiving net proceeds of $17.9 million.
In addition, on January 6, 2020, the Company filed an automatic shelf registration statement on Form
S-3
with the SEC, which became effective upon filing, on which the Company registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that the Company may determine, so long as the Company continues to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective.
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs for the treatment of neurological and psychiatric disorders.
 
6
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets.
Investment Securities
Investment securities consisted of the following (in thousands):
 
    
September 30, 2020
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
    
(Unaudited)
  
U.S. Government Agency Securities
    $ 159,237      $ 12      $ (32 )     $ 159,217  
Certificates of Deposit
      10,500        —          —          10,500  
Commercial Paper
      78,788        138        (2 )       78,924  
Corporate Notes/Bonds
      171,665        782        (129 )       172,318  
  
 
 
     
 
 
     
 
 
     
 
 
  
   $ 420,190      $ 932      $ (163 )     $ 420,959  
  
 
 
     
 
 
     
 
 
     
 
 
  
    
December 31, 2019
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
U.S. Government Agency Securities
    $ 35,462      $ 35      $ (3 )     $ 35,494  
Certificates of Deposit
      3,000        —          —          3,000  
Commercial Paper
      39,013        10        (5 )       39,018  
Corporate Notes/Bonds
      38,770        91        —          38,861  
  
 
 
     
 
 
     
 
 
     
 
 
  
   $ 116,245      $ 136      $ (8 )     $ 116,373  
  
 
 
     
 
 
     
 
 
     
 
 
  
The Company has classified all of its investment securities as
available-for-sale,
including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2020, and December 31, 2019, the Company held $197.3 million and $3.0 million, respectively, of
available-for-sale
investment securities with contractual maturity dates more than one year and less than two years.
The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect.
The aggregate related fair value of investments with unrealized losses as of September 30, 2020 was $192.8 million, which consisted of $110.4 million from U.S. government agency securities, $10.0 million of commercial paper, and $72.4 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2020 was approximately $163,000, which consisted of $32,000 from U.S. government agency securities, $2,000 from commercial paper, and $129,000 from corporate notes/bonds. The $192.8 million aggregate fair value of investments with unrealized losses as of September 30, 2020 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2019, the Company had approximately $29.6 million of investments with a continuous unrealized loss for 12 months or longer of which approximately $12.5 million had been held in a continuous loss position for 12 months or longer.
 
7
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant.
Fair Value Measurements
The Company applies the fair value method under ASC Topic 820,
Fair Value Measurements and Disclosures
. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
 
 
•
 
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
 
 
•
 
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
 
 
•
 
Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy.
The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2020 or December 31, 2019. The carrying value of cash held in money market funds of approximately $224.2 million as of September 30, 2020 and $49.9 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of certificates of deposit of approximately
$
47.6 million as of December 31, 2019 is also included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs. The carrying value of commercial paper of approximately $3.0 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs.
The fair value measurements of the Company’s cash equivalents and
available-for-sale
investment securities are identified in the following tables (in thousands):
 
           
Fair Value Measurements at
Reporting Date Using
  
    
September 30,
2020
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 224,239      $ 224,239      $ —      $ —  
U.S. Government Agency Securities
      159,217        —          159,217        —    
Certificates of Deposit
      10,500        —          10,500        —    
Commercial Paper
      78,924        —          78,924        —    
Corporate Notes/Bonds
      172,318        —          172,318        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
  
$
645,198
 
   
$
224,239
 
   
$
420,959
 
   
$
—  
  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
8
           
Fair Value Measurements at
Reporting Date Using
  
    
December 31,
2019
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 49,882      $ 49,882      $ —      $ —  
U.S. Government Agency Securities
      35,494        —          35,494        —    
Certificates of Deposit
      50,622        —          50,622        —    
Commercial Paper
      42,015        —          42,015        —    
Corporate Notes/Bonds
      38,861        —          38,861        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
  
$
216,874
 
   
$
49,882
 
   
$
166,992
 
   
$
—  
  
  
 
 
     
 
 
     
 
 
     
 
 
  
Financial Instruments
The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2020 and December 31, 2019. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing.
Restricted Cash
Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU
No. 2016-18,
“Restricted Cash” (“ASU
2016-18”)
and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows.
Accounts Receivable, net
The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees.
The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. For the three and nine months ended September 30, 2020, 96% of sales were generated from three major industry wholesalers, respectively.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine months ended September 30, 2020, all of the Company’s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 90 days. Three individual customers accounted for approximately 39%, 29%, and 28% of product sales for the three months ended September 30, 2020 as well as accounted for approximately 41%, 27% and 27% of product sales for the nine months ended September 30, 2020. As of September 30, 2020, the Company believes that such customers are of high credit quality.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
Inventory
The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a
first-in,
first-out
(“FIFO”) basis. The
 
9
Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales.
The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed.
Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs.
Property and Equipment
Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred.
When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360,
Property, Plant and Equipment
. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date.
Revenue Recognition
Effective January 1, 2018, the Company adopted FASB ASC Topic 606,
 Revenue from Contracts with Customers
(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact in the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine months ended September 30, 2020 reflect the application of ASC Topic 606.
To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see
Product Sales, net
(below).
To date, the Company’s only source of product sales has been from sales of CAPLYTA in the U.S., which the Company began shipping to customers in March 2020.
Product Sales, net
The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the
 
10
Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue.
Reserves for Variable Consideration
Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product.
These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include estimates that take into consideration a range of possible outcomes which are either considered more likely or probability-weighted in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA and historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, historical information related to similar products in their initial launch stages. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts after considering whether revenue should be constrained under ASC 606.
The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2020 and, therefore, the transaction price was not reduced further during the three and nine months ended September 30, 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known.
Trade Discounts and Allowances
— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of net sales within the condensed consolidated statements of operations through September 30, 2020, as well as a reduction to trade receivables, net on the condensed consolidated balance sheets.
Product Returns
— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any returns to date.
Provider Chargebacks and Discounts
— Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivables, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting
period-end
that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine months ended September 30, 2020, these amounts were not significant.
 
11
Government Rebates
— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.
Payer Rebates
— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Other Incentives
— Other incentives which the Company offers include voluntary patient assistance programs, such as the
co-pay
assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug
co-payments
required by payers. The calculation of the accrual for
co-pay
assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company estimates the number of claims through vouchers for product that is in the distribution channel inventories and reduces recognized revenue accordingly.
The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Cost of Product Sales
Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs).
For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations.
Prior to FDA approval of CAPLYTA, the Company
expensed all
costs associated with the manufacturing of lumateperone as part of research and development expenses
.
 From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production and no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the nine months ended September 30, 2020 are lower than incurred because of previously expensed inventory.
Research and Development, Including Clinical Trial Expenses
Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees.
Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be.
 
12
As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the nine-months ended September 30, 2020, the Company recorded a change in estimate of approximately $3.3 million of accrued expenses for clinical trials related to the first and second quarter of 2020 which resulted in an increase of clinical trial expense in the nine month period ending September 30, 2020. For the three and nine months ended September 30, 2020 and 2019, there were no material adjustments to the Company’s prior year estimates of accrued expenses for clinical trials.
 
Income Taxes
Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.
 109
). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not
threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.
The Company’s effective tax rate for the three and nine months ended September 30, 2020 and 2019 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit.
On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (CARES) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the three and nine months ended September 30, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020.
Comprehensive Income (Loss)
All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are incurred. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive income (loss) for each period.
 
13
Share-Based Compensation
Share-based payments are accounted for in accordance with the provisions of ASC Topic 718,
Compensation—Stock Compensation
. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.
For all awards granted with time based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the three and nine months ended September 30, 2020 and 2019 accounts for forfeitures as they occur.
The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. In the fourth quarter of 2019, expected volatility rates are based entirely on the historical volatility of the Company’s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term.
The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant.
A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company.
In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. In the first quarter of 2017, the Company granted performance-based RSUs, which vest based on the achievement of certain milestones that include (i) the submission of a new drug application (“NDA”) to the FDA for lumateperone for the treatment of schizophrenia, (ii) the approval of the NDA by the FDA (together, the “Milestone RSUs”) and (iii) the achievement of certain comparative shareholder returns against the Company’s peers (the “TSR RSUs”). The Milestone RSUs related to the NDA submission were fully amortized on December 31, 2018. The NDA submission milestone was achieved in the third quarter of 2018, so the Milestone RSUs related to the NDA submission vested on December 31, 2018. The Milestone RSU’s related to the NDA approval was achieved in the fourth quarter of 2019, so the RSU’s vested on December 31, 2019. The Milestone RSUs related to the approval of the NDA were fully amortized on December 31, 2019. The TSR RSUs were valued using the Monte Carlo Simulation method and were amortized over the life of the RSUs based on the agreements which vested on January 24, 2020.
In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements.
Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740,
Income Taxes
. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance.
 
14
Since the Company has losses and also maintains a full valuation allowance to cover its deferred tax assets as of September 30, 2020 and 2019, excess tax benefits, if any, recognized for the tax deductions related to share-based awards will add to the Company’s net operating loss deferred tax asset and covered by valuation allowances.
Equity instruments issued to
non-employees
for services are accounted for under the provisions of ASC Topic 718 and ASC Topic
505-50,
Equity/Equity-Based Payments to
Non-Employees
. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period.
In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants.
In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2020, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan.
 
Loss Per Share
Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs.
The following awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2020 and 2019:
 
    
Three and Nine Months Ended

September 30,
  
    
2020
     
2019
  
Stock options
      5,964,135        6,330,914  
RSUs
      1,702,538        1,425,459  
TSR RSUs
      43,022        134,170  
Recently Issued Accounting Standards
In June 2016, the FASB issued ASU
No. 2016-13,
“Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU
2016-13”).
This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For
available-for-sale
debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and
held-to-maturity
debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January 1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January 1, 2020 and for the three and nine month period ended September 30, 2020.
 
1
5
3. Inventory
Inventory consists of the following:
 
    
September 30,
2020
  
Raw materials
   
$
—  
  
Work in process
   
 
1,597,413
 
Finished goods
   
 
1,349,725
 
  
 
 
  
  
$
2,947,138
 
  
 
 
  
Inventory acquired prior to receipt of the FDA approval on December 20, 2019 for CAPLYTA was expensed as research and development expense as incurred. No inventory was produced from the FDA approval date through the end of 2019; therefore, no inventory was capitalized on the consolidated balance sheet as of December 31, 2019.
4. Property and Equipment
Property and equipment consist of the following:
 
    
September 30,
2020
     
December 31,
2019
  
Computer equipment
   
$
243,532
 
    $ 243,532  
Furniture and fixtures
   
 
423,097
 
      423,097  
Scientific equipment
   
 
4,053,185
 
      3,861,227  
Leasehold improvements
   
 
1,240,315
 
      1,240,315  
  
 
 
     
 
 
  
  
 
5,960,129
 
      5,768,171  
Less accumulated depreciation
   
 
(3,910,577
) 
      (3,508,431 ) 
  
 
 
     
 
 
  
  
$
2,049,552
 
    $ 2,259,740  
  
 
 
     
 
 
  
Depreciation expense for the three and nine months ended September 30, 2020 was $121,044 and $402,146, respectively, as compared to approximately $129,052 and $335,461, respectively, for the three and nine months ended September 30, 2019.
5. Right of Use Assets and Lease Liabilities
Real Estate Leases
In 2014, the Company entered into a long-term lease with a related party which, as amended, provides for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU
2016-02
for accounting purposes. In September 2018, the Company further amended the lease to obtain additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, the Company entered into a long-term lease for office space in Towson, Maryland beginning March 1, 2019. The lease has a term of 3.2 years ending in April 2022 and includes limited rent abatement and escalation provisions.
In adopting ASU
2016-02
as of January 1, 2019, the Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the condensed consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and
non-lease
components as a single lease component. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. The Company recognized those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the
 
16
present value of lease payments. On the lease commencement dates, the Company estimated the lease liabilities and the right of use assets at present value using its applicable incremental borrowing rates of its two long-term leases of 7.2% for the Company’s Maryland lease of 3.2 years and 9.1% for the Company’s New York leases of 14.3 years. On January 1, 2019, upon adoption of ASU
2016-02,
the Company recorded right of use assets of approximately $20.2 million, lease liabilities of $23.4 million and eliminated deferred rent of $3.2 million. At the execution of the Maryland lease in 2019, the Company recorded a right of use asset and a lease liability of $0.2 million, which represented a
non-cash
transaction.
M
aturity analysis under the lease agreements are as follows:
 
Three months ending December 31, 2020
    $ 845,566  
Year ending December 31, 2021
      3,448,323  
Year ending December 31, 2022
      3,491,166  
Year ending December 31, 2023
      3,566,466  
Year ending December 31, 2024
      3,675,196  
Thereafter
      17,627,040  
  
 
 
  
Total
      32,653,757  
Less: Present value discount
      (10,463,196 ) 
  
 
 
  
Total Lease liability
      22,190,561  
  
 
 
  
Less: Current portion
      (3,259,966 ) 
  
 
 
  
Long-term lease liabilities
    $ 18,930,595  
  
 
 
  
Lease expense for the three and nine months ended September 30, 2020 was approximately $0.8 million and $2.5 million, respectively, as compared to approximately $0.8 million and $2.5
 million
, respectively, for the three and nine months ended September 30, 2019.
Vehicle Fleet Lease
On May 17, 2019, the Company entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The Company began leasing vehicles under the Vehicle Lease in March 2020.
The contractual period of each lease is 12 months, followed by
month-to-month
renewal periods. The Company estimates the lease term for each vehicle to be 30 months based on industry standards. The lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.4 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease. The $1.4 million is recorded as restricted cash on the condensed consolidated balance sheet.
The nature of the lease is one commonly referred to as “TRAC” lease, as it contains a terminal rental adjustment clause, or “TRAC” clause.” The TRAC clause limits lessee
exposure, or likelihood of having a variable lease payment
due at lease termination. This variable lease payment amount would be any difference between the vehicle stipulated (capitalized) cost and the sum of the reserve and net proceeds from disposal as described in the Vehicle Lease. Further, the Lessor guarantees that the net proceeds will not be less than 20% of the vehicle capitalized cost in the first 12 months, and 30% of the vehicle capitalized cost at the beginning of subsequent
12-month
period increments.
Right of use asset and lease liability for the vehicle fleet lease were approximately $6.9 million and $6.9 million, respectively, as of September 30, 2020. The vehicle leases entered into since March 2020 represent
non-cash
transactions. The total operating lease cost for the nine months ended September 30, 2020 was $585,490. The operating cash outflows related to vehicle fleet operating lease obligations for the nine months ended September 30, 2020 were $585,490.
 
17
The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2020:
 
Lease Assets and Liabilities – Fleet
   
Classification
     
September 30, 2020
  
Assets
      
Right of use assets, net
      Operating lease right of use assets      $ 6,946,254  
     
 
 
  
      $ 6,946,254  
     
 
 
  
Liabilities
      
Current
      
Lease liabilities, short-term
      Operating lease liabilities      $ 2,007,292  
Non-Current
      
Lease liabilities
     
Non-current operating lease liabilities
        4,938,962  
     
 
 
  
Total lease liabilities
       $ 6,946,254  
     
 
 
  
Weighted average remaining lease term
         2.2 years  
Weighted average discount rate
         1.85 % 
 
18
The following table presents the maturity of the Company’s fleet lease liability as of
September
 30, 2020:
 
Time
Period
 
Three months ending December 31, 2020
    $ 530,799  
Year ending December 31, 2021
      2,112,506  
Year ending December 31, 2022
      3,207,898  
Year ending December 31, 2023
     
1,273,867
  
Thereafter
      —    
  
 
 
  
Total
      7,125,070  
Less: Present value discount
      (178,816 ) 
  
 
 
  
Total operating lease liabilities
      6,946,254  
  
 
 
  
Less: Current portion
      (2,007,292 ) 
  
 
 
  
Long-term lease liabilities
    $ 4,938,962  
  
 
 
  
Right of use assets and lease liabilities for
all
operating leases were approximately $24.3 million and $29.1 million, respectively, as of September 30, 2020.
6. Share-Based Compensation
On June 18, 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provided for the granting of share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. On May 27, 2020, the Company’s stockholders approved the Amended and Restated 2018 Equity Incentive Plan (the “Amended 2018 Plan”), which amended and restated the 2018 Plan. The Amended 2018 Plan provides for the granting of up to 
6,500,000
additional share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. In December 2019, the Company adopted the 2019 Inducement Award Plan (the “2019 Inducement Plan”) for the grant of equity awards of up to 
1,000,000 shares of common stock to newly hired employees.
As of December 31, 2019, the total number of shares reserved under all equity plans was 11,287,390 and the Company had 2,208,317 shares available for future issuance under the Amended 2018 Plan and the 2019 Inducement Plan. Stock options granted under the 2018 Plan and the 2019 Inducement Plan may be either incentive stock options (“ISOs”) as defined by the
Internal Revenue Code of 1986, as amended
, or
non-qualified
stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally one to three years) and the exercise prices of such options. Options have a maximum term of 10 years. The exercise price of
stock options
 granted under the Amended 2018 Plan and the 2019 Inducement Plan must be at least equal to the fair market value of the common stock on the date of grant.
Total
share
-based compensation expense related to all of the Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2020 and 2019, was comprised of the following:
 
    
Three Months Ended September 30,
     
Nine Months Ended September 30,
  
    
2020
     
2019
     
2020
     
2019
  
Inventoriable costs
   
$
345,460
 
    $ —     
$
996,802
 
    $ —  
Research and development
   
 
2,402,865
 
      2,023,700     
 
6,792,498
 
    $ 6,785,280  
General and administrative
   
 
4,152,394
 
      2,783,068     
 
11,562,850
 
      8,064,129  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total share-based compensation expense
   
$
6,900,719
 
    $ 4,806,768     
$
19,352,150
 
    $ 14,849,409  
  
 
 
     
 
 
     
 
 
     
 
 
  
The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2020 and 2019:
 
    
2020
  
2019
Dividend yield
   
0%
   0%
Expected volatility
   
91.6%-92.7%
  
83.7%-85.7%
Weighted-average risk-free interest rate
   
1.31%
   2.32%
Expected term (in years)
   
6.0
   6.0
 
19
Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      —        $ —     
Options granted in 2020
      39,728      $ 17.18        9.5 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      39,728      $ 17.18        9.5 years  
  
 
 
     
 
 
     
Vested or expected to vest at September 30, 2020
      39,728      $ 17.18     
  
 
 
     
 
 
     
Exercisable at September 30, 2020
      —        $ —     
  
 
 
     
 
 
     
Information regarding RSU awards under the 2019 Inducement Plan during the nine month period ended September 30, 2020 are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Grant
 
Date

Fair
 
Value
 
Per
 
Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      —        $ —     
Time based RSUs granted in 2020
      274,410      $ 16.01        2.6 years  
Time based RSUs cancelled in 2020
      (15,064 )     $ 15.81        2.5 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      259,346      $ 16.01        2.6 years  
  
 
 
     
 
 
     
Vested or expected to vest at September 30, 2020
      259,346      $ 16.01     
  
 
 
     
 
 
     
Exercisable at September 30, 2020
      —        $ —     
  
 
 
     
 
 
     
As of September 30, 2020, the Company issued options and time based RSUs totaling 314,138 shares in the 2019 Inducement Plan. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan.
Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      6,039,945      $ 16.81        7.0 years  
Options granted
      742,509      $ 23.85        9.4 years  
Options exercised
      (696,936 )     $ 12.79        4.8 years  
Options canceled or expired
      (161,111 )     $ 21.70        7.9 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      5,924,407      $ 18.03        6.8 years  
  
 
 
     
 
 
     
Vested or expected to vest at September 30, 2020
      5,924,407      $ 18.03     
  
 
 
     
 
 
     
Exercisable at September 30, 2020
      3,620,984      $ 18.85        5.7 years  
  
 
 
     
 
 
     
The fair value of the time based RSUs and the Milestone RSUs is based on the closing price of the Company’s common stock on the date of grant.
 
20
The fair value of the TSR RSUs was determined using the Monte Carlo simulation method. Information
regarding the time based RSU activity and changes during the nine month period ended September 30, 2020 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      1,268,679      $ 13.60        1.7 years  
Time based RSUs granted in 2020
      728,596      $ 23.05        2.7 years  
Time based RSUs vested in 2020
      (506,546 )     $ 13.78        0.9 years  
Time based RSUs cancelled in 2020
      (90,559 )     $ 17.03        1.5 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      1,400,170      $ 18.69        1.9 years  
  
 
 
     
 
 
     
 
 
  
Information related to the Company’s Milestone RSUs and TSR RSUs during the nine month period ended September 30, 2020 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      67,080      $ 17.08        0.2 years  
Milestone RSUs and TSR RSUs granted in 2020
      86,044      $ 32.56        2.4 years  
Milestone RSUs and TSR RSUs vested in 2020
      (67,080 )     $ 17.08        0.2 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      86,044      $ 32.56        2.4 years  
  
 
 
     
 
 
     
 
 
  
The weighted average estimated fair value per share of the TSR RSUs granted in 2017 was $17.08, which was derived from a Monte Carlo simulation. Significant assumptions utilized in estimating the value of the awards granted include an expected dividend yield of 0%, a risk free rate of 1.6%, and expected volatility of 95.4%. The TSR RSUs granted in 2017 entitled the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ended and vested on December 31, 2019, provided the grantee remained in the service of the Company on the settlement date. The Company expensed the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs was settled was a percentage of shares for which the award was targeted and depended on the Company’s total shareholder return (as defined below), expressed as a percentile ranking of the Company’s total shareholder return as compared to the Company’s peer group (as defined below). The number of shares for which the TSR RSUs were settled varied depending on the level of achievement of the goal. Total shareholder return was determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding January 1, 2020 by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2017, with a deemed reinvestment of any dividends declared during the performance period.
The Company’s peer group originally included 223 companies that comprised the Nasdaq Biotechnology Index at December 31, 2018, which was selected by the Compensation Committee of the Company’s Board of Directors and included a range of biotechnology companies operating in several business segments.
The weighted average estimated fair value per share of the TSR RSUs granted in 2020 was $32.56, which was derived from a Monte Carlo simulation. Significant assumptions utilized in estimating the value of the awards granted include an expected dividend yield of 0%, a risk free rate of 1.4%, and expected volatility of 91.3%. The TSR RSUs granted in 2020 will entitle the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ending and vesting on December 31, 2022, provided the grantee remained in the service of the Company on the settlement date. The Company is expensing the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs will be settled is a percentage of shares for which the award is targeted and depends on the Company’s total shareholder return, expressed as a percentile ranking of the Company’s total shareholder return as compared to the Company’s peer group, which is consistent with the TSR RSUs granted in 2017. The number of shares for which the TSR RSUs will be settled will vary depending on the level of achievement of the goal. Total shareholder return will be determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding January 1, 2023 by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2020, with a deemed reinvestment of any dividends declared during the performance period.
The Company’s peer group included companies that compromised the Nasdaq Biotechnology Index at December 31, 2019.
The Company recognized
non-cash
s
hare
-based compensation expense related to time based RSU’s for the three and nine months ended September 30, 2020 of approximately $3.2 million and $8.9 million, respectively, as compared to $1.7 million and $5.6 million for the three and nine months ended September 30, 2019, respectively. Total expense for all RSUs, including the time based
and performance based RSUs, is $3.4 million and $9.2 million for the three and nine months ended September 30, 2020, respectively, as
 
21
compared to $1.9 million and $6.1 million for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, there was $21.6 million of unrecognized compensation costs related to unvested time based RSUs. As of September 30, 2020, there was $1.0 million and $1.1 million of unrecognized compensation costs related to unvested Milestone RSUs and TSR RSUs, respectively.
7. Collaborations and License Agreements
The Bristol-Myers Squibb License Agreement
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and
know-how
of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company made an upfront payment of $1.0 million to BMS
 in 2005
, a milestone payment of $1.25 million in December 2013, and a milestone payment of $1.5 million in December 2014 following the initiation of the Company’s first Phase 3 clinical trial for lumateperone for patients with exacerbated schizophrenia. Upon FDA acceptance of an NDA filing for lumateperone, the Company was obligated to pay BMS a $2.0 million milestone payment, which was paid in January 2019. The FDA approved the NDA filing on December 23, 2019 and as a result the Company accrued an additional milestone liability of $5.0 million in the fourth quarter of 2019 which was paid in January 2020. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of
non-royalty
payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a
country-by-country
and
product-by-product
basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
In September 2016, the Company transferred certain of its rights under the BMS agreement to its wholly owned subsidiary, ITI Limited. In connection with the transfer, the Company guaranteed ITI Limited’s performance of its obligations under the BMS agreement. With the initial recognition of product sales revenue in the nine months ended September 30, 2020, the Company
expensed
approximately $506,000 in
cost of product sales
to satisfy its obligation under the BMS agreement.
 
Item 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following in conjunction with our unaudited condensed consolidated financial statements and the related notes thereto that appear elsewhere in this Quarterly Report on Form
10-Q
and the audited consolidated financial statements and notes thereto and under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form
10-K
filed on March 2, 2020. In addition to historical information, the following discussion and analysis includes forward-looking information that involves risks, uncertainties and assumptions. Our actual results and the timing of events could differ materially from those anticipated by these forward-looking statements as a result of many factors, including those discussed under “Risk Factors” in our Annual Report on Form
10-K
filed on March 2, 2020, as updated from time to time in our subsequent periodic and current reports filed with the SEC.
Overview
We are a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. In December 2019 CAPLYTA (lumateperone) was approved by the FDA for the treatment of schizophrenia in adults (42mg/day) and we initiated the commercial launch of CAPLYTA
in
 
22
late March 2020. In support of our commercialization efforts, we hired a national sales force consisting of approximately 240 sales representatives. As used in this report, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia.
Lumateperone is also in Phase 3 clinical development as a novel treatment for bipolar depression. Our lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. In September 2020, we announced positive topline results from Study 402, conducted globally, evaluating lumateperone as adjunctive therapy to lithium or valproate in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 402, once daily lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the Montgomery-Åsberg Depression Rating Scale, or MADRS, total score (p=0.0206; effect size = 0.27). Lumateperone 42 mg also met the key secondary endpoint, the Clinical Global Impression Scale for Bipolar for Severity of Illness, or
CGI-BP-S,
Depression Score (p=0.0082; effect size = 0.31). The lower lumateperone dose, 28 mg, showed a trend for a dose-related improvement in symptoms of depression but the results did not reach statistical significance. In the first quarter of 2020, we initiated our third monotherapy Phase 3 study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. Following the positive results in Study 402, we amended Study 403 to evaluate major depressive episodes with mixed features in bipolar disorder in patients with Bipolar I or Bipolar II disorder and mixed features in patients with major depressive disorder (“MDD”). We expect to complete Study 403 in 2022 and following completion we intend to discuss the results with the FDA to determine whether Study 403, as amended, will constitute a registration trial in support of a potential future regulatory filing for this indication.
In July 2019, we announced topline results from our first monotherapy study, Study 401, conducted in the U.S., and our second monotherapy study, Study 404, conducted globally, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder. In Study 404, lumateperone 42 mg met the primary endpoint for improvement in depression as measured by change from baseline versus placebo on the MADRS total score (p<0.0001; effect size = 0.56). These benefits were statistically significant in both Bipolar I and Bipolar II patients. Study 404 also met its key secondary endpoint, Clinical Global Impression Scale for Bipolar for Severity of Illness
(CGI-BP-S)
Total Score (p<0.001; effect size = 0.46). Study 401 tested two doses of lumateperone, 42 mg and 28mg along with placebo. In this trial, neither dose of lumateperone met the primary endpoint of statistical separation from placebo as measured by change from baseline on the MADRS total score. There was a high placebo response in this trial. Lumateperone was generally well-tolerated in all three bipolar depression studies, with a favorable safety profile. The rates of discontinuation due to treatment emergent adverse events for both doses of lumateperone were low.
In addition, while our Phase 3 bipolar depression trials were powered for the overall patient population and not powered for subpopulation analyses, statistically significant benefit versus placebo was seen in the subgroup of patients with Bipolar I and Bipolar II disorder in Study 404 and in patients with Bipolar I disorder in Study 402, but the Bipolar II subgroup was not statistically significant in Study 402. Based on the results of Study 402 and Study 404, we expect to submit a supplemental new drug application, or sNDA, to the FDA for potential regulatory approval of lumateperone for the treatment of bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy early in the first quarter of 2021 and, assuming the sNDA submission is accepted by the FDA, we anticipate an FDA target action date in the second half of 2021.
We are also pursuing clinical development of lumateperone for the treatment of additional CNS diseases and disorders. We believe lumateperone may have utility for treating agitation, aggression and sleep disturbances in diseases that include dementia, Alzheimer’s disease, or AD, Huntington’s disease and autism spectrum disorders. At a dose of 42 mg, lumateperone has been shown effective in treating the symptoms associated with schizophrenia, and we believe this dose may merit further investigation for the treatment of bipolar disorder, depressive disorders and other neuropsychiatric diseases. We have commenced our Phase 3 clinical program evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of MDD and we expect to initiate clinical conduct in two Phase 3 trials in 2021.
Within the lumateperone portfolio, we are also developing a long-acting injectable formulation to provide more treatment options to patients suffering from mental illness. We have completed the preclinical development of a long-acting injectable formulation. Following discussions with the FDA, we plan to initiate a Phase 1 clinical trial by the end of 2020. Given the encouraging tolerability data to date with oral lumateperone, we believe that a long-acting injectable option, in particular, may lend itself to being an important formulation choice for certain patients.
We may investigate the use of lumateperone, either on our own or with a partner, as a treatment for agitation, aggression and sleep disturbances in additional diseases that include autism spectrum disorders, depressive disorder, intermittent explosive disorder,
non-motor
symptoms and motor complications associated with Parkinson’s disease, and post-traumatic stress disorder. We hold exclusive, worldwide commercialization rights to lumateperone and a family of compounds from Bristol-Myers Squibb Company pursuant to an exclusive license.
We have a second major program called
ITI-002
that has yielded a portfolio of compounds that selectively inhibit the enzyme phosphodiesterase type 1, or PDE1. PDE1 enzymes are highly active in multiple disease states and our PDE1 inhibitors are designed
 
23
to reestablish normal function in these disease states. Abnormal PDE1 activity is associated with cellular proliferation and activation of inflammatory cells. Our PDE1 inhibitors ameliorate both of these effects in animal models. We intend to pursue the development of our phosphodiesterase, or PDE, program, for the treatment of several CNS and
non-CNS
conditions with a focus on diseases where excessive PDE1 activity has been demonstrated and increased inflammation is an important contributor to disease pathogenesis. Our potential disease targets include heart failure, immune system regulation, neurodegenerative diseases, and other
non-CNS
disorders.
ITI-214
is our lead compound in this program. We believe
ITI-214
is the first compound in its class to successfully advance into Phase 1 clinical trials. Following the favorable safety and tolerability results in our Phase 1 program, we initiated our development program for
ITI-214
for Parkinson’s disease and commenced patient enrollment in the third quarter of 2017 in a Phase 1/2 clinical trial of
ITI-214
in patients with Parkinson’s disease to evaluate safety and tolerability in this patient population, as well as motor and
non-motor
exploratory endpoints. In the fourth quarter of 2018, we announced that the Phase 1/2 clinical trial of
ITI-214
has been completed and topline results demonstrated
ITI-214
was generally well-tolerated with a favorable safety profile and clinical signs consistent with improvements in motor symptoms and dyskinesias. In addition, in the second quarter of 2020, we announced topline results from Study
ITI-214-104,
a Phase 1/2 translational study of single ascending doses of
ITI-214
in patients with chronic systolic heart failure with reduced ejection fraction. In this study,
ITI-214
improved cardiac output by increasing heart contractility and decreasing vascular resistance. Agents that both increase heart contractility (inotropism) and decrease vascular resistance (vasodilation) are called inodilators. Inodilators in current clinical use are associated with the development of arrhythmias, which are abnormal heart rhythms that when serious can impair heart function and lead to mortality.
ITI-214,
which acts through a novel mechanism of action, was not associated with arrhythmias in this study and was generally well tolerated in all patients.
Our pipeline also includes programs that are focused on advancing drugs for symptomatic and disease modifying treatments for schizophrenia, Parkinson’s disease, AD and other neuropsychiatric and neurodegenerative disorders. We have an ongoing early stage clinical program evaluating a new molecule as a potential treatment for behavioral disturbances in patients with dementia. We have completed single and multiple ascending dose studies in healthy volunteers and are currently evaluating safety and pharmacokinetics in a healthy elderly population.
We also have a development program with our
ITI-333
compound as a potential treatment for substance use disorders, pain and psychiatric comorbidities including depression and anxiety. There is a pressing need to develop new drugs to treat opioid addiction and safe, effective,
non-addictive
treatments to manage pain. We have initiated a clinical program with
ITI-333.
Following a
pre-IND
meeting with the FDA, we expect to initiate a single ascending dose safety and tolerability in late 2020 or early 2021. We have received a grant from the National Institute on Drug Abuse under the Helping to End Addiction Long-term Initiative, or NIH HEAL Initiative, that we expect will fund a significant portion of the early stage clinical development costs associated with this program.
We have assembled a management team with significant industry experience to lead the discovery, development and potential commercialization of our product candidates. We complement our management team with a group of scientific and clinical advisors that includes recognized experts in the fields of schizophrenia and other CNS disorders.
Results of Operations
The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.
Revenues
Net revenues from product sales consist of sales of CAPLYTA, which was approved by the FDA on December 2019. We initiated the commercial launch of CAPLYTA in late March 2020 and generated approximately $7.4 million and $10.1 million in net revenue from product sales for the three and nine months ended September 30, 2020, respectively. In addition, we had approximately $0 and $232,000 of grant revenues for the three and nine months ended September 30, 2020, respectively, compared to no grant revenue for the three and nine months ended September 30, 2019. We have received and may continue to receive grants from U.S. government agencies and foundations.
We do not expect any revenues that we may generate in the next several years to be significant enough to fund our operations.
Expenses
The process of researching, developing and commercializing drugs for human use is lengthy, unpredictable and subject to many risks. We are unable with certainty to estimate either the costs or the timelines in which those costs will be incurred. The costs associated with the commercialization of CAPLYTA will be substantial and will be incurred prior to our generating sufficient revenue to offset these costs. Costs for the clinical development of lumateperone for the treatment of bipolar depression consumes and, together with our anticipated clinical development programs for depressive disorders and
ITI-214,
will continue to consume a large portion of our current, as well as projected, resources. We intend to pursue other disease indications that lumateperone may address, but there are significant costs associated with pursuing FDA approval for those indications, which would include the cost of additional clinical trials.
 
24
Our
ITI-002
program has a compound,
ITI-214,
in Phase 1/2 development. We intend to pursue the development of our PDE program, including
ITI-214
for the treatment of several CNS and
non-CNS
conditions, including cardiovascular disease. We have ongoing development programs for
ITI-214
for Parkinson’s disease and for the treatment of heart failure. Our other projects are still in the preclinical stages, and will require extensive funding not only to complete preclinical testing, but to commence and complete clinical trials. Expenditures that we incur on these projects will be subject to availability of funding in addition to the funding required for the advancement of lumateperone. Any failure or delay in the advancement of lumateperone could require us to
re-allocate
resources from our other projects to the advancement of lumateperone, which could have a material adverse impact on the advancement of these other projects and on our results of operations. Our operating expenses are comprised of (i) costs of product sales; (ii) research and development expenses; (iii) general and administrative expenses and (iv) selling expenses.
Costs of product sales are comprised of:
 
  •  
Direct costs of formulating, manufacturing and packaging drug product;
 
  •  
Overhead costs consisting of labor, customs, share-based compensation, shipping, outside inventory management and other miscellaneous operating costs; and
 
  •  
Royalty payments on product sales.
Research and development costs are comprised of:
 
  •  
internal recurring costs, such as costs relating to labor and fringe benefits, materials, supplies, facilities and maintenance; and
 
  •  
fees paid to external parties who provide us with contract services, such as
pre-clinical
testing, manufacturing and related testing, clinical trial activities and license milestone payments.
General and administrative expenses are incurred in three major categories:
 
  •  
salaries and related benefit costs;
 
  •  
patent, legal, and professional costs; and
 
  •  
office and facilities overhead.
Selling expenses are incurred in three major categories:
 
  •  
salaries and related benefit costs of a dedicated sales force;
 
  •  
sales operation costs; and
 
  •  
marketing and promotion expenses.
Product sold through September 30, 2020 generally consisted of drug product that was previously charged to research and development expense prior to FDA approval of CAPLYTA. Because the Company previously expensed drug product, the cost of drug product sold is lower than it would have been and has a positive impact on our cost of product sales and related product gross margins for the three and nine months ended September 30, 2020. The Company’s reported cost of product sales as a percentage of product sales, net was 7.5% or approximately $0.6 million for the three months ended September 30, 2020 and was 7.4% or approximately $0.8 million for the nine months ended September 30, 2020.
We will expect to continue to have this favorable impact on cost of product sales and related product gross margins until our sales of CAPLYTA include drug product that is manufactured after the FDA approval. We are currently unable to estimate how long it will be until we begin selling product manufactured post FDA approval.
We expect that research and development expenses will increase moderately as we proceed with our clinical trials of lumateperone for the treatment of bipolar depression and depressive disorders, other clinical trials, increased manufacturing of drug product for clinical trials and
pre-clinical
development activities. We also expect that our selling, general and administrative costs will increase from prior periods primarily due to costs associated with building and maintaining infrastructure and promotional activities to support the commercial sales of CAPLYTA, which will include hiring additional personnel and increasing technological capabilities. On September 28, 2018, we signed a lease with a related party to acquire 15,534 square feet of additional office space in our current
 
25
headquarters facility. We granted options to purchase 1,833,102 shares of our common stock in 2019 and have granted options to purchase an additional 782,237 shares of our common stock in the nine months ended September 30, 2020. We also granted time based restricted stock units, or RSUs, for 950,449 shares of our common stock in 2019 and time based RSUs for 1,003,006 shares of our common stock in the nine months ended September 30, 2020. We will recognize expense associated with these RSUs and options over three years in research and development expenses, selling, general and administrative expenses, and inventoriable manufacturing expenses. In the first quarter of 2017, we also granted performance based RSUs, which vest based on the achievement of certain milestones that include (i) the submission of an NDA with the FDA, (ii) the approval of the NDA by the FDA, or the Milestone RSUs, and (iii) the achievement of certain comparative shareholder returns against our peers, or the TSR RSUs. The Milestone RSUs were valued at the closing price on March 8, 2017. The RSUs related to the NDA submission were amortized through December 31, 2018 based on the probable vesting date. The NDA submission milestone was achieved in the third quarter of 2018. The Milestone RSUs related to the NDA submission vested on December 31, 2018. The NDA approval milestone was achieved in the fourth quarter of 2019. The Milestone RSUs related to the NDA approval vested on December 31, 2019. The TSR RSUs were valued using the Monte Carlo simulation method and were amortized over the life of the RSU’s which vested on January 24, 2020. In the first quarter of 2020, we also granted performance based RSUs, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA, or the 2020 Milestone RSUs, and (ii) the achievement of certain comparative shareholder returns against our peers, or the 2020 TSR RSUs. The 2020 Milestone RSUs were valued at the closing price of our common stock on February 18, 2020. The 2020 TSR RSUs were valued using the Monte Carlo simulation method. We expect to continue to grant stock options and other share-based awards in the future, which with our growing employee base will increase our share-based compensation expense in future periods. The following table sets forth our revenues, operating expenses, interest income and income tax expense for the three and nine month periods ended September 30, 2020 and 2019 (in thousands):
 
    
For the Three Months

Ended September 30,
     
For the Nine Months

Ended September 30,
  
    
2020
     
2019
     
2020
    
2019
  
    
(Unaudited)
     
(Unaudited)
  
Revenues
           
Product sales, net
   
$
7,368
 
    $ —     
$
10,127
 
   $ —  
Grant revenue
   
 
—  
 
      —       
 
232
 
     —    
  
 
 
     
 
 
     
 
 
    
 
 
  
Total revenues, net
   
 
7,368
 
      —       
 
10,359
 
     —    
Expenses
           
Cost of product sales
   
 
556
 
      —       
 
754
 
     —    
Research and development
   
 
10,275
 
      21,340     
 
51,484
 
     70,059  
Selling, general and administrative
   
 
52,474
 
      15,036     
 
128,015
 
     42,184  
  
 
 
     
 
 
     
 
 
    
 
 
  
Total costs and expenses
   
 
63,305
 
      36,376     
 
180,253
 
     112,243  
  
 
 
     
 
 
     
 
 
    
 
 
  
Loss from operations
   
 
(55,937
) 
      (36,376 )    
 
(169,894
) 
     (112,243 ) 
Interest income
   
 
753
 
      1,514     
 
3,591
 
     5,106  
Income tax expense
   
 
—  
 
      —       
 
(3
) 
     (2 ) 
  
 
 
     
 
 
     
 
 
    
 
 
  
Net loss
   
$
(55,184
) 
    $ (34,862 )    
$
(166,306
) 
   $ (107,139 ) 
  
 
 
     
 
 
     
 
 
    
 
 
  
Comparison of Three and Nine Month Periods Ended September 30, 2020 and September 30, 2019
Total revenues, net
Total revenues, net for the three and nine months ended September 30, 2020 were approximately $7.4 million and $10.4 million, respectively, compared to $0 for the comparable periods in 2019. Net product sales were approximately $7.4 million and $10.1 million for the three and nine months ended September 30, 2020, respectively, and were comprised of sales of CAPYLTA, which was approved by the FDA on December 20, 2019 and became available to wholesalers in March 2020. No similar net product sales were recognized during the three and nine months ended September 30, 2019. In addition, revenue from a government grant was approximately $0 and $232,000 for the three and nine months ended September 30, 2020, respectively.
Cost of Product Sales
Cost of product sales was approximately $0.6 million for the three months ended September 30, 2020. Cost of product sales consisted primarily of product royalty fees, overhead and minimal direct costs. Product sold during the three months ended September 30, 2020 generally consisted of drug product that was previously charged to research and development expense prior to FDA approval of CAPLYTA. This minimal cost drug product had a positive impact on our cost of product sales and related product gross margins for the three months ended September 30, 2020. No similar cost of product sales was recognized during the three months ended September 30, 2019.
 
26
Cost of product sales was approximately $0.8 million for the nine months ended September 30, 2020. Cost of product sales consisted primarily of product royalty fees, overhead and minimal direct costs. Product sold during the nine months ended September 30, 2020 generally consisted of drug product that was previously charged to research and development expense prior to FDA approval of CAPLYTA. This minimal cost drug product had a positive impact on our cost of product sales and related product gross margins for the nine months ended September 30, 2020. No similar cost of product sales was recognized during the nine months ended September 30, 2019.
We will continue to have a lower cost of product sales that excludes the cost of the drug product that was incurred prior to FDA approval until our sales of CAPLYTA include drug product that is manufactured after the FDA approval. We expect that this will be the case for the near-term and as a result, our cost of product sales will be less than we anticipate it will be in future periods.
Research and Development Expenses
The following tables set forth our research and development expenses for the three and nine month periods ended September 30, 2020 and 2019 (in thousands):
 
    
Three Months Ended September 30,
     
Nine Months Ended September 30,
  
    
2020
      2019     
2020
      2019  
External costs
   
 
2,815
 
      14,372     
 
29,897
 
      48,302  
Internal costs
   
 
7,460
 
      6,968     
 
21,587
 
      21,757  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total research and development expenses
   
$
10,275
 
    $ 21,340     
$
51,484
 
    $ 70,059  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
    
Three Months Ended September 30,
     
Nine Months Ended September 30,
  
    
2020
      2019     
2020
      2019  
Lumateperone costs
   
 
4,360
 
      10,515     
 
30,402
 
      32,282  
Manufacturing costs
   
 
160
 
      3,061     
 
3,455
 
      14,920  
Share-based compensation
   
 
2,748
 
      2,024     
 
7,789
 
      6,785  
Other projects and overhead
   
 
3,007
 
      5,740     
 
9,838
 
      16,072  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total research and development expenses
   
$
10,275
 
    $ 21,340     
$
51,484
 
    $ 70,059  
  
 
 
     
 
 
     
 
 
     
 
 
  
Research and development expenses decreased to $10.3 million for the three month period ended September 30, 2020 as compared to $21.3 million for the three month period ended September 30, 2019, representing a decrease of approximately 52%. This decrease is due primarily to a decrease of approximately $6.2 million of lumateperone clinical and
non-clinical
costs and a decrease of approximately $2.9 million in research manufacturing costs, and a decrease of $2.7 million for other projects and overhead. These decreases are offset by an increase of approximately $0.7 million of share-based compensation expense. Manufacturing costs decreased because production of lumateperone prior to FDA approval was expensed and current production is now being capitalized in addition to less clinical trial manufacturing in 2020. Internal costs increased by approximately $0.5 million for the period due primarily to share-based compensation costs. The majority of the research and development expense incurred for the three and nine month periods ended September 30, 2020 and 2019 related to lumateperone.
Research and development expenses decreased to $51.5 million for the nine month period ended September 30, 2020 as compared to $70.1 million for the nine month period ended September 30, 2019, representing a decrease of approximately 27%. This decrease is due primarily to a decrease of approximately $11.5 million in manufacturing expense, a decrease of approximately $1.9 million of lumateperone clinical and
non-clinical
expenses and a decrease of approximately $6.2 million relating to other projects and overhead. This decrease is offset by an increase of approximately $1.0 million of share-based compensation expense. Internal costs decreased by approximately $0.2 million for the period due to lower bonus accrual, stock compensation expense, travel and other operating costs.
As development of lumateperone progresses, we anticipate costs for lumateperone to increase due primarily to ongoing and planned clinical trials relating to our lumateperone programs in the next several years as we conduct Phase 3 and other clinical trials. We are also required to complete
non-clinical
testing to obtain FDA approval and manufacture material needed for clinical trial use, which includes
non-clinical
testing of the drug product and the creation of an inventory of drug product in anticipation of possible FDA approval. We received FDA approval on December 20, 2019 for lumateperone for the treatment for schizophrenia in adults.
 
27
We currently have several projects, in addition to lumateperone, that are in the research and development stages, including in the areas of cognitive dysfunction and the treatment of neurodegenerative diseases, including AD, among others. We have used internal resources and incurred expenses not only in relation to the development of lumateperone, but also in connection with these additional projects as well, including our PDE program. We have not, however, reported these costs on a
project-by-project
basis, as these costs are broadly spread among these projects. The external costs for these projects have been modest and are reflected in the amounts discussed in this section “—Research and Development Expenses.”
The research and development process necessary to develop a pharmaceutical product for commercialization is subject to extensive regulation by numerous governmental authorities in the United States and other countries. This process typically takes years to complete and requires the expenditure of substantial resources. The steps required before a drug may be marketed in the United States generally include the following:
 
  •  
completion of extensive
pre-clinical
laboratory tests, animal studies, and formulation studies in accordance with the FDA’s Good Laboratory Practice, or GLP, regulations;
 
  •  
submission to the FDA of an Investigational New Drug application, or IND, for human clinical testing, which must become effective before human clinical trials may begin;
 
  •  
performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug for each proposed indication;
 
  •  
submission to the FDA of a New Drug Application, or NDA, after completion of all clinical trials;
 
  •  
satisfactory completion of an FDA
pre-approval
inspection of the manufacturing facility or facilities at which the active pharmaceutical ingredient, or API, and finished drug product are produced and tested to assess compliance with current Good Manufacturing Practices, or cGMPs;
 
  •  
satisfactory completion of FDA inspections of clinical trial sites to assure that data supporting the safety and effectiveness of product candidates has been generated in compliance with Good Clinical Practices; and
 
  •  
FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the United States.
The successful development of our product candidates and the approval process requires substantial time, effort and financial resources, and is uncertain and subject to a number of risks. We cannot be certain that any of our product candidates will prove to be safe and effective, will meet all of the applicable regulatory requirements needed to receive and maintain marketing approval, or will be granted marketing approval on a timely basis, if at all. Data from
pre-clinical
studies and clinical trials are susceptible to varying interpretations that could delay, limit or prevent regulatory approval or could result in label warnings related to or recalls of approved products. We, the FDA, or other regulatory authorities may suspend clinical trials at any time if we or they believe that the subjects participating in such trials are being exposed to unacceptable risks or if such regulatory agencies find deficiencies in the conduct of the trials or other problems with our product candidates. Other risks associated with our product candidates are described in the section entitled “Risk Factors” in our Annual Report on Form
10-K
for the year ended December 31, 2019, as updated by the section entitled “Risk Factors” in this Quarterly Report on Form
10-Q
and from time to time in our other periodic and current reports filed with the SEC.
Selling, General and Administrative Expenses
Selling, general and administrative costs for the three month period ended September 30, 2020 were $52.5 million as compared to $15.0 million in the three-month period ended September 30, 2019 which represents an increase of 249%. Below is a breakout of these expenses into selling and general administrative costs for the periods.
General and administrative expenses were $14.2 million in the three month period ended September 30, 2020 as compared to $8.6 million for the same period in 2019, an increase of 65%. This increase is due to increases in information technology costs of $2.4 million, professional fees of $1.4 million, stock compensation expense of $1.4 million, labor and related expenses of $0.4 million, and the remainder on insurance, lease expense, and other administrative expenses. Salaries, bonuses and related benefit costs for our general and administrative functions for the three months ended September 30, 2020 and 2019 constituted approximately 53% and 66%, respectively, of our general and administrative costs.
Selling costs were $38.3 million for the three month period ended September 30, 2020 as compared to
pre-commercialization
costs of $6.4 million in the same period in 2019, or an increase of 498%. This increase is primarily due to increases in sales related labor costs of $15.4 million and commercialization and marketing costs of $15.2 million. Salaries, bonuses and related benefit costs for our sales and marketing functions for the three months ended September 30, 2020 and 2019 constituted approximately 43% and 14%, respectively, of our selling costs.
 
28
Selling, general and administrative costs for the nine month period ended September 30, 2020 were $128.0 million as compared to $42.2 million in the nine month period ended September 30, 2019, which represents an increase of 203%.
General and administrative expenses for the nine months ended September 30, 2020 were $40.5 million in 2020 as compared to $22.8 million for the same period in 2019, an increase of 78%. This increase is due to increases in professional and consulting fees of $4.5 million, labor and related expenses of $2.6 million, information technology services of $5.5 million, stock compensation expense of $3.5 million, and the remainder consisting of insurance, lease expense, and other administrative expenses. Salaries, bonuses and related benefit costs for our general and administrative functions for the nine months ended September 30, 2020 and 2019 constituted approximately 52% and 64%, respectively, of our general and administrative costs.
Selling costs were $87.5 million for the nine month period ended September 30, 2020 as compared to
pre-commercialization
costs of $19.4 million in the same period in 2019, or an increase of 351%. This increase is primarily due to an increase in sales related labor costs of $40.3 million and commercialization costs of $25.5 million. Salaries, bonuses and related benefit costs for our sales and marketing functions for the nine months ended September 30, 2020 and 2019 constituted approximately 50% and 16%, respectively, of our selling costs.
We expect selling, general and administrative costs to increase moderately in the fourth quarter of 2020 as compared to the third quarter of 2020. We are expanding post approval marketing, including increased efforts to educate physicians due to the limitations related to the
COVID-19
virus pandemic and market access efforts as well as our administrative infrastructure.
Liquidity and Capital Resources
Through September 30, 2020, we provided funds for our operations by obtaining a total of approximately $1.6 billion of cash primarily through public and private offerings of our common stock and other securities, grants from government agencies and foundations and payments received under a terminated license and collaboration agreement. In the nine months ended September 30, 2020, we have collected $5.1 million from product sales, which we believe will increase going forward. We do not believe that grant revenue will be a significant source of funding in the near future.
On January 10, 2020, we completed a public offering of 10,000,000 shares of our common stock. All of the shares in the offering were sold by the Company, with gross proceeds to the Company of $295.0 million and net proceeds of approximately $277.0 million, after deducting underwriting discounts, commissions and offering expenses.
In June 2020, we sold 230,000 shares of common stock under our
at-the-market
equity program generating $5.6 million in net proceeds which was received in July 2020. In the third quarter of 2020, we sold an additional 512,791 shares of common stock utilizing our
at-the-market
program and received $12.3 million of net proceeds.
In September 2020 we completed a public offering of common stock in which we sold 12,666,667 shares of common stock at a public offering price of $30.00 per share for aggregate gross proceeds of $380.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8 million.
As of September 30, 2020, we had a total of approximately $723.3 million in cash and cash equivalents,
available-for-sale
investment securities and restricted cash, and approximately $38.0 million of short-term liabilities consisting entirely of liabilities from operations, including approximately $5.3 million of short-term lease obligations. In the nine months ended September 30, 2020, we spent approximately $170.7 million in cash for operations and equipment including $3.6 million of interest income and $5.1 million of collected product sales, resulting in net cash used in operations of $161.8 million. The use of cash was primarily for selling and marketing costs in connection with our commercial launch of CAPLYTA, conducting clinical trials and
non-clinical
testing, product manufacturing, and funding recurring operating expenses.
Based on our current operating plans, we expect that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the filing date of this quarterly report. During that time, we expect that our expenses will increase substantially due primarily to our commercialization activities and related infrastructure expansion in connection with the commercialization of CAPLYTA for the treatment of schizophrenia; the development of lumateperone in our late stage clinical programs; the development of our other product candidates, including
ITI-214;
the continuation of manufacturing activities for anticipated future sales of product and in connection with the development of lumateperone; and general operations.
For the fourth quarter of 2020, we expect to spend up to $85 million primarily related to the marketing and commercialization of CAPLYTA, lumateperone clinical development including clinical trial conduct, regulatory activities, manufacturing, expansion of our administrative infrastructure and other development activities. Our other development activities will include efforts related to our
 
29
ITI-214 and
ITI-333
programs, among others. However, the
COVID-19
pandemic may negatively impact our commercialization of CAPLYTA, our ability to complete our ongoing or planned preclinical and clinical trials, our ability to obtain approval of any product candidates from the FDA or other regulatory authorities, and our workforce and therefore our research, development and commercialization activities. This may ultimately have a material adverse effect on our liquidity, although we are unable to make any prediction with certainty given the rapidly changing nature of the pandemic and governmental and other responses to it.
We will require significant additional financing in the future to continue to fund our operations. We believe that we have the funding in place to commercialize CAPLYTA in patients with schizophrenia. With our existing cash, cash equivalents and
available-for-sale
investment securities, we believe that we have the funds to complete our ongoing clinical trial of lumateperone in bipolar disorder as a monotherapy and to file for approval with the FDA for this indication. We also plan to fund additional clinical trials of lumateperone for the treatment of depressive disorders and other CNS disorders; preclinical and clinical development of our
ITI-007
long acting injectable development program; additional clinical trials of lumateperone; continued clinical development of our PDE program, including
ITI-214;
research and preclinical development of our other product candidates; and the continuation of manufacturing activities in connection with the development of lumateperone. We anticipate requiring additional funds for further development of lumateperone in patients with depressive disorders and other indications, and for development of our other product candidates. We have incurred losses in every year since inception with the exception of 2011, when we received an
up-front
fee and a milestone payment related to a license agreement that has been terminated. These losses have resulted in significant cash used in operations. In the nine months ended September 30, 2020, we spent approximately $170.7 million in cash for operations and equipment, including $3.6 million of interest income and $5.1 million of collected product sales, resulting in net cash used in operations of $161.8 million. While we have several research and development programs underway, the lumateperone program has advanced the furthest and will continue to consume increasing amounts of cash for conducting clinical trials and the testing and manufacturing of product material. As we continue to conduct the activities necessary to pursue FDA approval of lumateperone beyond schizophrenia and our other product candidates, as well as commercialization efforts, we expect the amount of cash to be used to fund operations to increase over the next several years.
We seek to balance the level of cash, cash equivalents and investments on hand with our projected needs and to allow us to withstand periods of uncertainty relative to the availability of funding on favorable terms. Until we can generate significant revenues from operations, we will need to satisfy our future cash needs through public or private sales of our equity securities, sales of debt securities, incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of our product candidates and technology and, to a lesser extent, grant funding. On August 30, 2019, we filed a universal shelf registration statement on Form
S-3,
which was declared effective by the SEC on September 12, 2019, on which we registered for sale up to $350 million of any combination of our common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that we may determine, which includes up to $75 million of common stock that we could issue and sell from time to time, through SVB Leerink LLC acting as our sales agent, pursuant to the sale agreement that we entered into with SVB Leerink on August 29, 2019 for our
“at-the-market”
equity program. In the quarter ended June 30, 2020, we sold 230,000 shares of common stock under our
“at-the-market”
equity program which resulted in our receiving net proceeds of $5.6 million in July 2020. In the quarter ended September 30, 2020, we issued an additional 512,791 shares of common stock under our
“at-the-market”
equity program and received approximately $12.3 million of net proceeds. On September 10, 2020, we terminated the
“at-the-market”
equity program agreement with SVB Leerink LLC.
In addition, on January 6, 2020, we filed an automatic shelf registration statement on Form
S-3
with the SEC, which became effective upon filing, on which we registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that we may determine, so long as we continue to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective.
We cannot be sure that future funding will be available to us when we need it on terms that are acceptable to us, or at all. We sell securities and incur debt when the terms of such transactions are deemed favorable to us and as necessary to fund our current and projected cash needs. The amount of funding we raise through sales of our common stock or other securities depends on many factors, including, but not limited to, the magnitude of sales of CAPLYTA, the status and progress of our product development programs, projected cash needs, availability of funding from other sources, our stock price and the status of the capital markets. Due to the volatile nature of the financial markets, equity and debt financing may be difficult to obtain. Additionally, the continued spread of
COVID-19
and uncertain market conditions may limit our ability to access any financing. In addition, any unfavorable results in the commercialization of CAPLYTA and unfavorable development or delay in the progress of our lumateperone program could have a material adverse impact on our ability to raise additional capital.
In addition, following the closing of our September 2020 underwritten public offering of common stock, we have a limited number of authorized shares of common stock available for future issuance that are not already issued or reserved for issuance. We have 100.0 million authorized shares of common stock. As of September 30, 2020, we had 80.1 million shares of common stock
 
30
outstanding, 7.7 million shares of common stock issuable upon the exercise of outstanding stock options or the vesting of outstanding restricted stock units, and 7.2 million shares of common stock reserved for future issuance under our equity compensation plans. As a result, as of September 30, 2020, we had approximately 5.0 million authorized shares of common stock available for issuance. We will remain limited by the number of additional shares available for future capital raising transactions or strategic transactions unless we obtain stockholder approval to amend our restated certificate of incorporation to increase the number of authorized shares of common stock. This may cause a delay in our future capital raising, collaboration, partnership or other strategic transactions, and may have a material adverse effect on our business and financial condition.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.
If adequate funds are not available to us on a timely basis, we may be required to: (1) delay, limit, reduce or terminate
pre-clinical
studies, clinical trials or other clinical development activities for one or more of our product candidates, including our lead product candidate lumateperone,
ITI-214,
and our other product candidates; (2) delay, limit, reduce or terminate our discovery research or
pre-clinical
development activities; or (3) enter into licenses or other arrangements with third parties on terms that may be unfavorable to us or sell, license or relinquish rights to develop or commercialize our product candidates, technologies or intellectual property at an earlier stage of development and on less favorable terms than we would otherwise agree.
Our cash is maintained in checking accounts, money market accounts, money market mutual funds, U.S. government agency securities, certificates of deposit, commercial paper, corporate notes and corporate bonds at major financial institutions. Due to the current low interest rates available for these instruments, we are earning limited interest income. We do not expect interest income to be a significant source of funding over the next several quarters. Our investment portfolio has not been adversely impacted by the problems in the credit markets that have existed over the last several years, but there can be no assurance that our investment portfolio will not be adversely affected in the future.
In 2014, we entered into a long-term lease with a related party which, as amended, provided for a lease of 16,753 square feet of useable laboratory and office space located at 430 East 29th Street, New York, New York 10016. Concurrent with this lease, we entered into a license agreement to occupy certain vivarium related space in the same facility for the same term, rent and escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU
2016-02
for accounting purposes. In September 2018, we further amended the lease to obtain an additional 15,534 square feet of office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, we entered into a long-term lease for 3,164 square feet of office space in Towson, Maryland beginning March 1, 2019. The lease has a term of 3.2 years ending in April 2022. We anticipate acquiring additional space in 2020 to accommodate our commercial and infrastructure expansion which could result in a moderate increase in facility costs. On May 17, 2019, we entered into a vehicle fleet lease with a company to acquire motor vehicles for certain employees. The vehicle fleet lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. We began leasing vehicles under the vehicle fleet lease in March 2020.
Off-Balance
Sheet Arrangements
We do not have any
off-balance
sheet arrangements.
Critical Accounting Policies and Estimates
Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our condensed consolidated financial statements. We evaluate our estimates, judgments, and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. A summary of our critical accounting policies is presented in Part II, Item 7, of our Annual Report on Form
10-K
for the year ended December 31, 2019 and Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form
10-Q.
There have been no material changes to our critical accounting policies during the three and nine months ended September 30, 2020. With the launch of product sales during the first quarter of 2020, the accounting policy for revenue recognition which includes the reserves for variable consideration, which was previously developed, was implemented.
 
31
The discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States, or U.S. GAAP. The preparation of these financial statements requires management to make estimates and assumptions that affect reported amounts of assets and liabilities as of the date of the balance sheet and reported amounts of revenues and expenses for the periods presented. Judgments must also be made about the disclosure of contingent liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Management makes estimates and exercises judgment in research and development, including clinical trial accruals. Actual results may differ from those estimates and under different assumptions or conditions.
Recently Issued Accounting Pronouncements
We review new accounting standards to determine the expected financial impact, if any, that the adoption of each such standard will have. For the recently issued accounting standards that we believe may have an impact on our financial statements, see “Recently Issued Accounting Standards” in Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form
10-Q,
and “Recently Issued Accounting Standards” in Note 2 to our audited consolidated financial statements and “Recently Issued Accounting Pronouncements” in our Annual Report on
Form 10-K
for the year ended December 31, 2019 filed on March 2, 2020.
Certain Factors That May Affect Future Results of Operations
The SEC encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on
Form 10-Q
contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: the accuracy of our estimates regarding expenses, future revenues, uses of cash, cash equivalents and investment securities, capital requirements and the need for additional financing; our expectations regarding our commercialization of CAPLYTA, including the impact of
COVID-19
on the commercialization of CAPLYTA and our ability to adapt our approach as appropriate; the duration and severity of the
COVID-19
pandemic and its impact on our business; the supply and availability of and demand for our product, the initiation, cost, timing, progress and results of our development activities,
non-clinical
studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approval, or submit an application for regulatory approval, of lumateperone and our other existing product candidates, any product candidates that we may develop, and any related restrictions, limitations, and/or warnings in the label of any approved product candidates; our plans to research, develop and commercialize lumateperone and our other current and future product candidates; the election by any collaborator to pursue research, development and commercialization activities; our ability to obtain future reimbursement and/or milestone payments from our collaborators; our ability to attract collaborators with development, regulatory and commercialization expertise; our ability to obtain and maintain intellectual property protection for our product candidates; our ability to successfully commercialize lumateperone and our other product candidates; the performance of our third-party suppliers and manufacturers and our ability to obtain alternative sources of raw materials; our ability to obtain additional financing; our use of the proceeds from our securities offerings; our exposure to investment risk, interest rate risk and capital market risk; and our ability to attract and retain key scientific or management personnel.
Words such as “may,” “anticipate,” “estimate,” “expect,” “may,” “project,” “intend,” “plan,” “believe,” “potential,” “predict,” “project,” “likely,” “will,” “would,” “could,” “should,” “continue” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, the following: there are no guarantees that CAPLYTA will be commercially successful; we may encounter issues, delays or other challenges in commercializing CAPLYTA; the
COVID-19
pandemic may negatively impact our commercial plans and sales for CAPLYTA; the
COVID-19
pandemic may negatively impact the conduct of, and the timing of enrollment, completion and reporting with respect to, our clinical trials; whether CAPLYTA receives adequate reimbursement from third-party payers; the degree to which CAPLYTA receives acceptance from patients and physicians for its approved indication; challenges associated with execution of our sales activities, which in each case could limit the potential of our product; results achieved in CAPLYTA in the treatment of schizophrenia following commercialization may be different than observed in clinical trials, and may vary among patients; any other impacts on our business as a result of or related to the
COVID-19
pandemic; risks associated with our current and planned clinical trials; we may encounter unexpected safety or tolerability issues with CAPLYTA for the treatment of schizophrenia or in ongoing or future trials and other development activities; our other product candidates may not be successful or may take longer and be more costly than anticipated; product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety
 
32
and/or efficacy in larger-scale or later clinical trials; our proposals with respect to the regulatory path for our product candidates may not be acceptable to the FDA; our reliance on collaborative partners and other third parties for development of our product candidates; and the other risk factors detailed under the heading “Risk Factors” in our most recent Annual Report on Form
10-K,
as updated under the heading “Risk Factors” from time to time in our subsequent periodic and current reports filed with the SEC.
In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form
10-Q
or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form
10-Q.
We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to the Company or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.
 
Item 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Sensitivity.
As of September 30, 2020, we had cash, cash equivalents and marketable securities of approximately $723.3 million consisting of cash deposited in a highly rated financial institution in the United States, in a short-term U.S. Treasury money market fund, and in high-grade corporate bonds and commercial paper. The primary objective of our investment activities is to preserve our capital for the purpose of funding operations. We do not enter into investments for trading or speculative purposes. We believe that we do not have material exposure to high-risk investments such as mortgage-backed securities, auction rate securities or other special investment vehicles within our money-market fund investments. We believe that we do not have any material exposure to changes in fair value as a result of the recent changes in interest rates or through potential changes in the credit worthiness of the issuers of our
available-for-sale
securities. We recognized an unrealized gain of approximately $0.6 million for the nine months ended September 30, 2020, compared to an unrealized gain of approximately $0.1 million for the year
ended of December 31, 2019. We have the ability and plan to hold these investments to maturity. Declines in interest rates, however, would reduce future investment income.
Capital Market Risk.
We currently have limited product revenues and depend on funds raised through other sources. One possible source of funding is through further equity offerings. Our ability to raise funds in this manner depends upon capital market forces affecting our stock price.
 
Item 4.
CONTROLS AND PROCEDURES
(a)
 Evaluation of Disclosure Controls and Procedures
. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in
Rules 13a-15(e)
and
15d-15(e)
under the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this
Form 10-Q,
have concluded that, based on such evaluation, our disclosure controls and procedures were effective at a reasonable assurance level to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure.
(b)
 Changes in Internal Controls
. Beginning January 1, 2020, we implemented ASU
No. 2016-13,
“Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU
2016-13”).
Although the adoption of the new accounting standard did not materially impact our condensed consolidated balance sheet, statements of operations and cash flows as of and for the three months ended September 30, 2020, we did implement new internal control procedures to support the new accounting and reporting processes associated with adopting the guidance. There were no other changes in our internal control over financial reporting identified in connection with the evaluation of such internal control that occurred during the three months ended September 30, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
33
PART II: OTHER INFORMATION
 
Item 1.
LEGAL PROCEEDINGS
We are not currently a party to any material legal proceedings.
 
Item 1A.
RISK FACTORS
Except as set forth below, there have been no material changes to the risk factors discussed in Item 1A. Risk Factors in our Annual Report on Form
10-K
for the year ended December 31, 2019, filed with the Securities and Exchange Commission on March 2, 2020.
The outbreak of the novel strain of coronavirus,
SARS-CoV-2,
or similar public health crises, could have a material adverse impact on our business, financial condition and results of operations, including our commercial operations and sales, clinical trials and preclinical studies.
Public health crises, such as pandemics or similar outbreaks, could adversely impact our business. In December 2019, a novel strain of coronavirus,
SARS-CoV-2,
which causes coronavirus disease 2019
(COVID-19),
surfaced in Wuhan, China. Since then,
SARS-CoV-2
and
COVID-19
have spread to multiple countries, including the United States. The
COVID-19
pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions and other public health safety measures. In response to the spread of
SARS-CoV-2
and
COVID-19,
we have instructed the majority of our office-based employees to work from home. In connection with our commercial launch of CAPLYTA, which is approved by U.S. Food and Drug Administration for the treatment of schizophrenia in adults, our commercial organization and sales force and medical organization are having significantly reduced personal interactions with physicians and customers and increasingly conduct promotional activities virtually, and elected to cease
in-person
interactions with physicians and customers entirely for some period of time in the interest of employee and community safety. Even though certain of our sales force and medical organization have begun to have personal interactions with physicians and customers, we may have to cease such personal interactions depending on the
COVID-19
situation. In addition, the
COVID-19
situation has resulted in a decrease in the number of patient visits to healthcare providers. As a result of the
COVID-19
pandemic, or similar pandemics, we may experience disruptions that could severely impact our business, including our ability to successfully commercialize our only commercial product, CAPLYTA, in the U.S., and these disruptions could negatively impact our sales of CAPLYTA. Business interruptions from the current or future pandemics may also adversely impact the third parties we rely on to sufficiently manufacture CAPYLTA and to produce our product candidates in quantities we require, which may impair the commercialization and our research and development activities.
We are currently conducting clinical trials for our product candidates in many countries, including the United States, Europe and Russia and may expand to other geographies. Timely enrollment of, completion of and reporting on our clinical trials is dependent upon these global clinical trial sites which are, or in the future may be, adversely affected by the
COVID-19
pandemic or other pandemics. Some factors from the
COVID-19
pandemic that have or may adversely affect the timing and conduct of our clinical trials and adversely impact our business generally, include but are not limited to delays or difficulties in clinical site initiation, diversion of healthcare resources away from clinical trials to pandemic concerns, limitations on travel, regulatory delays and supply chain disruptions.
In response to the
COVID-19
pandemic, on March 10, 2020, the FDA announced its intention to temporarily postpone most inspections of foreign manufacturing facilities and products. On March 18, 2020, the FDA announced its intention to temporarily postpone routine surveillance inspections of domestic manufacturing facilities and provided guidance regarding the conduct of clinical trials, which has since been further updated. As of June 23, 2020, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the
COVID-19
pandemic in line with its user fee performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. As of July 2020, utilizing a rating system to assist in determining when and where it is safest to conduct such inspections based on data about the virus’ trajectory in a given state and locality and the rules and guidelines that are put in place by state and local governments, FDA is either continuing to, on a
case-by-case
basis, conduct only mission critical inspections, or, where possible to do so safely, resuming prioritized domestic inspections, which generally include
pre-approval
inspections. Foreign
pre-approval
inspections that are not deemed mission-critical remain postponed, while those deemed mission-critical will be considered for inspection on a
case-by-case
basis. FDA will use similar data to inform resumption of prioritized operations abroad as it becomes feasible and advisable to do so. The FDA may not be able to maintain this pace and delays or setbacks are possible in the future. Should FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, FDA has stated that it generally intends to issue a complete response letter. Further, if there is inadequate information to make a determination on the acceptability of a facility, FDA may defer action on the application until an inspection can be completed. Additionally, regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the
COVID-19
pandemic. If global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business.
 
34
The
COVID-19
pandemic continues to rapidly evolve, and the severity and duration of the pandemic remain uncertain. The extent to which the pandemic impacts our business, including our commercial results, clinical trials, and preclinical studies will depend on future developments, which are highly uncertain.
We have a limited number of authorized shares of common stock available for issuance, which may impair our ability to issue additional shares for future capital raising transactions or strategic transactions unless we obtain stockholder approval to amend our certificate of incorporation to increase the number of authorized shares of common stock.
Following the closing of our September 2020 underwritten public offering of common stock, we have a limited number of authorized shares of common stock available for future issuance that are not already issued or reserved for issuance. We have 100.0 million authorized shares of common stock. As of September 30, 2020, we had 80.1 million shares of common stock outstanding, 7.7 million shares of common stock issuable upon the exercise of outstanding stock options or the vesting of outstanding restricted stock units, and 7.2 million shares of common stock reserved for future issuance under our equity compensation plans. As a result, as of September 30, 2020, we had approximately 5.0 million authorized shares of common stock available for issuance. We will remain limited by the number of additional shares available for future capital raising transactions or strategic transactions unless we obtain stockholder approval to amend our restated certificate of incorporation to increase the number of authorized shares of common stock. This may cause a delay in our future capital raising, collaboration, partnership or other strategic transactions, and may have a material adverse effect on our business and financial condition.
 
Item 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Unregistered Sales of Equity Securities
Not applicable.
Issuer Purchases of Equity Securities
We did not repurchase any of our equity securities during the quarter ended September 30, 2020.
 
Item 3.
DEFAULTS UPON SENIOR SECURITIES
Not applicable.
 
Item 4.
MINE SAFETY DISCLOSURES
Not applicable.
 
Item 5.
OTHER INFORMATION
Not applicable.
 
35
Item 6.
EXHIBITS
 
Exhibit
Number
   
Exhibit Description
   
Filed
Herewith
   
Incorporated by
Reference herein
from Form
or Schedule
   
Filing Date
   
SEC File/
Reg. Number
  10.1*
    Master Services Agreement, effective as of January 10, 2017, by and between ITI Limited and Lonza Ltd.    X         
  31.1
    Certification of the Registrant’s Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.    X         
  31.2
    Certification of the Registrant’s Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.    X         
  32
    Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.    X         
101
    The following materials from the Registrant’s Quarterly Report on
Form 10-Q
for the quarter ended September 30, 2020, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of September 30, 2020 (unaudited) and December 31, 2019 (audited), (ii) Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2020 and 2019, (iii) Condensed Consolidated Statements of Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2020 and 2019, (iv) Condensed Consolidated Statements of Stockholders’ Equity (unaudited) for the three and nine months ended September 30, 2020 and 2019, (v) Condensed Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2020 and 2019, and (vi) Notes to Condensed Consolidated Financial Statements (unaudited).		    X         
104
    Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).    X         
 
*
Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets (“[***]”) because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
 
36
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
    INTRA-CELLULAR THERAPIES, INC.
Date: November 9, 2020     By:  
/s/ Sharon Mates, Ph.D.
      Sharon Mates, Ph.D.
      Chairman, President and Chief Executive Officer
Date: November 9, 2020     By:  
/s/ Lawrence J. Hineline
      Lawrence J. Hineline
      Senior Vice President of Finance and Chief Financial Officer
 
37
EX-10.1 2 d18633dex101.htm EX-10.1 EX-10.1

Exhibit 10.1

[Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.]

Master Services Agreement

Manufacture of ITI-007

CONFIDENTIAL

Manufacturing Services Agreement

(the “Agreement”)

by and between

Lonza Ltd

Münchensteinerstrasse 38

CH-4002 Basel

Switzerland

- hereinafter “Lonza” -

and

ITI Limited

2 Church Street, Hamilton HM 11, Bermuda

- hereinafter “Customer” -

Effective as of January 10, 2017 (the “Effective Date”)

 

CONFIDENTIAL

 

Table of Contents

 

          Page  
1    Definitions and Interpretation      1  
2    Performance of Services      5  
3    Project Management / Steering Committee      6  
4    Quality      7  
5    Insurance      7  
6    Forecasting, Ordering and Cancellation      7  
7    Delivery and Acceptance      9  
8    Price and Payment      10  
9    Capital Equipment      11  
10    Intellectual Property      11  
11    Warranties      12  
12    Indemnification and Liability      13  
13    Confidentiality      14  
14    Term and Termination      15  
15    Force Majeure      16  
16    Miscellaneous      16  

Appendix A

Appendix B

 

CONFIDENTIAL

 

Recitals

WHEREAS, Customer is engaged in the development and research of certain products and requires assistance in the development and manufacture of product;

WHEREAS, Lonza and its Affiliates have expertise in the evaluation, development and manufacture of products;

WHEREAS, Customer wishes to engage Lonza for Services relating to the development and manufacture of the Product as described in this Agreement; and

WHEREAS, Lonza, or its Affiliate, is prepared to perform such Services for Customer on the terms and subject to the conditions set out herein.

NOW, THEREFORE, in consideration of the mutual promises contained herein, and for other good and valuable consideration, the parties intending to be legally bound, agree as follows:

 

1

Definitions and Interpretation

 

“Affiliate”   

means any company, partnership or other entity which directly or indirectly Controls, is Controlled by or is under common Control with the relevant Party. “Control” means the ownership of more than fifty percent (50%) of the issued share capital or the legal power to direct or cause the direction of the general management and policies of the relevant Party.

“Agreement”   

means this agreement incorporating all Appendices, as amended from time to time by written agreement of the Parties.

“Applicable Laws”   

means all relevant U.S. and European Union federal, state and local laws, statutes, rules, and regulations which are applicable to a Party’s activities hereunder, including, without limitation, the applicable regulations and guidelines of any Governmental Authority and all applicable cGMP together with amendments thereto.

“Approval”   

means the first marketing approval by the FDA or EMA of Product from the Facility for commercial supply.

“Background Intellectual Property”   

means any Intellectual Property either (i) owned or controlled by a Party prior to the Effective Date or (ii) developed or acquired by a Party independently from the performance of the Services hereunder during the Term of this Agreement.

“Batch”   

means the Product derived from a single run of the Manufacturing Process.

“Batch Price”   

means the Price of each Batch.

“Campaign”   

means a series of no less than three (3) cGMP Batches manufactured consecutively.

“Cancellation Fee”   

has the meaning given in Clause 6.6.

 

1

CONFIDENTIAL

 

“Capital Equipment”   

means those certain pieces of equipment described in the Project Plan used to produce the Product that are purchased by Customer or for which Customer reimburses Lonza, including, without limitation, the related documentation regarding the design, validation, operation, calibration and maintenance of such equipment.

“Certificate of Analysis”   

means a document prepared by Lonza for each Batch that lists each of the tests performed by Lonza or approved External Laboratories, the Specifications for each test and the test results.

“Certificate of Compliance”   

means a document prepared by Lonza: (i) listing the manufacturing date, unique Batch number, and concentration of Product in such Batch, (ii) certifying that such Batch was manufactured in accordance with the Master Batch Record and cGMP, if applicable.

“cGMP”   

means those laws and regulations applicable in the U.S. and Europe, relating to the manufacture of medicinal products for human use, including, without limitation, current good manufacturing practices as specified in the ICH guidelines, including without limitation, ICH Q7A “ICH Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients”, US Federal Food Drug and Cosmetic Act at 21CFR (Chapters 210, 211, 600 and 610) and the Guide to Good Manufacturing Practices for Medicinal Products as promulgated under European Directive 91/356/EEC. For the avoidance of doubt, Lonza’s operational quality standards are defined in internal cGMP policy documents.

“cGMP Batches”   

means any Batches which are required under the Project Plan to be manufactured in accordance with cGMP.

“Change”   

means any change to the Services, pricing or Scope of Work incorporated into a written amendment to the Agreement in accordance with clause 16.2 or effected in accordance with the Quality Agreement.

“Commencement Date”   

means the date of commencement of manufacturing activities for a Batch hereunder.

“Competitor”   

means an entity that derived greater than twenty-five (25) percent of its revenues from providing contract manufacturing services to third parties in the last completed fiscal year prior to the date of the proposed assignment.

“Confidential Information”   

means Customer Information and Lonza Information, as the context requires.

“Customer Information”   

means all technical and other information not known to Lonza or in the public domain relating to the Manufacturing Process and the Product, from time to time supplied by the Customer to Lonza, including any materials supplied by Customer to Lonza in accordance with the Project Plan.

 

2

CONFIDENTIAL

 

“Customer Materials”   

means any Raw Materials, components of Product, or other materials of any nature provided by Customer.

“EMA”   

means the European Medicines Agency, or any successor agency thereto.

“Engineering Batches”   

means a Batch that is intended to demonstrate the transfer of the Manufacturing Process to the Facility.

“External Laboratories”   

means any Third Party instructed by Lonza, with Customer’s prior consent, to conduct any of the activities required to complete the Services.

“Facility”   

means Lonza’s manufacturing facilities in [***] or such other Lonza facility as may be agreed upon by the Parties.

“FDA”   

means the United States Food and Drug Administration, or any successor agency thereto.

“Governmental Authority”   

means any Regulatory Authority and any national, multi-national, regional, state or local regulatory agency, department, bureau, or other governmental entity in the U.S. or European Union.

“Intellectual Property”   

means (i) inventions (whether or not patentable), patents, trade secrets, copyrights, trademarks, trade names and domain names, rights in designs, rights in computer software, database rights, rights in confidential information (including know-how) and any other intellectual property rights, in each case whether registered or unregistered, (ii) all applications (or rights to apply) for, and renewals or extensions of, any of the rights described in the foregoing clause (i) and (iii) and all rights and applications that are similar or equivalent to the rights and application described in the foregoing clauses (i) and (ii), which exist now, or which come to exist in the future, in any part of the world.

“Lonza Information”   

means all information that is proprietary to Lonza or any Affiliate of Lonza and that is maintained in confidence by Lonza or any Affiliate of Lonza and that is disclosed by Lonza or any Affiliate of Lonza to Customer under or in connection with this Agreement, including without limitation, any and all Lonza know-how and trade secrets.

“Manufacturing Process”   

means the production process provided by Customer for the manufacture of Product, as such process may be improved or modified from time to time by agreement of the Parties in writing.

“Master Batch Record”   

means the document, proposed by Lonza and approved by Customer, which defines the manufacturing methods, test methods and other procedures, directions and controls associated with the manufacture and testing of Product, and which may be amended from time to time by agreement of the Parties in writing.

“New Customer Intellectual Property”   

has the meaning given in Clause 10.2.

 

3

CONFIDENTIAL

 

“New General Application Intellectual Property”   

has the meaning given in Clause 10.3.

“Party”   

means each of Lonza and Customer and, together, the “Parties”.

“Price”   

means the price for the Services and Products as set out in Appendix A.

“Process Validation Batch”   

means a Batch that is produced with the intent to show reproducibility of the Manufacturing Process and is required to complete process validation studies.

“Product”   

means the proprietary molecule identified by Customer as ITI-007, to be manufactured by Lonza for Customer using the Manufacturing Process as specified in the Project Plan.

“Project Plan”   

means the plan(s) describing the Services to be performed by Lonza under this Agreement, including any update and amendment of the Project Plan to which the Parties may agree from time to time in writing. The initial Project Plan is attached hereto as Appendix A.

“Quality Agreement”   

means the written quality agreement, to be entered into by the Parties in accordance with Section 4.1 of this Agreement, setting out the responsibilities of each of the Parties in relation to Product quality as required for compliance with cGMP, and which shall be consistent with this Agreement and Applicable Laws (including meeting the requirements of the FDA’s then-current Guidance for Industry regarding “Contract Manufacturing Arrangements for Drugs: Quality Agreements” and the ICH guidance regarding “Q10 Pharmaceutical Quality Systems”).

“Raw Materials”   

means all ingredients, solvents and other components of the Product required to perform the Manufacturing Process or Services set forth in the bill of materials detailing the same (but excluding any consumables). “Regulatory Authority” means the FDA, EMA and any other similar regulatory authorities as may be agreed upon in writing by the Parties.

“Regulatory Approval”   

means any approval (including any supplements, amendments, pre- and post-marketing approvals, and pricing and reimbursement approvals, and including the Approval), licenses, registrations or any other authorizations required by a Regulatory Authority necessary for the manufacture, distribution, sale or use of the Product.

“Release”   

has the meaning given in Clause 7.1.

“Services”   

means all or any part of the services to be performed by Lonza under this Agreement (including, without limitation, process and analytical method transfer; process development; process optimization; validation; clinical and commercial manufacturing; and quality control and quality assurance activities), particulars of which are set out in a Project Plan.

 

4

CONFIDENTIAL

 

“Specifications”   

means the mutually agreed upon specifications, including test procedures and acceptance criteria, of the Product as specified in Appendix B, which may be amended from time to time in accordance with this Agreement.

“Term”   

has the meaning given in Clause 14.1.

“Third Party”   

means any party other than Customer, Lonza and their respective Affiliates.

In this Agreement references to the Parties are to the Parties to this Agreement, headings are used for convenience only and do not affect its interpretation, references to a statutory provision include references to the statutory provision as modified or re-enacted or both from time to time and to any subordinate legislation made under the statutory provision, references to the singular include the plural and vice versa, and references to the word “including” are to be construed without limitation.

 

2

Performance of Services

 

2.1

Performance of Services. Subject to Clause 2.3, Lonza shall itself and through its Affiliates, diligently carry out the Services as provided in the Project Plan and in accordance with this Agreement and use commercially reasonable efforts to perform the Services without any material defect and according to the estimated timelines as set forth in the Project Plan. Lonza shall retain appropriately qualified and trained personnel with the requisite knowledge and experience to perform the Services in accordance with this Agreement. Lonza may not subcontract or delegate any of its rights or obligations under this Agreement to perform the Services without Customer’s prior written consent not to be unreasonably withheld or delayed; provided, that any approved subcontractors and approved External Laboratories shall be subject to the same obligations and other provisions contained in this Agreement or any applicable Project Plan, including the obligation to maintain Customer Information in confidence under terms no less stringent than as set forth herein. Except as otherwise agreed to by the Parties or as otherwise agreed to under the Quality Agreement, Lonza shall be liable and responsible for the compliance by such subcontractors and External Laboratories with the applicable provisions of this Agreement.

 

2.2

Technology Transfer. The Parties expressly agree that they shall work together to transfer the Manufacturing Process to the Facility, including implementing the technology transfer plan set forth in Project Plan. Customer shall fully support such technology transfer as reasonably requested by Lonza.

 

2.3

Engineering Batches. Lonza shall manufacture Engineering Batches in accordance with the Project Plan. Customer shall have the right to make whatever further use of the non-cGMP Engineering Batches as it shall determine, provided that Customer pays for such Batches, such use is not for human use and does not violate any Applicable Laws. Lonza makes no warranty that Engineering Batches will meet cGMP or the Specifications. If Lonza determines that an Engineering Batch does meet cGMP and the Specifications, it will release such Engineering Batch as a cGMP Batch. Regardless of whether any Engineering Batch meets cGMP or the Specifications, Customer shall pay to Lonza the Price for such Engineering Batch in accordance with the terms of this Agreement.

 

2.4

cGMP Batches. Lonza will, in accordance with the terms of this Agreement and the Quality Agreement, manufacture at the Facility and Release to Customer, cGMP Batches that comply with the Manufacturing Process, cGMP and the Specifications and this Agreement, and each released Batch will be accompanied by a Certificate of Analysis; provided, however, that cGMP manufacture shall not commence until at least one (1) successful Engineering Batch has been manufactured in compliance with cGMP and Specifications. Prior to commencement of cGMP manufacturing, Lonza shall review the process assumptions. In the event that there is a material difference in the process assumptions as compared with the process results demonstrated during the manufacture

 

5

CONFIDENTIAL

 

 

of Engineering Batches, the Parties shall meet to discuss in good faith a revision to the Batch Price to reflect such difference.

 

2.5

Process Validation Batches. Lonza shall manufacture and deliver Process Validation Batches as mutually agreed by Parties sufficient to document the operability and reproducibility of the Manufacturing Process and permit the Parties to complete and file the necessary regulatory documents.

 

  2.5.1

Prior to commencement of Process Validation Batches, Lonza and Customer shall agree a process validation plan identifying the validation requirements of the Manufacturing Process. All process validation activities are excluded from the Price of Process Validation Batches shall be approved by the Customer in advance and shall be paid for by the Customer at the Price set out in the applicable Project Plan.

 

  2.5.2

Any regulatory support activities (including pre-Approval inspection) required and agreed to by Customer to support the Approval of the Product from the Facility shall be performed and supported by Lonza as reasonably requested by Customer. All such regulatory support activities are excluded from the Price of Process Validation Batches, shall be approved by the Customer in advance, and shall be paid for by the Customer at the Price set out in the applicable Project Plan.

 

2.6

Supply of Customer Information and Customer Materials. Customer shall supply to Lonza all Customer Information and Customer Materials and other information or materials that may be reasonably required by Lonza to perform the Services. Lonza shall not be responsible for any delays arising out of Customer’s failure to provide to Lonza such Customer Information, Customer Materials, or other information or materials reasonably required to perform the Services. Customer shall be responsible for all additional costs and expenses arising out of such delay, including, if applicable, any idle Facility capacity costs.

 

2.7

Raw Materials. Lonza shall procure all required Raw Materials as well as consumables other than those Raw Materials that are Customer Materials. Customer shall be responsible for payment for all consumables and Raw Materials ordered or irrevocably committed to be procured by Lonza hereunder where the Parties agree that such Raw Materials are included in the Price as identified in the Project Plan. Upon cancellation of any Batch or termination of the Agreement, all unused Raw Materials shall be paid for by Customer within thirty (30) days of invoice and at Customer’s option will either be (a) held by Lonza for future use for the production of Product, (b) delivered to Customer, or (c) disposed of by Lonza. Lonza may not use any Raw Materials or Customer Materials for any purpose other than to perform Services in accordance with this Agreement.

 

3

Project Management / Steering Committee

 

3.1

Project Plans. With respect to a new project to be governed by this Agreement, a new Project Plan shall be added by agreement in a writing signed by the Parties and appended to Appendix A. Each Project Plan shall include a description of the Services to be provided, the Product to be manufactured, Specifications, a schedule for completion of the Project Plan, pricing details, and such other information as is necessary for relevant Services. In the event of a conflict between the terms of a Project Plan and this Agreement, the terms of this Agreement will govern, except to the extent that the applicable Project Plan expressly and specifically states an intent to supersede this Agreement on a specific matter.

 

3.2

Project Management. With respect to each Project Plan, each Party will appoint a project manager who will be the person responsible for overseeing the Project Plan on behalf of the respective Party.

 

3.3

Steering Committee. Each Party shall name a mutually agreed upon equal number of representatives for the Steering Committee, which shall meet twice per calendar year, or as

 

6

CONFIDENTIAL

 

 

otherwise mutually agreed by the Parties. In the event that a Steering Committee dispute cannot be resolved, such dispute shall be escalated to a senior executive of each of Customer and Lonza.

The primary function of the Steering Committee is to ensure the ongoing communication between the Parties and to discuss and resolve any issues arising under this Agreement. In addition to the primary function described above, the Steering Committee shall take on the following responsibilities:

 

  3.3.1

discuss and seek resolution of issues around management of the Services;

 

  3.3.2

agree and monitor deadlines and milestones for the Services; and

 

  3.3.3

discuss and recommend any changes to the Services (although such changes will not take effect until they have been incorporated into a written amendment to the Project Plan which has been signed by the Parties).

The Steering Committee may not waive or modify the terms of this Agreement, or take any action that would bind a Party without its prior written consent.

 

3.4

Person in Plant. Customer shall be permitted to have, at no additional cost, one (1) employee at the Facility as reasonably requested by Customer, at any time during the Manufacturing Process for the purpose of observing, reporting on, and consulting as to the performance of the Services. Such employee shall be subject to and agree to abide by confidentiality obligations to Third Parties and Lonza’s customary practices and operating procedures regarding persons in plant, and such employee agrees to comply with all instructions of Lonza’s employees at the Facility.

 

4

Quality

 

4.1

Responsibility for quality assurance and quality control of Product shall be allocated between Customer and Lonza as set forth in the Quality Agreement and in Lonza standard operating procedures. If there is a conflict between the terms and conditions of this Agreement and the Quality Agreement, the terms and conditions of this Agreement shall prevail. If the Quality Agreement is not in place at the Effective Date, Lonza and Customer commit to enter into the Quality Agreement in a timely manner, but in no event later than the commencement of cGMP manufacturing. Provisions regarding inspections by Regulatory Authorities and audits shall be set out in the Quality Agreement.

 

5

Insurance

 

5.1

Each Party shall, during the Term and [***] after delivery of the last Product manufactured or Services provided under this Agreement, obtain and maintain at its own cost and expense from a qualified insurance company, comprehensive general liability insurance including, but not limited to product liability coverage in the amount of at least [***] per claim in the case of a Lonza insurance policy and [***] in the case of a Customer insurance policy. Each Party shall provide the respective other Party with a certificate of such insurance upon reasonable request.

 

6

Forecasting, Ordering and Cancellation

 

6.1

Forecasting and Ordering. No later than [***], Customer shall supply Lonza with a written forecast showing Customer’s good faith estimated quarterly requirements for Batches for the following [***] (the “Forecast”). No later than [***] following Lonza’s receipt of a Forecast, Lonza shall provide written notice to Customer with an estimated production schedule showing the estimated Commencement Date and delivery date of each Batch; provided that if the Forecast for any [***] exceeds the capacity reserved for such [***] in Section 6.4 of this Agreement or agreed between the Parties in accordance with Section 6.9 of this Agreement (the “Reserved Capacity”), Lonza

 

7

CONFIDENTIAL

 

 

shall notify Customer within [***] of receipt of the Forecast of its ability (as of the date of receipt of the Forecast) to manufacture the number of Batches forecasted in excess of the Reserved Capacity. The [***] of any Forecast shall be binding (“Binding Forecast”). Except as otherwise provided in Section 6.4 below, binding purchase orders (“Purchase Orders”) for the [***] shall be submitted by Customer on the basis of the Binding Forecast within [***] of submission of the Forecast. No Forecast shall amend any previous Binding Forecast, and all Purchase Orders shall be for an amount not less than [***].

 

6.2

Order Confirmation. Lonza shall confirm the delivery date(s) and quantity of Product to be delivered as set out in each Purchase Order within [***] days of receipt from Customer of the relevant Purchase Order. Upon confirmation, each Purchase Order will be regarded by the Parties as a binding commitment by Lonza to manufacture and to deliver to Customer the relevant quantity of Product according to the requirements set out in such Purchase Order. Lonza shall confirm and accept each Purchase Order that is consistent with the corresponding Forecast. Any delivery date set forth in Lonza’s written confirmation of a purchase order shall be an estimated delivery date only. All ordered Batches shall be scheduled in a single Campaign in each calendar year unless otherwise agreed by Lonza. Any additional or inconsistent terms or conditions of any Customer purchase order, acknowledgement, invoice, or similar standardized form given or received pursuant to this Agreement shall have no effect and such terms and conditions are hereby rejected.

 

6.3

Rescheduling. Lonza shall have the right to reschedule a Commencement Date of any Batch or Campaign upon reasonable prior written notice to Customer, provided that the rescheduled Commencement Date is no earlier or no later than [***] from the Commencement Date originally estimated at the time of Lonza’s acceptance of the binding purchase order. If the Customer requests to change the Commencement Date, Lonza will make all reasonable attempts to accommodate the request; provided, however, in the event that this change would impact other projects scheduled for occupancy in the designated suite or suites, manufacture of the Customer’s Batch or Campaign may be delayed until an adequate time period is available in the Facility schedule, and any such change requested by Customer may result in a rescheduling fee, all of which shall be confirmed by their Parties in writing. Any delay requested by Customer of more than [***] shall be considered a cancellation pursuant to Section 6.6.

 

6.4

Dedicated Supply: Lonza will reserve capacity for Customer, sufficient for the manufacture of approximately (i) [***] for [***], until [***], at which time the commitment for [***] capacity becomes binding; (ii) [***] for [***]; and (iii) [***] for [***]. Customer may cancel this reservation in writing by [***], only if Approval is not received, on or before end [***] without penalty. For [***], the Reserved Capacity becomes binding [***] prior to the estimated Commencement Date of the campaign.

 

6.5

Product Quantities. Quantities of Product arising from a Campaign up to a maximum of [***] above or below the Purchase Order will be invoiced according to the [***] price as outlined in the Project Plan. In case of additional surplus quantities or quantities below [***] of the target quantity the Parties will negotiate in good faith a reasonable price. The Purchase Order shall be fulfilled if at least [***] of the target quantity is delivered.

 

6.6

Cancellation of a Binding Purchase Order. Customer may cancel a binding purchase order upon written notice to Lonza, subject to the payment of a cancellation fee as calculated below (the “Cancellation Fee”):

 

  6.6.1

In the event that Customer provides written notice of cancellation to Lonza [***] prior to the Commencement Date of one or more Batches, then [***] of the Batch Price of each such Batch cancelled is payable; or

 

  6.6.2

In the event Customer provides written notice of cancellation more than [***] prior to the Commencement Date of a Batch, then [***] Cancellation Fee is payable.

 

8

CONFIDENTIAL

 

6.7

Payment of Cancellation Fee. Any Cancellation Fee shall be payable within [***] following the written notice of cancellation associated with the cancelled Batch. Any Cancellation Fee shall include all costs associated with the cancelled Batch, including any Raw Materials.

 

6.8

Replacement Project. Notwithstanding the foregoing, Lonza will use commercially reasonable efforts to secure a new project (but excluding any project then under contract with Lonza) for the cGMP manufacturing space, and for the same dates and duration that would have been occupied by Customer, and then, in such case, the Cancellation Fee for each Batch cancelled that is replaced by a Batch of the new project shall be reduced by an amount equal to [***] of the production fees associated with such replacement Batch.

 

6.9

Commercial Supply Negotiations: Prior to [***], Customer and Lonza will enter good faith negotiations to develop and finalize an operating model that can support projected commercial supply of Product starting in [***].

 

7

Delivery and Acceptance

 

7.1

Delivery. All Product shall be delivered FCA (as defined by Incoterms® 2010) the Facility. Lonza shall deliver to Customer the Certificate of Analysis, the Certificate of Compliance and such other documentation as is reasonably required to meet all applicable regulatory requirements of the Governmental Authorities not later than the date of delivery of Batches to the common carrier chosen by Customer (the “Release”). With respect to any Customer Materials, title and risk of loss shall remain with the Customer and shall not transfer to Lonza. With respect to Product, title and risk of loss shall transfer to Customer upon Release in accordance with this provision.

 

7.2

Storage. Customer shall arrange for shipment and take delivery of such Batch from the Facility, at Customer’s expense, within [***] after Release or pay applicable storage costs. Lonza shall provide storage on a bill and hold basis for such Batch(es) at no charge for up to [***]; provided that any additional storage beyond [***] will be subject to availability and, if available, will be charged to Customer and will be subject to a separate agreement. In addition to Section 8.2, Customer shall be responsible for all value added tax (VAT) and any other applicable taxes, levies, import, duties and fees of whatever nature imposed as a result of any storage. Notwithstanding anything to the contrary contained in this Agreement, in no event shall Lonza be required to store any Batch for more than [***] after Release. Within [***] following a written request from Lonza, Customer shall provide Lonza with a letter in form satisfactory to Lonza confirming the bill and hold status of each stored Batch.

 

7.3

Acceptance/Rejection of Product.

 

  7.3.1

Promptly following Release of Batches, Customer shall inspect such Batches and shall have the right to test such Batches to determine compliance with the Specifications. Customer shall notify Lonza in writing of any rejection of a Batch based on any claim that it fails to meet Specifications within [***] of Release, after which time all unrejected Batches shall be deemed accepted. Customer shall inform Lonza in writing in case of concealed or latent defects (i.e. not discovered by routine quality control means), promptly upon discovery of such defects but no later than [***] after delivery of the Product.

 

  7.3.2

In the event that Lonza believes that a Batch has been incorrectly rejected, Lonza may require that Customer provide to it Batch samples for testing. Lonza may retain and test the samples of such Batch. In the event of a discrepancy between Customer’s and Lonza’s test results such that Lonza’s test results fall within relevant Specifications, or there exists a dispute between the Parties over the extent to which such failure is attributable to a given Party, the Parties shall cause an independent laboratory promptly to review records, test data and perform comparative tests and analyses on samples of the Product that allegedly fails to conform to Specifications. Such independent laboratory shall be mutually agreed upon by the Parties. The independent laboratory’s results shall be in writing and shall be

 

9

 

final and binding save for manifest error. Unless otherwise agreed to by the Parties in writing, the costs associated with such testing and review shall be borne by the Party against whom the independent laboratory rules.

 

  7.3.3

For Engineering Batches, Lonza shall, at its own expense, reprocess any Engineering Batch or, if reprocessing is not possible, replace any Engineering Batch that failed to conform with the Specifications (a “Failed Engineering Batch”). Following completion of Engineering Batches, before proceeding to Process Validation Batches, the Parties shall agree, in writing, that the Process is validation ready. Following such agreement to proceed with Process Validation Batches, Lonza shall, at its own expense, reprocess any Batch or, if reprocessing is not possible, replace any Batch that failed to conform with the Specifications (a “Failed Batch”). Such reprocessing or replacement shall be made as promptly as practicable, in light of available manufacturing capacity. Where possible, any replacement Batch shall be manufactured with the next scheduled cGMP Batch or Campaign. Customer acknowledges and agrees that its sole remedy with respect to a Failed Engineering Batch or a Failed Batch is as set forth in this Clause 7.3.3, and in furtherance thereof, Customer hereby waives all other remedies at law or in equity regarding the foregoing claims. Lonza shall be responsible for the cost of Raw Materials or Customer Materials consumed in any Failed Batch. Customer shall be responsible for the cost of Raw Materials or Customer Materials consumed in any Failed Engineering Batch; provided, however that in the event that it is determined (by the Parties or an independent laboratory) that a Failed Engineering Batch was solely due to Lonza’s material breach of its obligations hereunder, gross negligence or operator error, then Lonza shall be responsible for the cost of Raw Materials or Customer Materials consumed in such Failed Engineering Batch. Lonza shall promptly destroy each Failed Engineering Batch or Failed Batch at its cost and expense, if reprocessing is not possible.

 

8

Price and Payment

 

8.1

Pricing for the Services provided by Lonza are set out in, and based on the assumptions and information set out in, the applicable Project Plan. In the event of changes to the Services based on Customer’s request, the Parties shall discuss and agree upon any additional costs.

 

8.2

Unless otherwise indicated in writing by Lonza, all Prices and charges are exclusive of value added tax (VAT) and of any other applicable taxes, levies, import, duties and fees of whatever nature imposed by or under the authority of any government or public authority and all such charges applicable to the Services shall be paid by Customer (other than taxes based on Lonza’s income).

 

8.3

Lonza shall issue invoices to Customer for [***] of the Price for Products or Services upon the confirmation of a Purchase Order for the applicable Batch or Campaign, [***] of the Price for Products or Services upon commencement of the manufacturing of Products or Services, and [***] upon Release of applicable Batches or completion of applicable Services, unless otherwise stated in the Project Plan. To the extent not included in the Price, charges for Raw Materials for each Batch shall be invoiced upon the Release of each Batch, provided, that any Raw Materials required to be ordered more than [***] in advance shall be invoiced [***] at the time of order by Lonza and [***] upon Release of the Batch. All undisputed invoices are payable within [***] of date of invoice. Payment shall be made without deduction, deferment, set-off, lien or counterclaim.

 

8.4

If in default of payment of any undisputed invoice on the due date, interest shall accrue on any amount overdue at the lesser of (i) rate of [***] per month above the London Interbank Offered Rate (LIBOR) or (ii) [***]; and Lonza shall, at its sole discretion, and without prejudice to any other of its accrued rights, be entitled upon [***] notice to suspend the provision of the Services and or delivery of Product until all overdue amounts have been paid in full including interest for late payments.

 

10

CONFIDENTIAL

 

8.5

Price adjustments.

 

  8.5.1

Not more than once per calendar year, Lonza may adjust the Price in accordance with the European Union Manufacturing Producer Prices Index (or any successor index) increase for the previous calendar year. The new Price reflecting such Batch Price adjustment shall be effective for any Batch for which the Commencement Date is on or after the date of Lonza’s notice to Customer of the Price adjustment.

 

  8.5.2

In addition to the above, the Price may be changed by Lonza, upon reasonable prior written notice to Customer (providing reasonable detail and documentation in support thereof), to reflect (i) an increase in variable costs (such as energy or Raw Materials) by more than [***] (based on the initial Price or any previously amended Price), or for a process adjustment or assumption changes, and (ii) any material change in an environmental, safety or regulatory standard that substantially impacts Lonza’s cost and ability to perform the Services.

 

  8.5.3

The Prices outlined in the Project Plan are based on the currency exchange rate of the [***] to the United States Dollars (USD) at the Effective Date. Lonza shall bear the risk of any increase or decrease of the [***]/USD exchange rate up to [***] from the base currency exchange rate. If the [***]/USD exchange rate is more than [***] the base currency exchange rate at the date on which the Prices become due for payment, then the Prices will be adjusted to compensate all exchange rate differences higher than [***]. The currency adjustments to be made, if any, shall be based on the market rate of exchange as published by Bloomberg.

 

9

Capital Equipment

 

9.1

Any Capital Equipment required for the performance of the Services shall be acquired on terms to be agreed by the Parties prior to commencement of the relevant Services.

 

10

Intellectual Property

 

10.1

Except as expressly otherwise provided herein, neither Party will, as a result of this Agreement, acquire any right, title, or interest in any Background Intellectual Property of the other Party, including any improvements made thereto during the Services under this Agreement.

 

10.2

Subject to Clause 10.3, Customer shall own all right, title, and interest in and to any and all Intellectual Property that Lonza and its Affiliates, the External Laboratories or other contractors or agents of Lonza develops, conceives, invents, first reduces to practice or makes, solely or jointly with Customer or others, that is a direct derivative of or improvement to Customer Information or Customer Background Intellectual Property, or that cannot be practiced without use of Customer Information or Customer Background Intellectual Property (collectively, the “New Customer Intellectual Property”). For avoidance of doubt, “New Customer Intellectual Property” shall include any material, processes or other items that embody, or that are claimed or covered by, any of the foregoing Intellectual Property, but excluding any New General Application Intellectual Property.

 

10.3

Notwithstanding Clause 10.2, and subject to the license granted in Clause 10.5, Lonza shall own all right, title and interest in Intellectual Property that Lonza and its Affiliates, the External Laboratories or other contractors or agents of Lonza, solely or with each other (and without Customer), develops, conceives, invents, or first reduces to practice or makes in the course of performance of the Services that is generally applicable to the development or manufacture of chemical or biological products or product components (“New General Application Intellectual Property”). For avoidance of doubt, “New General Application Intellectual Property” shall include any material, processes or other items that embody, or that are claimed or covered by, any of the foregoing Intellectual Property.

 

11

CONFIDENTIAL

 

10.4

Lonza hereby assigns to Customer all of its right, title and interest in any New Customer Intellectual Property. Lonza shall execute, and shall require its personnel as well as its Affiliates, External Laboratories or other contractors or agents and their personnel involved in the performance of the Services to execute, any documents reasonably required to confirm Customer’s ownership of the New Customer Intellectual Property, and any documents required to apply for, maintain and enforce any patent or other right in the New Customer Intellectual Property.

 

10.5

Subject to the terms and conditions set forth herein (including the payment of the Price as required above), Lonza hereby grants to Customer a non-exclusive, world-wide, fully paid-up, irrevocable, transferable license, including the right to grant sublicenses, under the New General Application Intellectual Property, to use, sell and import the Product manufactured under this Agreement.

 

10.6

Customer hereby grants Lonza the non-exclusive right to use the Customer Information, Customer Background Intellectual Property and New Customer Intellectual Property during the Term solely for the purpose of fulfilling its obligations under this Agreement and in accordance with the terms of this Agreement.

 

10.7

Customer will have the right to transfer the Manufacturing Process to itself and any Third Party for the manufacture of that Product (but no other product); provided, however, to the extent such technology transfer includes Lonza Confidential Information, Lonza Background Intellectual Property or New General Application Intellectual Property, such technology transfer shall be subject to (i) approval by Lonza in writing; (ii) a reasonable royalty and licensing fee; and (iii) terms to be agreed upon by the Parties. Lonza shall provide reasonably necessary documents to complete such technology transfer and Customer shall reimburse Lonza for any costs (based on a full-time employee rate for such support) and expenses.

 

11

Warranties

 

11.1

Lonza warrants, represents and covenants to Customer that:

 

  11.1.1

the Services shall be performed in accordance with all Applicable Laws;

 

  11.1.2

except with respect to any development services and Engineering Batches, the manufacture of Product shall be performed in accordance with cGMP and will meet the Specifications at the date of delivery;

 

  11.1.3

To its knowledge, any Intellectual Property provided and used by Lonza and its Affiliates in performance of Services which relate to developing, formulation, manufacturing, filling, processing, packaging, analyzing or testing the Product shall not infringe, violate or misappropriate any third party Intellectual Property rights, and this warranty shall not apply to the extent such infringement, violation or misappropriation of any third Party Intellectual Property is based upon, in part or whole, Client’s written instructions, Specifications or use of Client Materials.

 

  11.1.4

Lonza is not debarred, and has not been convicted of a crime which could lead to debarment, under 21 U.S.C. §335(a) or (b) (“the Debarment Act”), and Lonza will not in the performance of its obligations under this Agreement use the services of any person debarred or suspended under the Debarment Act. If Lonza becomes debarred or receives notice of action with respect to its debarment, Lonza shall promptly notify Customer;

 

  11.1.5

no transactions or dealings under this Agreement shall be conducted with or for an individual or entity that is designated as the target of any sanctions, restrictions or embargoes administered by the United Nations, European Union, United Kingdom or the United States of America;

 

12

CONFIDENTIAL

 

  11.1.6

it or its Affiliate holds all necessary permits, registrations, approvals, consents and licenses to enable it to perform the Services at the Facility; and

 

  11.1.7

it has the necessary corporate authorizations to enter into and perform this Agreement.

 

11.2

Customer warrants that:

 

11.3

To its knowledge, Customer has all the rights to Customer Information and Customer Background Intellectual Property necessary to permit Lonza to perform the Services without infringing the Intellectual Property rights of any Third Party and the use of Customer Information and Customer Background Intellectual Property in the performance of the Services shall not infringe any Third Party Intellectual Property rights;

 

11.4

Customer will promptly notify Lonza in writing if it receives or is notified of a formal written claim from a Third Party that Customer Information and Customer Intellectual Property or that the use by Lonza thereof for the provision of the Services infringes any Intellectual Property or other rights of any Third Party; and

 

11.5

Customer has the necessary corporate authorizations to enter into this Agreement.

 

11.6

DISCLAIMER: THE WARRANTIES EXPRESSLY SET FORTH IN THIS AGREEMENT ARE IN LIEU OF ALL OTHER WARRANTIES, AND ALL OTHER WARRANTIES, BOTH EXPRESS AND IMPLIED, ARE EXPRESSLY DISCLAIMED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 

12

Indemnification and Liability

 

12.1

Indemnification by Lonza. Lonza shall indemnify the Customer, its Affiliates, and their respective officers, employees and agents (“Customer Indemnitees”) for any loss, damage, costs and expenses (including reasonable attorney fees) that Customer Indemnitees may suffer as a result of any Third Party claim arising directly out of (i) any material breach of the warranties given by Lonza in Clause 11.1 above or (ii) any claims alleging that the Services (excluding use by Lonza of Customer Information and Customer Background Intellectual Property) infringe any Intellectual Property rights of a Third Party except, in each case, to the extent that such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Customer Indemnitees.

 

12.2

Indemnification by Customer. Customer shall indemnify Lonza, its Affiliates, and their respective officers, employees and agents (“Lonza Indemnitees”) from and against any loss, damage, costs and expenses (including reasonable attorney fees) that Lonza Indemnitees may suffer as a result of any Third Party claim arising directly out of (i) any material breach of the warranties given by Customer in Clause 11.2 above; or (ii) any claims alleging that Lonza’s use of Customer Information or Customer Background Intellectual Property in accordance with this Agreement infringes any Intellectual Property rights of third parties; or (iii) the use, sale, or distribution of any Product, including any claims of product liability but excluding claims covered by Lonza’s indemnification obligation in Section 12.2(ii); except, in each case, to the extent that such claims resulted from the negligence, intentional misconduct or breach of this Agreement by any Lonza Indemnitees.

 

12.3

Indemnification Procedure. If the Party to be indemnified intends to claim indemnification under this Clause 12, it shall promptly notify the indemnifying Party in writing of such claim. The indemnitor shall have the right to control the defense and settlement thereof; provided, however, that any indemnitee shall have the right to retain its own counsel at its own expense. The indemnitee, its employees and agents, shall reasonably cooperate with the indemnitor in the investigation of any liability covered by this Clause 12, and shall not consent to any settlement or judgment of such claim, nor make any admission, without the indemnifying Party’s prior written consent. The failure to deliver prompt written notice to the indemnitor of any claim, to the extent prejudicial to its ability to defend such claim, shall relieve the indemnitor of any obligation to the indemnitee under this Clause 12.

 

13

CONFIDENTIAL

 

12.4

DISCLAIMER OF CONSEQUENTIAL DAMAGES. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL, INDIRECT, SPECIAL, PUNITIVE OR CONSEQUENTIAL DAMAGES, LOST PROFITS OR LOST REVENUES ARISING FROM OR RELATED TO THIS AGREEMENT, EXCEPT TO THE EXTENT RESULTING FROM FRAUD, GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT.

 

12.5

[***]

 

13

Confidentiality

 

13.1

A Party receiving Confidential Information (the “Receiving Party”) agrees to strictly keep secret any and all Confidential Information received during the Term from or on behalf of the other Party (the “Disclosing Party”) using at least the same level of measures as it uses to protect its own Confidential Information, but in any case at least commercially reasonable and customary efforts. Confidential Information shall include information disclosed in any form including but not limited to in writing, orally, graphically or in electronic or other form to the Receiving Party, observed by the Receiving Party or its employees, agents, consultants, or representatives, or otherwise learned by the Receiving Party under this Agreement, which the Receiving Party knows or reasonably should know is confidential or proprietary.

 

13.2

Notwithstanding the foregoing, Receiving Party may disclose to any courts and/or other authorities Confidential Information of the Disclosing Party which is or will be required pursuant to applicable governmental or administrative or public law, rule, regulation or order. In such case the Party that received the Confidential Information will, to the extent legally permitted, inform the other Party promptly in writing and cooperate with the Disclosing Party in seeking to minimize the extent of Confidential Information which is required to be disclosed to the courts and/or authorities.

 

13.3

The obligation to maintain confidentiality under this Agreement does not apply to Confidential Information, which:

 

  13.3.1

at the time of disclosure was publicly available; or

 

  13.3.2

is or becomes publicly available other than as a result of a breach of this Agreement by the Receiving Party; or

 

  13.3.3

as the Receiving Party can establish by competent proof, was rightfully in its possession at the time of disclosure by the Disclosing Party and had not been received from or on behalf of Disclosing Party; or

 

  13.3.4

is supplied to a Party by a Third Party which was not in breach of an obligation of confidentiality to Disclosing Party or any other party; or

 

  13.3.5

is developed by the Receiving Party independently from and without use of the Disclosing Party’s Confidential Information, as evidenced by the Receiving Party’s contemporaneous written records.

 

13.4

The Receiving Party will use the Disclosing Party’s Confidential Information only for the purposes of this Agreement and will not make any use of the Confidential Information for its own separate benefit or the benefit of any Third Party including, without limitation, with respect to research or product development or any reverse engineering or similar testing. The Receiving Party agrees to return or destroy promptly (and certify such destruction) on Disclosing Party’s request all written or tangible Confidential Information of the Disclosing Party, except that one copy of such Confidential Information may be kept by the Receiving Party in its confidential files for record keeping purposes only.

 

14

CONFIDENTIAL

 

13.5

Each Party will restrict the disclosure of Confidential Information to such officers, employees, consultants and representatives of itself and its Affiliates who have been informed of the confidential nature of the Confidential Information and who have a need to know such Confidential Information for the purpose of this Agreement. Prior to disclosure to such persons, the Receiving Party shall bind its and its Affiliates’ officers, employees, consultants and representatives to confidentiality and non-use obligations no less stringent than those set forth herein. The Receiving Party shall notify the Disclosing Party as promptly as practicable of any unauthorized use or disclosure of its Confidential Information.

 

13.6

The Receiving Party shall at any time be fully liable for any and all breaches of the confidentiality obligations in this Clause 13 by any of its Affiliates or the employees, consultants and representatives of itself or its Affiliates.

 

13.7

Each Party hereto expressly agrees that any breach or threatened breach of the undertakings of confidentiality provided under this Clause 13 by a Party may cause irreparable harm to the other Party and that money damages may not provide a sufficient remedy to the non-breaching Party for any breach or threatened breach. In the event of any breach and/or threatened breach, then, in addition to all other remedies available at law or in equity, the non-breaching Party shall be entitled to seek injunctive relief and any other relief deemed appropriate by the non-breaching Party, without posting a bond.

 

14

Term and Termination

 

14.1

Term. This Agreement shall commence on the Effective Date and shall end on the seventh (7th) anniversary of the Effective Date, or the fifth (5th) anniversary of Approval, whichever is longer, unless terminated earlier as provided herein or extended by mutual written consent of the Parties (the “Term”). Notwithstanding the foregoing, each Project Plan may have separate term and termination provisions so long as the term of any Project Plan does not extend beyond the Term.

 

14.2

Termination. This Agreement may be terminated as follows:

 

  14.2.1

by either Party for any reason upon twenty-four (24) months prior written notice to the other Party;

 

  14.2.2

by either Party if the other Party breaches a material provision of this Agreement or a Project Plan and fails to cure such breach to the reasonable satisfaction of the non-breaching Party within [***] for non-payment) following written notification of such breach from the non-breaching party to the breaching party; provided, however, that such [***] period shall be extended as agreed by the Parties if the identified breach is incapable of cure within [***] and if the breaching Party provides a plan and timeline to cure the breach, promptly commences efforts to cure the breach and diligently prosecutes such cure (it being understood that this extended period shall be unavailable for any breach regarding non-payment), in which case such Party shall have an additional [***] to cure the breach;

 

  14.2.3

Termination for NDA Rejection. Customer may terminate this Agreement if Customer receives notice that the New Drug Application for Product has been rejected, suspended indefinitely or terminated by the FDA. Customer must provide [***] written notice of termination in advance of the date of termination. For the avoidance of doubt, in the event of termination by Customer, Customer shall remain liable for all fees actually incurred by Lonza, including, but not limited to, work conducted prior to the effective date of termination (including all un-cancellable labor commitments, non-cancellable Third Party fees, and all work in process including all professional services rendered through the effective date of

 

15

 

termination), for any charges for materials that have already been purchased for the project and for any wind- down costs agreed by the Parties to be performed by Lonza.

 

  14.2.4

by either Party, immediately, if the other Party becomes insolvent, is dissolved or liquidated, makes a general assignment for the benefit of its creditors, or files or has filed against it, a petition in bankruptcy that is not dismissed within 90 days or has a receiver appointed for a substantial part of its assets; or

 

  14.2.5

by either Party pursuant to Clause 15.

 

14.3

Consequences of Termination. In the event of termination hereunder, Lonza shall be compensated for (i) Services rendered up to the date of termination, including in respect of any Product in-process; (ii) all costs incurred through the date of termination, including Raw Materials costs for Raw Materials used or purchased for use in accordance with the Project Plan; (iii) all unreimbursed Capital Equipment and related decommissioning charges incurred pursuant to Clause 9; (iv) all amounts due under Clause 6.4, without proration of the final calendar year and (v) any applicable Cancellation Fees. In the case of termination by Lonza for Customer’s material breach, Cancellation Fees shall be calculated as of the effective date of termination.

 

14.4

Survival. The rights and obligations of each Party which by their nature survive the termination or expiration of this Agreement shall survive the termination or expiration of this Agreement, including Clauses 1, 10-13 and 16 (to the extent relevant).

 

15

Force Majeure

 

15.1

If Lonza or its Affiliate or permitted contractor, as applicable, is prevented or delayed in the performance of any of its obligations under the Agreement by Force Majeure and gives written notice thereof to Customer specifying the matters constituting Force Majeure together with such evidence as Lonza reasonably can give and specifying the period for which it is estimated that such prevention or delay will continue, Lonza shall be excused from the performance or the punctual performance of such obligations as the case may be from the date of such notice for so long as such cause of prevention or delay shall continue. Provided that, if such Force Majeure persists for a period of [***] or more, Customer may terminate this Agreement by delivering written notice to Lonza.

 

15.2

“Force Majeure” means any reason or cause beyond Lonza’s reasonable control and that is not foreseeable nor due to Lonza’s negligence and affecting the performance by Lonza of its obligations under the Agreement, which may include, but is not limited to, any cause arising from or attributable to acts of God, strike, lockouts, labor troubles, restrictive governmental orders or decrees, riots, insurrection, war, terrorists acts, or the inability of Lonza to obtain any required raw material, energy source, equipment, labour or transportation.

 

16

Miscellaneous

 

16.1

Severability. If any provision hereof is or becomes at any time illegal, invalid or unenforceable in any respect, neither the legality, validity nor enforceability of the remaining provisions hereof shall in any way be affected or impaired thereby. The Parties hereto undertake to substitute any illegal, invalid or unenforceable provision by a provision which is as far as possible commercially equivalent considering the legal interests and the Purpose.

 

16.2

Amendments/Assignment. Modifications and/or amendments of this Agreement must be in writing and signed by the Parties. Lonza shall be entitled to instruct one or more of its Affiliates to perform any of Lonza’s obligations contained in this Agreement, but Lonza shall remain fully responsible in respect of those obligations, and its Affiliates’ actions and omissions shall be deemed made by Lonza. Subject thereto, neither Party may assign its interest under this Agreement without the prior

 

16

CONFIDENTIAL

 

 

written consent of the other Party, such consent not to be unreasonably withheld, conditioned or delayed, provided, however that (a) Lonza may assign this Agreement to any Affiliate of Lonza or (b) either Party may assign this Agreement to any third party in connection with the sale or transfer (by whatever method) of all or substantially all of the assets of the business related to this Agreement; provided, however, that Customer shall not assign this Agreement to a Competitor of Lonza, and (c) Lonza shall be entitled to sell, assign and/or transfer its payment receivables resulting from this Agreement without the consent of the Customer. For purposes of this Clause 16.2, the terms “assign” and “assignment” shall include, without limitation (i) the sale of fifty percent (50%) or more of the outstanding stock of such Party to an Affiliate of such Party or an unrelated entity or natural person, (ii) the sale or transfer or other assignment of all or substantially all of the assets of the Party or the line of business or Product to which this Agreement relates, and (iii) a merger, consolidation, acquisition or other form of business combination. Any purported assignment without a required consent shall be void. No assignment shall relieve any Party of responsibility for the performance of any obligation that accrued prior to the effective date of such assignment. This Agreement shall be binding upon the Parties’ successors and permitted assigns.

 

16.3

Notice. All notices must be written and sent to the address of the Party first set forth above. All notices must be given (a) by personal delivery, with receipt acknowledged, (b) by facsimile followed by hard copy delivered by the methods under (c) or (d), (c) by prepaid certified or registered mail, return receipt requested, or (d) by prepaid recognized next business day delivery service. Notices will be effective upon receipt or at a later date stated in the notice.

 

16.4

Governing Law/Jurisdiction. This Agreement is governed in all respects by the laws of New York, USA, without regard to its conflicts of laws principles. The Parties agree to submit to the jurisdiction of the courts of New York, USA.

 

16.5

Entire Agreement. This Agreement and the Project Plan and Quality Agreement, together with the Appendices referenced and incorporated herein, constitute the entire agreement between the Parties as to the subject matter hereof and supersedes all prior and contemporaneous agreements with respect to the subject matter hereof. This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document. Each Party acknowledges that an original signature or a copy thereof transmitted by facsimile or by .pdf shall constitute an original signature for purposes of this Agreement.

 

16.6

Waiver. Failure by a Party to insist upon strict compliance with any term of this Agreement in any one or more instances will not be deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure.

 

16.7

Further Assurances. The Parties shall execute, acknowledge and deliver such further instruments and to take all such other incidental acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.

 

16.8

No Third Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person or entity other than the Parties and their respective successors and permitted assigns.

 

16.9

Publicity. Neither Party will make any press release or other public disclosure regarding this Agreement or the transactions contemplated hereby without the other Party’s express prior written consent, except as required under Applicable Laws, by any governmental agency or by the rules of any stock exchange on which the securities of the disclosing party are listed, in which case the party required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the other party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or making the public disclosure. In addition, neither Party shall use the other Party’s name in a manner that could be construed as an endorsement of the other Party’s product or service, including any scientific conclusion as to safety or efficacy.

 

17

CONFIDENTIAL

 

IN WITNESS WHEREOF, each of the Parties hereto has caused this Manufacturing Services Agreement to be executed by its duly authorized representative effective as of the Effective Date.

 

LONZA LTD
By:   /s/ Cordula Altekrüger
 

Name: Cordula Altekrüger

Title: Senior Legal Counsel

 

By:   /s/ Bart A.M. van Aarnhem
 

Name: Bart A.M. van Aarnhem

Title: Senior Legal Counsel

 

ITI Limited
By:   /s/ Michael Halstead
 

Name: Michael Halstead

Title: SVP, General Counsel

 

By:   /s/ Sharon Mates
 

Name: Sharon Mates

Title: CEO

 

18

CONFIDENTIAL

 

APPENDIX A

Project Plan A -1

[***]

 

1

EX-31.1 3 d18633dex311.htm EX-31.1 EX-31.1

Exhibit 31.1

CERTIFICATIONS UNDER SECTION 302

I, Sharon Mates, Ph.D., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2020

 

/s/ Sharon Mates, Ph.D.

Sharon Mates, Ph.D.

Chairman, President and Chief Executive Officer

(principal executive officer)

 EX-31.2 4 d18633dex312.htm EX-31.2 EX-31.2

Exhibit 31.2

CERTIFICATIONS UNDER SECTION 302

I, Lawrence J. Hineline, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Intra-Cellular Therapies, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 9, 2020

 

/s/ Lawrence J. Hineline

Lawrence J. Hineline
Senior Vice President of Finance and Chief Financial Officer (principal financial officer)
 EX-32 5 d18633dex32.htm EX-32 EX-32

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Intra-Cellular Therapies, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report for the quarter ended September 30, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Dated: November 9, 2020    

/s/ Sharon Mates, Ph.D.

    Sharon Mates, Ph.D.
    Chairman, President and Chief Executive Officer
    (principal executive officer)
Dated: November 9, 2020    

/s/ Lawrence J. Hineline

    Lawrence J. Hineline
    Senior Vice President of Finance and Chief Financial Officer
    (principal financial officer)
 EX-101.SCH 6 itci-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Cover Page link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:definitionLink link:calculationLink 1007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 1008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - Organization link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Inventory link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Right of Use Assets and Lease Liabilities link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Share-Based Compensation link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Collaborations and License Agreements link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - Inventory (Tables) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Organization - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - Property and Equipment - Property and Equipment (Detail) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Property and Equipment - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail) link:presentationLink link:definitionLink link:calculationLink 1038 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail) link:presentationLink link:definitionLink link:calculationLink 1039 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) link:presentationLink link:definitionLink link:calculationLink 1040 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) link:presentationLink link:definitionLink link:calculationLink 1041 - Disclosure - Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail) link:presentationLink link:definitionLink link:calculationLink 1042 - Disclosure - Collaborations and License Agreements - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 itci-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 itci-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 itci-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 itci-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 d18633d10q_htm.xml IDEA: XBRL DOCUMENT 0001567514 2020-01-01 2020-09-30 0001567514 2020-07-01 2020-09-30 0001567514 2019-07-01 2019-09-30 0001567514 2019-01-01 2019-09-30 0001567514 2019-12-31 0001567514 2020-09-30 0001567514 2020-01-10 2020-01-10 0001567514 2020-09-15 2020-09-15 0001567514 2020-09-15 0001567514 2020-01-10 0001567514 2019-01-01 2019-12-31 0001567514 2019-12-20 2019-12-31 0001567514 2020-11-06 0001567514 2019-09-30 0001567514 2020-09-10 2020-09-10 0001567514 2020-09-10 0001567514 2019-06-30 0001567514 2018-12-31 0001567514 2020-06-30 0001567514 us-gaap:CertificatesOfDepositMember 2020-09-30 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001567514 us-gaap:CommercialPaperMember 2020-09-30 0001567514 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2020-09-30 0001567514 itci:InducementAwardPlanMember 2020-09-30 0001567514 itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember 2020-09-30 0001567514 us-gaap:ComputerEquipmentMember 2020-09-30 0001567514 us-gaap:FurnitureAndFixturesMember 2020-09-30 0001567514 us-gaap:EquipmentMember 2020-09-30 0001567514 us-gaap:LeaseholdImprovementsMember 2020-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2020-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001567514 itci:MilestoneRestrictedStockUnitsMember 2020-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-09-30 0001567514 us-gaap:FairValueInputsLevel3Member 2020-09-30 0001567514 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-09-30 0001567514 itci:RealEstatesLeaseMember 2020-09-30 0001567514 itci:VehicleFleetLeaseMember 2020-09-30 0001567514 us-gaap:FinancialStandbyLetterOfCreditMember itci:VehicleFleetLeaseMember 2020-09-30 0001567514 itci:ItciInducementAwardPlanMember 2020-09-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2019-12-31 0001567514 us-gaap:CommercialPaperMember 2019-12-31 0001567514 us-gaap:CertificatesOfDepositMember 2019-12-31 0001567514 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001567514 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001567514 itci:ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember 2019-12-31 0001567514 us-gaap:ComputerEquipmentMember 2019-12-31 0001567514 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001567514 us-gaap:EquipmentMember 2019-12-31 0001567514 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2019-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0001567514 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001567514 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001567514 us-gaap:CashAndCashEquivalentsMember 2019-12-31 0001567514 srt:MaximumMember itci:ItciInducementAwardPlanMember 2019-12-31 0001567514 us-gaap:CommercialPaperMember 2019-12-31 0001567514 itci:InventoriableCostsMember 2020-07-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0001567514 us-gaap:GeneralAndAdministrativeExpenseMember 2020-07-01 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001567514 us-gaap:ProductMember 2020-07-01 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-07-01 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0001567514 itci:CustomerOneMember us-gaap:AccountsReceivableMember 2020-07-01 2020-09-30 0001567514 itci:CustomerTwoMember us-gaap:AccountsReceivableMember 2020-07-01 2020-09-30 0001567514 itci:CustomerThreeMember us-gaap:AccountsReceivableMember 2020-07-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001567514 us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001567514 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001567514 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001567514 itci:InventoriableCostsMember 2020-01-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0001567514 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 srt:MaximumMember us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001567514 itci:InducementAwardPlanMember 2020-01-01 2020-09-30 0001567514 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MinimumMember 2020-01-01 2020-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember srt:MaximumMember 2020-01-01 2020-09-30 0001567514 us-gaap:GrantMember 2020-01-01 2020-09-30 0001567514 us-gaap:ProductMember 2020-01-01 2020-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2020-01-01 2020-09-30 0001567514 srt:MaximumMember 2020-01-01 2020-09-30 0001567514 srt:MinimumMember 2020-01-01 2020-09-30 0001567514 itci:VehicleFleetLeaseMember 2020-01-01 2020-09-30 0001567514 itci:VehicleFleetLeaseMember 2020-01-01 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember itci:ITCINationalDemocraticAllianceMemberMember 2020-01-01 2020-09-30 0001567514 us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0001567514 itci:CustomerOneMember us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0001567514 itci:CustomerTwoMember us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0001567514 itci:CustomerThreeMember us-gaap:AccountsReceivableMember 2020-01-01 2020-09-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2020-01-01 2020-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-09-30 0001567514 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001567514 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001567514 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2019-01-01 2019-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0001567514 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001567514 itci:TimeBasedRestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001567514 itci:RealEstateLeaseMember 2019-01-01 2019-09-30 0001567514 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0001567514 us-gaap:IPOMember 2020-01-10 2020-01-10 0001567514 srt:MaximumMember us-gaap:CommonStockMember 2019-09-12 0001567514 srt:MaximumMember 2019-09-12 0001567514 itci:AmtTaxCreditMember 2020-03-27 0001567514 itci:PerformanceBasedRestrictedStockUnitsMember 2020-03-31 2020-03-31 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2018-06-30 0001567514 itci:TwoThousandEighteenEquityIncentivePlanMember 2020-05-31 0001567514 stpr:NY 2018-09-30 0001567514 stpr:MD 2019-02-28 0001567514 stpr:NY us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 stpr:MD us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-12-31 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2019-01-01 2019-12-31 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2017-01-01 2017-03-31 0001567514 itci:TotalShareholderReturnRestrictedStockUnitsMember 2020-01-01 2020-03-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2005-05-31 2005-05-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2013-12-01 2013-12-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2014-12-01 2014-12-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember 2019-01-31 0001567514 itci:BristolMyersSquibbCompanyMember us-gaap:ProductMember itci:NationalDemocraticAllianceMember 2019-12-23 2019-12-23 0001567514 us-gaap:IPOMember 2020-09-15 2020-09-15 0001567514 srt:MaximumMember 2019-09-12 2019-09-12 0001567514 us-gaap:CommonStockMember 2020-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001567514 us-gaap:RetainedEarningsMember 2020-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001567514 us-gaap:CommonStockMember 2020-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001567514 us-gaap:RetainedEarningsMember 2020-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001567514 us-gaap:CommonStockMember 2019-06-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001567514 us-gaap:RetainedEarningsMember 2019-06-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001567514 us-gaap:CommonStockMember 2019-09-30 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001567514 us-gaap:RetainedEarningsMember 2019-09-30 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2019-12-31 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2019-12-31 0001567514 us-gaap:CommonStockMember 2019-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001567514 us-gaap:RetainedEarningsMember 2019-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001567514 us-gaap:RestrictedStockUnitsRSUMember 2020-09-30 0001567514 itci:MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember 2020-09-30 0001567514 itci:InducementAwardPlanMember 2019-12-31 0001567514 us-gaap:CommonStockMember 2018-12-31 0001567514 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001567514 us-gaap:RetainedEarningsMember 2018-12-31 0001567514 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 iso4217:USD shares pure utr:Month utr:Year iso4217:USD shares itci:Segment itci:Customers false 2020 Q3 P3Y 0001567514 --12-31 Intra-Cellular Therapies, Inc. 10-Q true 2020-09-30 false 001-36274 DE 36-4742850 430 East 29th Street New York NY 10016 646 440-9333 Common Stock ITCI NASDAQ Yes Yes Large Accelerated Filer false false false 80157554 300988981 107636849 420958509 116373335 1400000 7480604 2947138 11090774 6313785 744866006 230323969 2049552 2259740 24292167 18252074 264609 86084 86084 771293809 251186476 8569148 7425024 12186380 16138909 5267258 3187435 12005931 9472651 38028717 36224019 23869557 19955186 61898274 56179205 0.0001 0.0001 100000000 100000000 80142797 80142797 55507497 55507497 8014 5551 1585023637 904971772 -876404854 -710098369 768738 128317 709395535 195007271 771293809 251186476 7368594 10126999 231710 7368594 10358709 556107 753957 10275368 21339792 51483551 70059113 52473573 15036444 128015496 42184078 63305048 36376236 180253004 112243191 -55936454 -36376236 -169894295 -112243191 752829 1513837 3591091 5105464 -55183625 -34862399 -166303204 -107137727 3281 1600 -55183625 -34862399 -166306485 -107139327 -0.79 -0.63 -2.48 -1.94 69530039 55207400 67030991 55155854 -55183625 -34862399 -166306485 -107139327 -399361 -33396 640421 866805 -55582986 -34895795 -165666064 -106272522 55186745 5519 891183518 -634653119 232444 256768362 54332 6 152373 152379 6502 48571 48571 4806768 4806768 -34862399 -34862399 -33396 -33396 55247579 5525 896191230 -669515518 199048 226880285 54895295 5490 880753339 -562376191 -667757 317714881 338054 34 442792 442826 14230 1 145690 145691 14849409 14849409 -107139327 -107139327 866805 866805 55247579 5525 896191230 -669515518 199048 226880285 66777737 6678 1199576320 -821221229 1168099 379529868 13179458 1318 370137298 370138616 5705186 5705186 183516 18 2650587 2650605 2086 0 53527 53527 6900719 6900719 -55183625 -55183625 -399361 -399361 80142797 8014 1585023637 -876404854 768738 709395535 55507497 5551 904971772 -710098369 128317 195007271 23409458 2341 652709670 652712011 1218188 121 7829463 7829584 7654 1 160582 160583 19352150 19352150 -166306485 -166306485 640421 640421 80142797 8014 1585023637 -876404854 768738 709395535 -166306485 -107139327 402146 335461 19352150 14849409 160583 145691 177374 871412 7480604 2947138 4776989 -4020430 -264609 1144124 -7730137 -1419249 3462560 -45899 -161830126 -92927325 488524539 58332886 184757160 199383553 191958 1350688 -303959337 139699979 7829584 442826 652712011 660541595 442826 194752132 47215480 107636849 54947502 302388981 102162982 7750959 219703 300988981 102162982 1400000 302388981 102162982 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">1. Organization </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiaries, ITI, Inc. (“ITI”) and ITI Limited, is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In December 2019, the Company announced that CAPLYTA<div style="font-size: 85%; vertical-align: top;;display:inline;;font-size:9.4px">TM</div> (lumateperone) had been approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA in late March 2020. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia. Lumateperone is in Phase 3 clinical development as a novel treatment for bipolar depression. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On January 10, 2020, the Company completed a public offering of common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $29.50 per share for aggregate gross proceeds of $295.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $277.0 million.<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>On September 15, 2020<div style="letter-spacing: 0px; top: 0px;;display:inline;">, </div>the Company completed a public offering of common stock in which the Company sold 12,666,667 shares of common stock at an offering price of $30.00 per share for aggregate gross proceeds of $380.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8 million. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In order to further its commercial activities and research projects and support its collaborations, the Company will require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s product candidates and technology and, to a lesser extent, grant funding. On August 30, 2019, the Company filed a universal shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3,</div> which was declared effective by the SEC on September 12, 2019, on which the Company registered for sale up to $350 million of any combination of its common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that the Company may determine, which includes up to $75 million of common stock that the Company may issue and sell from time to time, through SVB Leerink LLC acting as its sales agent, pursuant to the sale agreement that the Company entered into with SVB Leerink on August 29, 2019 for the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“at-the-market”</div></div> equity program. On September 10, 2020, the Company terminated the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“at-the-market”</div></div> equity program sales agreement with SVB Leerink LLC. Through the date of the termination of the sales agreement on September 10, 2020, the Company had issued an aggregate 742,791 shares of common stock under the Company’s <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">“at-the-market”</div></div> equity program which resulted in the Company receiving net proceeds of $17.9 million.</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In addition, on January 6, 2020, the Company filed an automatic shelf registration statement on Form <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">S-3</div> with the SEC, which became effective upon filing, on which the Company registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that the Company may determine, so long as the Company continues to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective. </div></div></div> 10000000 29.50 295000000.0 277000000.0 12666667 30.00 380000000.0 357800000 350000000 75000000 75000000 742791 17900000 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">2. Summary of Significant Accounting Policies </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs for the treatment of neurological and psychiatric disorders. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment Securities </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Investment securities consisted of the following (in thousands):<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 66%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">159,237</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(32</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">159,217</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,788</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">138</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">171,665</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">782</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(129</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,318</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">420,190</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">932</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(163</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">420,959</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: 'Times New Roman';"/> <td colspan="16" style="height: 12pt; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">35,462</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">35</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">35,494</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,000</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,000</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,013</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,018</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">38,770</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">91</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">38,861</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,245</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(8</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,373</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has classified all of its investment securities as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale,</div></div> including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2020, and December 31, 2019, the Company held $197.3 million and $3.0 million, respectively, of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities with contractual maturity dates more than one year and less than two years.</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate related fair value of investments with unrealized losses as of September 30, 2020 was $192.8 million, which consisted of $110.4 million from U.S. government agency securities, $10.0 million of commercial paper, and $72.4 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2020 was approximately $163,000, which consisted of $32,000 from U.S. government agency securities, $2,000 from commercial paper, and $129,000 from corporate notes/bonds. The $192.8 million aggregate fair value of investments with unrealized losses as of September 30, 2020 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2019, the Company had approximately $29.6 million of investments with a continuous unrealized loss for 12 months or longer of which approximately $12.5 million had been held in a continuous loss position for 12 months or longer. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. </div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the fair value method under ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div>. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div></div></div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div></div></div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div></div></div></div></td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2020 or December 31, 2019. The carrying value of cash held in money market funds of approximately $224.2 million as of September 30, 2020 and $49.9 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of certificates of deposit of approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>47.6 million as of December 31, 2019 is also included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs. The carrying value of commercial paper of approximately $3.0 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The fair value measurements of the Company’s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands):</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at<br/> Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">224,239</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">224,239</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">159,217</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">159,217</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,318</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,318</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">645,198</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">224,239</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">420,959</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-size: 8pt; break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at<br/> Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-size: 8pt; break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">49,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">49,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"/> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"/></tr> <tr style="font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">35,494</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">35,494</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">50,622</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">50,622</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">42,015</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">42,015</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">38,861</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">38,861</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; width: 56%;"/> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: bottom; width: 56%;"/> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">216,874</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">49,882</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">166,992</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; width: 56%;"/> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2020 and December 31, 2019. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Cash </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-18,</div> “Restricted Cash” (“ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-18”)</div> and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. For the three and nine months ended September 30, 2020, 96% of sales were generated from three major industry wholesalers, respectively. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine months ended September 30, 2020, all of the Company’s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 90 days. Three individual customers accounted for approximately 39%, 29%, and 28% of product sales for the three months ended September 30, 2020 as well as accounted for approximately 41%, 27% and 27% of product sales for the nine months ended September 30, 2020. As of September 30, 2020, the Company believes that such customers are of high credit quality. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </div></div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (“FIFO”) basis. The </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs. </div></div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from <span style="-sec-ix-hidden:hidden15634066">three</span> to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment</div></div>. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Effective January 1, 2018, the Company adopted FASB ASC Topic 606,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Revenue from Contracts with Customers </div></div>(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact in the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine months ended September 30, 2020 reflect the application of ASC Topic 606. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div>(below). </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, the Company’s only source of product sales has been from sales of CAPLYTA in the U.S., which the Company began shipping to customers in March 2020. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reserves for Variable Consideration </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include estimates that take into consideration a range of possible outcomes which are either considered more likely or probability-weighted in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA and historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, historical information related to similar products in their initial launch stages. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts after considering whether revenue should be constrained under ASC 606. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2020 and, therefore, the transaction price was not reduced further during the three and nine months ended September 30, 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Discounts and Allowances</div></div>— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of net sales within the condensed consolidated statements of operations through September 30, 2020, as well as a reduction to trade receivables, net on the condensed consolidated balance sheets. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns</div></div>— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any returns to date. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provider Chargebacks and Discounts</div></div>— Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivables, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-end</div> that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine months ended September 30, 2020, these amounts were not significant. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Rebates</div></div>— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Payer Rebates</div></div>— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Incentives</div></div>— Other incentives which the Company offers include voluntary patient assistance programs, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> required by payers. The calculation of the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company estimates the number of claims through vouchers for product that is in the distribution channel inventories and reduces recognized revenue accordingly. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div></div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of Product Sales </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to FDA approval of CAPLYTA, the Company </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expensed all </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs associated with the manufacturing of lumateperone as part of research and development expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div> From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production and no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the nine months ended September 30, 2020 are lower than incurred because of previously expensed inventory. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development, Including Clinical Trial Expenses </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be.</div></div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the nine-months ended September 30, 2020, the Company recorded a change in estimate of approximately $3.3 million of accrued expenses for clinical trials related to the first and second quarter of 2020 which resulted in an increase of clinical trial expense in the nine month period ending September 30, 2020. For the three and nine months ended September 30, 2020 and 2019, there were no material adjustments to the Company’s prior year estimates of accrued expenses for clinical trials.</div></div></div><div style="font-size: 10pt;;display:inline;"> </div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> 109</div></div>). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s effective tax rate for the three and nine months ended September 30, 2020 and 2019 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (CARES) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the three and nine months ended September 30, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Income (Loss) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are incurred. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive income (loss) for each period.</div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based Compensation </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Share-based payments are accounted for in accordance with the provisions of ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation—Stock Compensation</div></div>. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For all awards granted with time based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the three and nine months ended September 30, 2020 and 2019 accounts for forfeitures as they occur. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. In the fourth quarter of 2019, expected volatility rates are based entirely on the historical volatility of the Company’s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. In the first quarter of 2017, the Company granted performance-based RSUs, which vest based on the achievement of certain milestones that include (i) the submission of a new drug application (“NDA”) to the FDA for lumateperone for the treatment of schizophrenia, (ii) the approval of the NDA by the FDA (together, the “Milestone RSUs”) and (iii) the achievement of certain comparative shareholder returns against the Company’s peers (the “TSR RSUs”). The Milestone RSUs related to the NDA submission were fully amortized on December 31, 2018. The NDA submission milestone was achieved in the third quarter of 2018, so the Milestone RSUs related to the NDA submission vested on December 31, 2018. The Milestone RSU’s related to the NDA approval was achieved in the fourth quarter of 2019, so the RSU’s vested on December 31, 2019. The Milestone RSUs related to the approval of the NDA were fully amortized on December 31, 2019. The TSR RSUs were valued using the Monte Carlo Simulation method and were amortized over the life of the RSUs based on the agreements which vested on January 24, 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the Company has losses and also maintains a full valuation allowance to cover its deferred tax assets as of September 30, 2020 and 2019, excess tax benefits, if any, recognized for the tax deductions related to share-based awards will add to the Company’s net operating loss deferred tax asset and covered by valuation allowances. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Equity instruments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> for services are accounted for under the provisions of ASC Topic 718 and ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">505-50,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity/Equity-Based Payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employees</div></div></div>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2020, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan. </div></div></div> </div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2020 and 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three and Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,964,135</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">6,330,914</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,702,538</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,425,459</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TSR RSUs</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">43,022</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">134,170</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Standards </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-13,</div> “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13”).</div> This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-to-maturity</div></div> debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January 1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January 1, 2020 and for the three and nine month period ended September 30, 2020.</div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basis of Presentation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs for the treatment of neurological and psychiatric disorders. </div></div> 1 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Use of Estimates </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash and Cash Equivalents </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets. </div></div> P3M more than three months <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment Securities </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Investment securities consisted of the following (in thousands):<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 66%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">159,237</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(32</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">159,217</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,788</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">138</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">171,665</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">782</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(129</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,318</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">420,190</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">932</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(163</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">420,959</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: 'Times New Roman';"/> <td colspan="16" style="height: 12pt; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">35,462</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">35</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">35,494</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,000</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,000</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,013</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,018</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">38,770</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">91</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">38,861</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,245</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(8</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,373</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company has classified all of its investment securities as <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale,</div></div> including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2020, and December 31, 2019, the Company held $197.3 million and $3.0 million, respectively, of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities with contractual maturity dates more than one year and less than two years.</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The aggregate related fair value of investments with unrealized losses as of September 30, 2020 was $192.8 million, which consisted of $110.4 million from U.S. government agency securities, $10.0 million of commercial paper, and $72.4 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2020 was approximately $163,000, which consisted of $32,000 from U.S. government agency securities, $2,000 from commercial paper, and $129,000 from corporate notes/bonds. The $192.8 million aggregate fair value of investments with unrealized losses as of September 30, 2020 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2019, the Company had approximately $29.6 million of investments with a continuous unrealized loss for 12 months or longer of which approximately $12.5 million had been held in a continuous loss position for 12 months or longer. </div></div>The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Investment Securities </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Investment securities consisted of the following (in thousands):<div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 66%;"/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 4%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td colspan="14" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(Unaudited)</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">159,237</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(32</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">159,217</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,788</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">138</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(2</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">171,665</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">782</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(129</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,318</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">420,190</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">932</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(163</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">420,959</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1pt;"> <td style="height: 12pt; font-family: 'Times New Roman';"/> <td colspan="16" style="height: 12pt; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="14" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31, 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Amortized<br/> Cost</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> Gains</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Unrealized<br/> (Losses)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Estimated<br/> Fair<br/> Value</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">35,462</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">35</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(3</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">35,494</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,000</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,000</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,013</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(5</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,018</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 66%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">38,770</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">91</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">38,861</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,245</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">136</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">(8</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">116,373</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 66%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 4%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> 159237000 12000 32000 159217000 10500000 10500000 78788000 138000 2000 78924000 171665000 782000 129000 172318000 420190000 932000 163000 420959000 35462000 35000 3000 35494000 3000000 3000000 39013000 10000 5000 39018000 38770000 91000 38861000 116245000 136000 8000 116373000 197300000 3000000.0 192800000 110400000 10000000.0 72400000 163000 32000 2000 129000 192800000 29600000 12500000 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Fair Value Measurements </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company applies the fair value method under ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurements and Disclosures</div></div>. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement: </div></div></div><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities. </div></div></div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </div></div></div></div></td></tr></table><div style="font-size: 6pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 6pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 9%;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="width: 3%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">•</div></div></td> <td style="width: 1%; vertical-align: top;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: top; font-size: 10pt;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </div></div></div></div></td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2020 or December 31, 2019. The carrying value of cash held in money market funds of approximately $224.2 million as of September 30, 2020 and $49.9 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of certificates of deposit of approximately <div style="letter-spacing: 0px; top: 0px;;display:inline;">$</div>47.6 million as of December 31, 2019 is also included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs. The carrying value of commercial paper of approximately $3.0 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The fair value measurements of the Company’s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands):</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at<br/> Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">224,239</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">224,239</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">159,217</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">159,217</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,318</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,318</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">645,198</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">224,239</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">420,959</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-size: 8pt; break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at<br/> Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-size: 8pt; break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">49,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">49,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"/> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"/></tr> <tr style="font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">35,494</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">35,494</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">50,622</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">50,622</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">42,015</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">42,015</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">38,861</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">38,861</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; width: 56%;"/> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: bottom; width: 56%;"/> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">216,874</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">49,882</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">166,992</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; width: 56%;"/> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 0 0 0 0 224200000 49900000 47600000 3000000.0 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The fair value measurements of the Company’s cash equivalents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> investment securities are identified in the following tables (in thousands):</div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at<br/> Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">224,239</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">224,239</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">159,217</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">159,217</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">10,500</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">78,924</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,318</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">172,318</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">645,198</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">224,239</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">420,959</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 56%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 56%;"/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 6%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 5%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-size: 8pt; break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="10" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Value Measurements at<br/> Reporting Date Using</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-size: 8pt; break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Quoted Prices<br/> in Active<br/> Markets for<br/> Identical<br/> Assets<br/> (Level 1)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Other<br/> Observable<br/> Inputs<br/> (Level 2)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Significant<br/> Unobservable<br/> Inputs<br/> (Level 3)</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Money Market Funds</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">49,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">49,882</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"/> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"/></tr> <tr style="font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">U.S. Government Agency Securities</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">35,494</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">35,494</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Certificates of Deposit</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">50,622</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">50,622</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Commercial Paper</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">42,015</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">42,015</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 10pt; break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 56%;"><div style="text-indent: -1em; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Corporate Notes/Bonds</div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">38,861</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"> </td> <td style="vertical-align: bottom;;text-align:right;">38,861</td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; width: 56%;"/> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr> <tr style="font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: bottom; width: 56%;"/> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">216,874</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">49,882</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">166,992</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; width: 56%;"/> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td> <td style="vertical-align: bottom; width: 5%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td> </td></tr></table> 224239000 224239000 159217000 159217000 10500000 10500000 78924000 78924000 172318000 172318000 645198000 224239000 420959000 49882000 49882000 35494000 35494000 50622000 50622000 42015000 42015000 38861000 38861000 216874000 49882000 166992000 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial Instruments </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2020 and December 31, 2019. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing. </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Restricted Cash </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-18,</div> “Restricted Cash” (“ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-18”)</div> and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Accounts Receivable, net </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. For the three and nine months ended September 30, 2020, 96% of sales were generated from three major industry wholesalers, respectively. </div></div> 0.96 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Concentration of Credit Risk </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine months ended September 30, 2020, all of the Company’s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 90 days. Three individual customers accounted for approximately 39%, 29%, and 28% of product sales for the three months ended September 30, 2020 as well as accounted for approximately 41%, 27% and 27% of product sales for the nine months ended September 30, 2020. As of September 30, 2020, the Company believes that such customers are of high credit quality. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk. </div></div></div></div> 3 0.39 0.29 0.28 0.41 0.27 0.27 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-in,</div> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">first-out</div> (“FIFO”) basis. The </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs. </div></div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and Equipment </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from <span style="-sec-ix-hidden:hidden15634066">three</span> to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Property, Plant and Equipment</div></div>. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date.</div> P5Y 0 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenue Recognition </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Effective January 1, 2018, the Company adopted FASB ASC Topic 606,<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> Revenue from Contracts with Customers </div></div>(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact in the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine months ended September 30, 2020 reflect the application of ASC Topic 606. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div>(below). </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">To date, the Company’s only source of product sales has been from sales of CAPLYTA in the U.S., which the Company began shipping to customers in March 2020. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Sales, net </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the </div></div></div></div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Reserves for Variable Consideration </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include estimates that take into consideration a range of possible outcomes which are either considered more likely or probability-weighted in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA and historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, historical information related to similar products in their initial launch stages. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts after considering whether revenue should be constrained under ASC 606. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2020 and, therefore, the transaction price was not reduced further during the three and nine months ended September 30, 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Trade Discounts and Allowances</div></div>— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of net sales within the condensed consolidated statements of operations through September 30, 2020, as well as a reduction to trade receivables, net on the condensed consolidated balance sheets. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Product Returns</div></div>— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any returns to date. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Provider Chargebacks and Discounts</div></div>— Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivables, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">period-end</div> that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine months ended September 30, 2020, these amounts were not significant. </div></div></div> <div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Government Rebates</div></div>— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.</div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Payer Rebates</div></div>— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Other Incentives</div></div>— Other incentives which the Company offers include voluntary patient assistance programs, such as the <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-payments</div> required by payers. The calculation of the accrual for <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">co-pay</div> assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company estimates the number of claims through vouchers for product that is in the distribution channel inventories and reduces recognized revenue accordingly. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets. </div></div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Cost of Product Sales </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs). </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Prior to FDA approval of CAPLYTA, the Company </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">expensed all </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">costs associated with the manufacturing of lumateperone as part of research and development expenses<div style="letter-spacing: 0px; top: 0px;;display:inline;">.</div> From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production and no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the nine months ended September 30, 2020 are lower than incurred because of previously expensed inventory. </div></div> 0.05 0.09 0 0 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and Development, Including Clinical Trial Expenses </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be.</div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the nine-months ended September 30, 2020, the Company recorded a change in estimate of approximately $3.3 million of accrued expenses for clinical trials related to the first and second quarter of 2020 which resulted in an increase of clinical trial expense in the nine month period ending September 30, 2020. For the three and nine months ended September 30, 2020 and 2019, there were no material adjustments to the Company’s prior year estimates of accrued expenses for clinical trials.</div></div></div><div style="font-size: 10pt;;display:inline;"> </div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income Taxes </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> 109</div></div>). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">more-likely-than-not</div> threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s effective tax rate for the three and nine months ended September 30, 2020 and 2019 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (CARES) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the three and nine months ended September 30, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020. </div></div> 0 0.21 265000 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Comprehensive Income (Loss) </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are incurred. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-owner</div> sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive income (loss) for each period.</div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Share-Based Compensation </div></div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Share-based payments are accounted for in accordance with the provisions of ASC Topic 718, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Compensation—Stock Compensation</div></div>. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option. </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">For all awards granted with time based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the three and nine months ended September 30, 2020 and 2019 accounts for forfeitures as they occur. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. In the fourth quarter of 2019, expected volatility rates are based entirely on the historical volatility of the Company’s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. In the first quarter of 2017, the Company granted performance-based RSUs, which vest based on the achievement of certain milestones that include (i) the submission of a new drug application (“NDA”) to the FDA for lumateperone for the treatment of schizophrenia, (ii) the approval of the NDA by the FDA (together, the “Milestone RSUs”) and (iii) the achievement of certain comparative shareholder returns against the Company’s peers (the “TSR RSUs”). The Milestone RSUs related to the NDA submission were fully amortized on December 31, 2018. The NDA submission milestone was achieved in the third quarter of 2018, so the Milestone RSUs related to the NDA submission vested on December 31, 2018. The Milestone RSU’s related to the NDA approval was achieved in the fourth quarter of 2019, so the RSU’s vested on December 31, 2019. The Milestone RSUs related to the approval of the NDA were fully amortized on December 31, 2019. The TSR RSUs were valued using the Monte Carlo Simulation method and were amortized over the life of the RSUs based on the agreements which vested on January 24, 2020. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740, <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Income Taxes</div></div>. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance.</div><div style="font-size: 8pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; line-height: 12pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Since the Company has losses and also maintains a full valuation allowance to cover its deferred tax assets as of September 30, 2020 and 2019, excess tax benefits, if any, recognized for the tax deductions related to share-based awards will add to the Company’s net operating loss deferred tax asset and covered by valuation allowances. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Equity instruments issued to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-employees</div> for services are accounted for under the provisions of ASC Topic 718 and ASC Topic <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">505-50,</div> <div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Equity/Equity-Based Payments to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Employees</div></div></div>. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants. </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2020, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan. </div></div></div> </div> 0 86000 4750000 6500000 1000000 314138 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Loss Per Share </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2020 and 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three and Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,964,135</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">6,330,914</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,702,538</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,425,459</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TSR RSUs</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">43,022</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">134,170</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2020 and 2019: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 76%;"/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three and Nine Months Ended</div></div><br/> <div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Stock options</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,964,135</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">6,330,914</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">RSUs</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,702,538</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,425,459</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 76%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">TSR RSUs</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">43,022</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">134,170</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> </table> 5964135 6330914 1702538 1425459 43022 134170 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Recently Issued Accounting Standards </div></div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In June 2016, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">No. 2016-13,</div> “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-13”).</div> This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">available-for-sale</div></div> debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">held-to-maturity</div></div> debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January 1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January 1, 2020 and for the three and nine month period ended September 30, 2020.</div></div></div> <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">3. Inventory </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consists of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Work in process</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,597,413</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1pt;"> <td style="height: 6pt; font-family: 'Times New Roman';"/> <td colspan="4" style="height: 6pt; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,349,725</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,947,138</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory acquired prior to receipt of the FDA approval on December 20, 2019 for CAPLYTA was expensed as research and development expense as incurred. No inventory was produced from the FDA approval date through the end of 2019; therefore, no inventory was capitalized on the consolidated balance sheet as of December 31, 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventory consists of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Raw materials</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">—  </div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Work in process</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,597,413</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1pt;"> <td style="height: 6pt; font-family: 'Times New Roman';"/> <td colspan="4" style="height: 6pt; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 84%;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Finished goods</div></div> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,349,725</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; font-family: &quot;Times New Roman&quot;; width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,947,138</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> 0 1597413 1349725 2947138 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">4. Property and Equipment </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">243,532</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">243,532</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">423,097</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">423,097</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scientific equipment</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,053,185</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,861,227</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,240,315</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,240,315</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,960,129</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,768,171</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,910,577</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(3,508,431</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,049,552</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,259,740</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Depreciation expense for the three and nine months ended September 30, 2020 was $121,044 and $402,146, respectively, as compared to approximately $129,052 and $335,461, respectively, for the three and nine months ended September 30, 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consist of the following: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 73%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,<br/> 2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,<br/> 2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">243,532</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">243,532</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">423,097</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">423,097</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Scientific equipment</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,053,185</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,861,227</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,240,315</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,240,315</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">5,960,129</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,768,171</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">(3,910,577</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">) </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(3,508,431</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,049,552</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">2,259,740</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> 243532 243532 423097 423097 4053185 3861227 1240315 1240315 5960129 5768171 3910577 3508431 2049552 2259740 121044 402146 129052 335461 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">5. Right of Use Assets and Lease Liabilities </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Real Estate Leases </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">In 2014, the Company entered into a long-term lease with a related party which, as amended, provides for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> for accounting purposes. In September 2018, the Company further amended the lease to obtain additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, the Company entered into a long-term lease for office space in Towson, Maryland beginning March 1, 2019. The lease has a term of 3.2 years ending in April 2022 and includes limited rent abatement and escalation provisions.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">In adopting ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02</div> as of January 1, 2019, the Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the condensed consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-lease</div> components as a single lease component. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. The Company recognized those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">present value of lease payments. On the lease commencement dates, the Company estimated the lease liabilities and the right of use assets at present value using its applicable incremental borrowing rates of its two long-term leases of 7.2% for the Company’s Maryland lease of 3.2 years and 9.1% for the Company’s New York leases of 14.3 years. On January 1, 2019, upon adoption of ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">2016-02,</div> the Company recorded right of use assets of approximately $20.2 million, lease liabilities of $23.4 million and eliminated deferred rent of $3.2 million. At the execution of the Maryland lease in 2019, the Company recorded a right of use asset and a lease liability of $0.2 million, which represented a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transaction.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">M</div>aturity analysis under the lease agreements are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%; font-family: 'Times New Roman';"/> <td style="width: 5%; vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three months ending December 31, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">845,566</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2021</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,448,323</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2022</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,491,166</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2023</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,566,466</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2024</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,675,196</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">17,627,040</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">32,653,757</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(10,463,196</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease liability</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">22,190,561</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(3,259,966</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term lease liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">18,930,595</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease expense for the three and nine months ended September 30, 2020 was approximately $0.8 million and $2.5 million, respectively, as compared to approximately $0.8 million and $2.5<div style="letter-spacing: 0px; top: 0px;;display:inline;"> million</div>, respectively, for the three and nine months ended September 30, 2019. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">Vehicle Fleet Lease </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">On May 17, 2019, the Company entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The Company began leasing vehicles under the Vehicle Lease in March 2020. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The contractual period of each lease is 12 months, followed by <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">month-to-month</div></div> renewal periods. The Company estimates the lease term for each vehicle to be 30 months based on industry standards. The lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.4 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease. The $1.4 million is recorded as restricted cash on the condensed consolidated balance sheet.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The nature of the lease is one commonly referred to as “TRAC” lease, as it contains a terminal rental adjustment clause, or “TRAC” clause.” The TRAC clause limits lessee<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>exposure, or likelihood of having a variable lease payment<div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"> </div></div>due at lease termination. This variable lease payment amount would be any difference between the vehicle stipulated (capitalized) cost and the sum of the reserve and net proceeds from disposal as described in the Vehicle Lease. Further, the Lessor guarantees that the net proceeds will not be less than 20% of the vehicle capitalized cost in the first 12 months, and 30% of the vehicle capitalized cost at the beginning of subsequent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">12-month</div> period increments.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Right of use asset and lease liability for the vehicle fleet lease were approximately $6.9 million and $6.9 million, respectively, as of September 30, 2020. The vehicle leases entered into since March 2020 represent <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> transactions. The total operating lease cost for the nine months ended September 30, 2020 was $585,490. The operating cash outflows related to vehicle fleet operating lease obligations for the nine months ended September 30, 2020 were $585,490. </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 44%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Assets and Liabilities – Fleet</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets, net</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">Operating lease right of use assets</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">6,946,254</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">6,946,254</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities, short-term</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">Operating lease liabilities</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">2,007,292</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current operating lease liabilities</div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">4,938,962</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">6,946,254</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">2.2 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">1.85</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the maturity of the Company’s fleet lease liability as of <div style="letter-spacing: 0px; top: 0px;;display:inline;">September</div> 30, 2020:</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Time</div></div></div></div></td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Period </div></div></div></div></div></td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Three months ending December 31, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">530,799</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2021</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,112,506</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2022</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,207,898</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2023</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,273,867</div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">7,125,070</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(178,816</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">6,946,254</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(2,007,292</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term lease liabilities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">4,938,962</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr></table><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets and lease liabilities for <div style="letter-spacing: 0px; top: 0px;;display:inline;">all </div>operating leases were approximately $24.3 million and $29.1 million, respectively, as of September 30, 2020. </div></div> P14Y3M18D P3Y2M12D 0.072 P3Y2M12D 0.091 P14Y3M18D 20200000 23400000 3200000 200000 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">M</div>aturity analysis under the lease agreements are as follows: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 83%; font-family: 'Times New Roman';"/> <td style="width: 5%; vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> <td style="font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Three months ending December 31, 2020</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">845,566</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2021</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,448,323</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2022</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,491,166</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2023</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,566,466</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2024</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,675,196</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">17,627,040</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">32,653,757</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(10,463,196</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total Lease liability</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">22,190,561</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; background-color: rgba(255, 255, 255, 0);;text-align:right;">(3,259,966</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term lease liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">18,930,595</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> </table> 845566 3448323 3491166 3566466 3675196 17627040 32653757 10463196 22190561 3259966 18930595 800000 2500000 800000 2500000 P12M 1400000 1400000 0.20 0.30 6900000 6900000 585490 585490 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2020: </div></div> <div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 44%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> </tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Lease Assets and Liabilities – Fleet</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Classification</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Assets</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Right of use assets, net</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">Operating lease right of use assets</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">6,946,254</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">6,946,254</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Liabilities</div></div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Current</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities, short-term</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;">Operating lease liabilities</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">2,007,292</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-Current</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Lease liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-current operating lease liabilities</div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">4,938,962</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total lease liabilities</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">6,946,254</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="vertical-align: bottom;"> <div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> </td> <td style="font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average remaining lease term</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">2.2 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> </tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"> <div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted average discount rate</div></div> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;;width:6%;">1.85</td> <td style="vertical-align: bottom; white-space: nowrap;">% </td> </tr> </table> 6946254 6946254 2007292 4938962 6946254 P2Y2M12D 0.0185 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the maturity of the Company’s fleet lease liability as of <div style="letter-spacing: 0px; top: 0px;;display:inline;">September</div> 30, 2020:</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"/><div style="font-size: 18pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-size: 18pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></div></div> <table cellpadding="0" cellspacing="0" style="border: 0px currentcolor; width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="page-break-inside: avoid;"> <td style="width: 4%; vertical-align: top;;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Time</div></div></div></div></td> <td style="vertical-align: top;;text-align:left;"><div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 0pt; margin-bottom: 0pt; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Period </div></div></div></div></div></td></tr></table><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 68%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 84%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Three months ending December 31, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">530,799</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2021</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,112,506</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2022</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,207,898</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Year ending December 31, 2023</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">1,273,867</div></td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Thereafter</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">7,125,070</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Present value discount</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(178,816</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total operating lease liabilities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">6,946,254</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(204, 238, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Less: Current portion</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255); width: 6%;">  </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(204, 238, 255);"> </td> <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);;text-align:right;">(2,007,292</td> <td style="vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255);">) </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; break-inside: avoid;"> <td style="vertical-align: top; background-color: rgb(255, 255, 255); width: 84%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Long-term lease liabilities</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);">$</td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);;text-align:right;">4,938,962</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 84%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255); width: 6%;">  </td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: &quot;Times New Roman&quot;; background-color: rgb(255, 255, 255);"> </td></tr></table> 530799 2112506 3207898 1273867 0 7125070 178816 6946254 2007292 4938962 24300000 29100000 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">6. Share-Based Compensation </div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">On June 18, 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provided for the granting of share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. On May 27, 2020, the Company’s stockholders approved the Amended and Restated 2018 Equity Incentive Plan (the “Amended 2018 Plan”), which amended and restated the 2018 Plan. The Amended 2018 Plan provides for the granting of up to </div>6,500,000 <div style="letter-spacing: 0px; top: 0px;;display:inline;">additional share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. In December 2019, the Company adopted the 2019 Inducement Award Plan (the “2019 Inducement Plan”) for the grant of equity awards of up to </div>1,000,000 shares of common stock to newly hired employees. </div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">As of December 31, 2019, the total number of shares reserved under all equity plans was 11,287,390 and the Company had 2,208,317 shares available for future issuance under the Amended 2018 Plan and the 2019 Inducement Plan. Stock options granted under the 2018 Plan and the 2019 Inducement Plan may be either incentive stock options (“ISOs”) as defined by the <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">Internal Revenue Code of 1986, as amended</div></div>, or <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-qualified</div> stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally one to three years) and the exercise prices of such options. Options have a maximum term of 10 years. The exercise price of <div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">stock options</div></div> granted under the Amended 2018 Plan and the 2019 Inducement Plan must be at least equal to the fair market value of the common stock on the date of grant.</div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">share</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">-based compensation expense related to all of the Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2020 and 2019, was comprised of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended September 30,</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended September 30,</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 55%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventoriable costs</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">345,460</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">996,802</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 55%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,402,865</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,023,700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,792,498</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">6,785,280</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 55%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,152,394</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,783,068</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,562,850</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8,064,129</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 55%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,900,719</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">4,806,768</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,352,150</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14,849,409</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2020 and 2019: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;; width: 14%;"/> <td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;; width: 13%;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; width: 69%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); width: 13%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0%</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; width: 13%;;text-align:center;">0%</td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">91.6%-92.7%</div></div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; width: 13%;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">83.7%-85.7%</div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average risk-free interest rate</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.31%</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; width: 13%;;text-align:center;">2.32%</td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.0</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; width: 13%;;text-align:center;">6.0</td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,728</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.18</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">9.5 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,728</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.18</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">9.5 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested or expected to vest at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,728</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.18</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding RSU awards under the 2019 Inducement Plan during the nine month period ended September 30, 2020 are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;">Grant<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>Date</div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>Value<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>Per<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>Share</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs granted in 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">274,410</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.01</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.6 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs cancelled in 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(15,064</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">15.81</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.5 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">259,346</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.01</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.6 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested or expected to vest at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">259,346</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.01</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">As of September 30, 2020, the Company issued options and time based RSUs totaling 314,138 shares in the 2019 Inducement Plan. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan. </div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">6,039,945</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.81</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">7.0 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">742,509</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">23.85</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">9.4 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(696,936</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12.79</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">4.8 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options canceled or expired</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(161,111</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">21.70</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">7.9 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,924,407</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">18.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">6.8 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested or expected to vest at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,924,407</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">18.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,620,984</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">18.85</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">5.7 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the time based RSUs and the Milestone RSUs is based on the closing price of the Company’s common stock on the date of grant.</div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the TSR RSUs was determined using the Monte Carlo simulation method. Information </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> regarding the time based RSU activity and changes during the nine month period ended September 30, 2020 are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 61%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,268,679</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13.60</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">1.7 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs granted in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">728,596</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">23.05</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.7 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs vested in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(506,546</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13.78</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">0.9 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs cancelled in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(90,559</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">1.5 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,400,170</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">18.69</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">1.9 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to the Company’s Milestone RSUs and TSR RSUs during the nine month period ended September 30, 2020 are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">67,080</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.08</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">0.2 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone RSUs and TSR RSUs granted in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">86,044</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">32.56</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.4 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone RSUs and TSR RSUs vested in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(67,080</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.08</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">0.2 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">86,044</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">32.56</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.4 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average estimated fair value per share of the TSR RSUs granted in 2017 was $17.08, which was derived from a Monte Carlo simulation. Significant assumptions utilized in estimating the value of the awards granted include an expected dividend yield of 0%, a risk free rate of 1.6%, and expected volatility of 95.4%. The TSR RSUs granted in 2017 entitled the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ended and vested on December 31, 2019, provided the grantee remained in the service of the Company on the settlement date. The Company expensed the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs was settled was a percentage of shares for which the award was targeted and depended on the Company’s total shareholder return (as defined below), expressed as a percentile ranking of the Company’s total shareholder return as compared to the Company’s peer group (as defined below). The number of shares for which the TSR RSUs were settled varied depending on the level of achievement of the goal. Total shareholder return was determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding January 1, 2020 by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2017, with a deemed reinvestment of any dividends declared during the performance period. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s peer group originally included 223 companies that comprised the Nasdaq Biotechnology Index at December 31, 2018, which was selected by the Compensation Committee of the Company’s Board of Directors and included a range of biotechnology companies operating in several business segments. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The weighted average estimated fair value per share of the TSR RSUs granted in 2020 was $32.56, which was derived from a Monte Carlo simulation. Significant assumptions utilized in estimating the value of the awards granted include an expected dividend yield of 0%, a risk free rate of 1.4%, and expected volatility of 91.3%. The TSR RSUs granted in 2020 will entitle the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ending and vesting on December 31, 2022, provided the grantee remained in the service of the Company on the settlement date. The Company is expensing the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs will be settled is a percentage of shares for which the award is targeted and depends on the Company’s total shareholder return, expressed as a percentile ranking of the Company’s total shareholder return as compared to the Company’s peer group, which is consistent with the TSR RSUs granted in 2017. The number of shares for which the TSR RSUs will be settled will vary depending on the level of achievement of the goal. Total shareholder return will be determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding January 1, 2023 by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2020, with a deemed reinvestment of any dividends declared during the performance period. </div><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The Company’s peer group included companies that compromised the Nasdaq Biotechnology Index at December 31, 2019. </div></div></div></div><div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The Company recognized <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-cash</div> s<div style="letter-spacing: 0px; top: 0px;;display:inline;">hare</div>-based compensation expense related to time based RSU’s for the three and nine months ended September 30, 2020 of approximately $3.2 million and $8.9 million, respectively, as compared to $1.7 million and $5.6 million for the three and nine months ended September 30, 2019, respectively. Total expense for all RSUs, including the time based <div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">and performance based RSUs, is $3.4 million and $9.2 million for the three and nine months ended September 30, 2020, respectively, as </div></div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">compared to $1.9 million and $6.1 million for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, there was $21.6 million of unrecognized compensation costs related to unvested time based RSUs. As of September 30, 2020, there was $1.0 million and $1.1 million of unrecognized compensation costs related to unvested Milestone RSUs and TSR RSUs, respectively. </div></div> 6500000 1000000 11287390 2208317 P3Y P10Y <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">share</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">-based compensation expense related to all of the Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2020 and 2019, was comprised of the following: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 92%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 55%;"/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 3%; vertical-align: bottom;"/> <td/> <td/> <td/> <td style="width: 2%; vertical-align: bottom;"/> <td/> <td/> <td/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended September 30,</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;">  </td> <td colspan="6" style="vertical-align: bottom;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended September 30,</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"> </td></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 55%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Inventoriable costs</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">345,460</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">996,802</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 55%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Research and development</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,402,865</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,023,700</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,792,498</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">6,785,280</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 55%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">General and administrative</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">4,152,394</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">2,783,068</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">11,562,850</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">8,064,129</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 55%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Total share-based compensation expense</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6,900,719</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">4,806,768</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td> <td style="vertical-align: bottom;;text-align:right;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">19,352,150</div></div></td> <td style="vertical-align: bottom; white-space: nowrap;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">14,849,409</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 55%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> 345460 996802 2402865 2023700 6792498 6785280 4152394 2783068 11562850 8064129 6900719 4806768 19352150 14849409 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2020 and 2019: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 76%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;; width: 14%;"/> <td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;; width: 13%;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; width: 69%;"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0); width: 13%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2019</div></div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Dividend yield</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">0%</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; width: 13%;;text-align:center;">0%</td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected volatility</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">91.6%-92.7%</div></div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; width: 13%;;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">83.7%-85.7%</div></td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Weighted-average risk-free interest rate</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.31%</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; width: 13%;;text-align:center;">2.32%</td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 69%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Expected term (in years)</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom; width: 14%;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">6.0</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;"> </td> <td style="vertical-align: bottom; width: 13%;;text-align:center;">6.0</td></tr></table> 0 0 0.916 0.927 0.837 0.857 0.0131 0.0232 P6Y P6Y <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 69%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 4%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,728</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.18</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">9.5 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,728</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.18</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">9.5 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested or expected to vest at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">39,728</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.18</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr></table> 0 0 39728 17.18 P9Y6M 39728 17.18 P9Y6M 39728 17.18 0 0 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding RSU awards under the 2019 Inducement Plan during the nine month period ended September 30, 2020 are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;">Grant<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>Date</div><br/> <div style="letter-spacing: 0px; top: 0px;;display:inline;">Fair<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>Value<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>Per<div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div>Share</div></div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs granted in 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">274,410</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.01</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.6 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs cancelled in 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(15,064</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">15.81</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.5 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">259,346</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.01</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.6 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested or expected to vest at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">259,346</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.01</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 60%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom; white-space: nowrap;">$</td> <td style="vertical-align: bottom; white-space: nowrap;;text-align:right;">—  </td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 60%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 6%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 7%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr></table> 0 0 274410 16.01 P2Y7M6D 15064 15.81 P2Y6M 259346 16.01 P2Y7M6D 259346 16.01 0 0 314138 <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 2%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 3%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Exercise<br/> Price</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">6,039,945</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">16.81</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">7.0 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options granted</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">742,509</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">23.85</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">9.4 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options exercised</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(696,936</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">12.79</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">4.8 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Options canceled or expired</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(161,111</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">21.70</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">7.9 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,924,407</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">18.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">6.8 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Vested or expected to vest at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">5,924,407</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">18.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top; width: 70%;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Exercisable at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">3,620,984</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">18.85</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">5.7 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 70%;"/> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 2%;">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;; width: 3%;">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/></tr></table> 6039945 16.81 P7Y 742509 23.85 P9Y4M24D 696936 12.79 P4Y9M18D 161111 21.70 P7Y10M24D 5924407 18.03 P6Y9M18D 5924407 18.03 3620984 18.85 P5Y8M12D <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The fair value of the TSR RSUs was determined using the Monte Carlo simulation method. Information </div></div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> regarding the time based RSU activity and changes during the nine month period ended September 30, 2020 are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 61%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 5%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,268,679</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13.60</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">1.7 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs granted in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">728,596</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">23.05</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.7 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs vested in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(506,546</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">13.78</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">0.9 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Time based RSUs cancelled in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(90,559</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.03</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">1.5 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">1,400,170</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">18.69</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">1.9 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> 1268679 13.60 P1Y8M12D 728596 23.05 P2Y8M12D 506546 13.78 P0Y10M24D 90559 17.03 P1Y6M 1400170 18.69 P1Y10M24D <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Information related to the Company’s Milestone RSUs and TSR RSUs during the nine month period ended September 30, 2020 are summarized as follows: </div></div><div style="font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div> <table cellpadding="0" cellspacing="0" style="margin: 0px auto; border: 0px currentcolor; width: 84%; font-family: 'Times New Roman'; font-size: 10pt; border-collapse: collapse; border-spacing: 0px;"> <tr style="font-size: 0px;"> <td style="width: 60%; font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 6%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="width: 7%; vertical-align: bottom; font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/> <td style="font-family: &quot;Times New Roman&quot;;"/></tr> <tr style="font-family: Times New Roman; font-size: 8pt; page-break-inside: avoid;"> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Number of<br/> Shares</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-Average<br/> Grant Date<br/> Fair Value Per Share</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';">  </td> <td colspan="2" style="vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1pt; border-bottom-style: solid;;text-align:center;"><div style="font-weight: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted-<br/> Average<br/> Contractual<br/> Life</div></div></td> <td style="vertical-align: bottom; padding-bottom: 0.5pt; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at December 31, 2019</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">67,080</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.08</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">0.2 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone RSUs and TSR RSUs granted in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">86,044</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">32.56</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.4 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid; background-color: rgb(204, 238, 255);"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Milestone RSUs and TSR RSUs vested in 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">(67,080</td> <td style="vertical-align: bottom; white-space: nowrap;">) </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">17.08</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">0.2 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr> <tr style="font-family: Times New Roman; font-size: 10pt; page-break-inside: avoid;"> <td style="vertical-align: top;"><div style="text-indent: -1em; font-family: 'Times New Roman'; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; line-height: normal;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Outstanding at September 30, 2020</div></div></td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom;;text-align:right;">86,044</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;">$</td> <td style="vertical-align: bottom;;text-align:right;">32.56</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';"> </td> <td style="vertical-align:bottom;text-align:right;">2.4 years</td> <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman';"> </td></tr> <tr style="font-size: 1px;"> <td style="vertical-align: bottom; font-family: 'Times New Roman';"/> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td> <td style="vertical-align: bottom; font-family: 'Times New Roman';">  </td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="vertical-align: bottom;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td> <td style="font-family: 'Times New Roman';"> </td></tr></table> 67080 17.08 P0Y2M12D 86044 32.56 P2Y4M24D 67080 17.08 P0Y2M12D 86044 32.56 P2Y4M24D 17.08 0 0.016 0.954 32.56 0 0.014 0.913 3200000 8900000 1700000 5600000 3400000 9200000 1900000 6100000 21600000 1000000.0 1100000 <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-weight:bold;display:inline;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">7. Collaborations and License Agreements </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;">The Bristol-Myers Squibb License Agreement </div></div></div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;">On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">know-how</div> of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">Under the agreement, the Company made an upfront payment of $1.0 million to BMS<div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"> in 2005</div></div>, a milestone payment of $1.25 million in December 2013, and a milestone payment of $1.5 million in December 2014 following the initiation of the Company’s first Phase 3 clinical trial for lumateperone for patients with exacerbated schizophrenia. Upon FDA acceptance of an NDA filing for lumateperone, the Company was obligated to pay BMS a $2.0 million milestone payment, which was paid in January 2019. The FDA approved the NDA filing on December 23, 2019 and as a result the Company accrued an additional milestone liability of $5.0 million in the fourth quarter of 2019 which was paid in January 2020. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-royalty</div> payments made in consideration of any sublicense.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;">The agreement extends, and royalties are payable, on a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">country-by-country</div></div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">product-by-product</div></div> basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.</div> <div style="font-family: Times New Roman; font-size: 10pt; margin-top: 12pt; margin-bottom: 0pt;"><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">In September 2016, the Company transferred certain of its rights under the BMS agreement to its wholly owned subsidiary, ITI Limited. In connection with the transfer, the Company guaranteed ITI Limited’s performance of its obligations under the BMS agreement. With the initial recognition of product sales revenue in the nine months ended September 30, 2020, the Company </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">expensed</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> approximately $506,000 in </div><div style="font-size: 10pt; font-family: 'Times New Roman', serif; letter-spacing: 0px; top: 0px;;display:inline;"><div style="letter-spacing: 0px; top: 0px;;display:inline;">cost of product sales</div></div><div style="font-family: 'Times New Roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"> to satisfy its obligation under the BMS agreement.</div></div> 1000000.0 1250000 1500000 2000000.0 5000000.0 5000000.0 14750000 0.05 0.09 through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product 506000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2020
Nov. 06, 2020
Cover [Abstract]    
Amendment Flag false  
Document Type 10-Q  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Document Quarterly Report true  
Entity Central Index Key 0001567514  
Document Transition Report false  
Current Fiscal Year End Date --12-31  
Document Period End Date Sep. 30, 2020  
Entity Registrant Name Intra-Cellular Therapies, Inc.  
Trading Symbol ITCI  
Entity Filer Category Large Accelerated Filer  
Entity Emerging Growth Company false  
Entity Small Business false  
Entity Interactive Data Current Yes  
Entity Current Reporting Status Yes  
Entity Shell Company false  
Entity File Number 001-36274  
Entity Tax Identification Number 36-4742850  
Entity Incorporation, State or Country Code DE  
Entity Address, Address Line One 430 East 29th Street  
Entity Address, City or Town New York  
Entity Address, State or Province NY  
Entity Address, Postal Zip Code 10016  
City Area Code 646  
Local Phone Number 440-9333  
Title of 12(b) Security Common Stock  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   80,157,554
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 300,988,981 $ 107,636,849
Investment securities, available-for-sale 420,958,509 116,373,335
Restricted cash 1,400,000  
Accounts receivable, net 7,480,604  
Inventory 2,947,138  
Prepaid expenses and other current assets 11,090,774 6,313,785
Total current assets 744,866,006 230,323,969
Property and equipment, net 2,049,552 2,259,740
Right of use assets, net 24,292,167 18,252,074
Deferred tax asset, net   264,609
Other assets 86,084 86,084
Total assets 771,293,809 251,186,476
Current liabilities:    
Accounts payable 8,569,148 7,425,024
Accrued and other current liabilities 12,186,380 16,138,909
Lease liabilities, short-term 5,267,258 3,187,435
Accrued employee benefits 12,005,931 9,472,651
Total current liabilities 38,028,717 36,224,019
Lease liabilities 23,869,557 19,955,186
Total liabilities 61,898,274 56,179,205
Stockholders' equity:    
Common stock, $0.0001 par value: 100,000,000 shares authorized; 80,142,797 and 55,507,497 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively 8,014 5,551
Additional paid-in capital 1,585,023,637 904,971,772
Accumulated deficit (876,404,854) (710,098,369)
Accumulated comprehensive income 768,738 128,317
Total stockholders' equity 709,395,535 195,007,271
Total liabilities and stockholders' equity $ 771,293,809 $ 251,186,476
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Common stock, par value $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 80,142,797 55,507,497
Common stock, shares outstanding 80,142,797 55,507,497
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue $ 7,368,594   $ 10,358,709  
Operating expenses:        
Cost of product sales 556,107   753,957  
Research and development 10,275,368 $ 21,339,792 51,483,551 $ 70,059,113
Selling, general and administrative 52,473,573 15,036,444 128,015,496 42,184,078
Total operating expenses 63,305,048 36,376,236 180,253,004 112,243,191
Loss from operations (55,936,454) (36,376,236) (169,894,295) (112,243,191)
Interest income 752,829 1,513,837 3,591,091 5,105,464
Loss before provision for income taxes (55,183,625) (34,862,399) (166,303,204) (107,137,727)
Income tax expense     3,281 1,600
Net loss $ (55,183,625) $ (34,862,399) $ (166,306,485) $ (107,139,327)
Net loss per common share:        
Basic & Diluted $ (0.79) $ (0.63) $ (2.48) $ (1.94)
Weighted average number of common shares:        
Basic & Diluted 69,530,039 55,207,400 67,030,991 55,155,854
Product sales, net [Member]        
Revenue $ 7,368,594   $ 10,126,999  
Grant revenue [Member]        
Revenue     $ 231,710  
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Statement of Comprehensive Income [Abstract]        
Net loss $ (55,183,625) $ (34,862,399) $ (166,306,485) $ (107,139,327)
Other comprehensive income (loss):        
Unrealized gain (loss) on investment securities (399,361) (33,396) 640,421 866,805
Comprehensive loss $ (55,582,986) $ (34,895,795) $ (165,666,064) $ (106,272,522)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Accumulated Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2018 $ 317,714,881 $ 5,490 $ 880,753,339 $ (562,376,191) $ (667,757)
Balance, shares at Dec. 31, 2018   54,895,295      
Exercise of stock options and issuances of restricted stock (Value) 442,826 $ 34 442,792    
Exercise of stock options and issuances of restricted stock (Shares)   338,054      
Stock issued for services 145,691 $ 1 145,690    
Stock issued for services, shares   14,230      
Share-based compensation 14,849,409   14,849,409    
Net loss (107,139,327)     (107,139,327)  
Other comprehensive gain (loss) 866,805       866,805
Balance at Sep. 30, 2019 226,880,285 $ 5,525 896,191,230 (669,515,518) 199,048
Balance, shares at Sep. 30, 2019   55,247,579      
Balance at Jun. 30, 2019 256,768,362 $ 5,519 891,183,518 (634,653,119) 232,444
Balance, shares at Jun. 30, 2019   55,186,745      
Exercise of stock options and issuances of restricted stock (Value) 152,379 $ 6 152,373    
Exercise of stock options and issuances of restricted stock (Shares)   54,332      
Stock issued for services 48,571   48,571    
Stock issued for services, shares   6,502      
Share-based compensation 4,806,768   4,806,768    
Net loss (34,862,399)     (34,862,399)  
Other comprehensive gain (loss) (33,396)       (33,396)
Balance at Sep. 30, 2019 226,880,285 $ 5,525 896,191,230 (669,515,518) 199,048
Balance, shares at Sep. 30, 2019   55,247,579      
Balance at Dec. 31, 2019 195,007,271 $ 5,551 904,971,772 (710,098,369) 128,317
Balance, shares at Dec. 31, 2019   55,507,497      
Common shares issued 652,712,011 $ 2,341 652,709,670    
Common shares issued, shares   23,409,458      
Exercise of stock options and issuances of restricted stock (Value) 7,829,584 $ 121 7,829,463    
Exercise of stock options and issuances of restricted stock (Shares)   1,218,188      
Stock issued for services 160,583 $ 1 160,582    
Stock issued for services, shares   7,654      
Share-based compensation 19,352,150   19,352,150    
Net loss (166,306,485)     (166,306,485)  
Other comprehensive gain (loss) 640,421       640,421
Balance at Sep. 30, 2020 709,395,535 $ 8,014 1,585,023,637 (876,404,854) 768,738
Balance, shares at Sep. 30, 2020   80,142,797      
Balance at Jun. 30, 2020 379,529,868 $ 6,678 1,199,576,320 (821,221,229) 1,168,099
Balance, shares at Jun. 30, 2020   66,777,737      
Common shares issued 370,138,616 $ 1,318 370,137,298    
Common shares issued, shares   13,179,458      
Common shares receivable collected 5,705,186   5,705,186    
Exercise of stock options and issuances of restricted stock (Value) 2,650,605 $ 18 2,650,587    
Exercise of stock options and issuances of restricted stock (Shares)   183,516      
Stock issued for services 53,527 $ 0 53,527    
Stock issued for services, shares   2,086      
Share-based compensation 6,900,719   6,900,719    
Net loss (55,183,625)     (55,183,625)  
Other comprehensive gain (loss) (399,361)       (399,361)
Balance at Sep. 30, 2020 $ 709,395,535 $ 8,014 $ 1,585,023,637 $ (876,404,854) $ 768,738
Balance, shares at Sep. 30, 2020   80,142,797      
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flows used in operating activities    
Net loss $ (166,306,485) $ (107,139,327)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 402,146 335,461
Share-based compensation 19,352,150 14,849,409
Stock issued for services 160,583 145,691
Amortization of premiums and discounts on investment securities, net (177,374) (871,412)
Changes in operating assets and liabilities:    
Accounts receivable, net (7,480,604)  
Inventory (2,947,138)  
Prepaid expenses and other assets (4,776,989) 4,020,430
Long term deferred tax asset, net 264,609  
Accounts payable 1,144,124 (7,730,137)
Accrued liabilities and other (1,419,249) 3,462,560
Lease liabilities, net (45,899)  
Net cash used in operating activities (161,830,126) (92,927,325)
Cash flows (used in) provided by investing activities    
Purchases of investments (488,524,539) (58,332,886)
Maturities of investments 184,757,160 199,383,553
Purchases of property and equipment (191,958) (1,350,688)
Net cash (used in) provided by investing activities (303,959,337) 139,699,979
Cash flows provided by financing activities    
Proceeds from exercise of stock options 7,829,584 442,826
Proceeds of public offering, net 652,712,011  
Net cash provided by financing activities 660,541,595 442,826
Net increase in cash, cash equivalents, and restricted cash 194,752,132 47,215,480
Cash, cash equivalents, and restricted cash at beginning of period 107,636,849 54,947,502
Cash, cash equivalents, and restricted cash at end of period 302,388,981 102,162,982
Vehicle Fleet Lease [Member]    
Non-cash investing and financing activities    
Right of use assets under operating $ 7,750,959  
Real Estate Lease [Member]    
Non-cash investing and financing activities    
Right of use assets under operating   $ 219,703
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2018
Statement of Cash Flows [Abstract]        
Cash and cash equivalents $ 300,988,981 $ 107,636,849 $ 102,162,982  
Restricted cash 1,400,000      
Total cash, cash equivalents and restricted cash $ 302,388,981 $ 107,636,849 $ 102,162,982 $ 54,947,502
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Organization
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization
1. Organization
Intra-Cellular Therapies, Inc. (the “Company”), through its wholly-owned operating subsidiaries, ITI, Inc. (“ITI”) and ITI Limited, is a biopharmaceutical company focused on the discovery, clinical development and commercialization of innovative, small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (“CNS”). In December 2019, the Company announced that CAPLYTA
TM
(lumateperone) had been approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of schizophrenia in adults (42mg/day). The Company initiated the commercial launch of CAPLYTA in late March 2020. As used in these Notes to Condensed Consolidated Financial Statements, “CAPLYTA” refers to lumateperone approved by the FDA for the treatment of schizophrenia in adults, and “lumateperone” refers to, where applicable, CAPLYTA as well as lumateperone for the treatment of indications beyond schizophrenia. Lumateperone is in Phase 3 clinical development as a novel treatment for bipolar depression.
On January 10, 2020, the Company completed a public offering of common stock in which the Company sold 10,000,000 shares of common stock at an offering price of $29.50 per share for aggregate gross proceeds of $295.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $277.0 million.
 
On September 15, 2020
,
the Company completed a public offering of common stock in which the Company sold 12,666,667 shares of common stock at an offering price of $30.00 per share for aggregate gross proceeds of $380.0 million. After deducting underwriting discounts, commissions and offering expenses, the net proceeds to the Company were approximately $357.8 million.
In order to further its commercial activities and research projects and support its collaborations, the Company will require additional financing until such time, if ever, that revenue streams are sufficient to generate consistent positive cash flow from operations. The Company currently projects that its cash, cash equivalents and investments will be sufficient to fund operating expenses and capital expenditures for at least one year from the date that these financial statements are filed with the Securities and Exchange Commission (the “SEC”). Possible sources of funds include public or private sales of the Company’s equity securities, sales of debt securities, the incurrence of debt from commercial lenders, strategic collaborations, licensing a portion or all of the Company’s product candidates and technology and, to a lesser extent, grant funding. On August 30, 2019, the Company filed a universal shelf registration statement on Form
S-3,
which was declared effective by the SEC on September 12, 2019, on which the Company registered for sale up to $350 million of any combination of its common stock, preferred stock, debt securities, warrants, rights and/or units from time to time and at prices and on terms that the Company may determine, which includes up to $75 million of common stock that the Company may issue and sell from time to time, through SVB Leerink LLC acting as its sales agent, pursuant to the sale agreement that the Company entered into with SVB Leerink on August 29, 2019 for the Company’s
“at-the-market”
equity program. On September 10, 2020, the Company terminated the
“at-the-market”
equity program sales agreement with SVB Leerink LLC. Through the date of the termination of the sales agreement on September 10, 2020, the Company had issued an aggregate 742,791 shares of common stock under the Company’s
“at-the-market”
equity program which resulted in the Company receiving net proceeds of $17.9 million.
In addition, on January 6, 2020, the Company filed an automatic shelf registration statement on Form
S-3
with the SEC, which became effective upon filing, on which the Company registered for sale an unlimited amount of any combination of its common stock, preferred stock, debt securities, warrants, rights, and/or units from time to time and at prices and on terms that the Company may determine, so long as the Company continues to satisfy the requirements of a “well-known seasoned issuer” under SEC rules. These registration statements will remain in effect for up to three years from the respective dates they became effective.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
2. Summary of Significant Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs for the treatment of neurological and psychiatric disorders.
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets.
Investment Securities
Investment securities consisted of the following (in thousands):
 
    
September 30, 2020
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
    
(Unaudited)
  
U.S. Government Agency Securities
    $ 159,237      $ 12      $ (32 )     $ 159,217  
Certificates of Deposit
      10,500        —          —          10,500  
Commercial Paper
      78,788        138        (2 )       78,924  
Corporate Notes/Bonds
      171,665        782        (129 )       172,318  
  
 
 
     
 
 
     
 
 
     
 
 
  
   $ 420,190      $ 932      $ (163 )     $ 420,959  
  
 
 
     
 
 
     
 
 
     
 
 
  
    
December 31, 2019
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
U.S. Government Agency Securities
    $ 35,462      $ 35      $ (3 )     $ 35,494  
Certificates of Deposit
      3,000        —          —          3,000  
Commercial Paper
      39,013        10        (5 )       39,018  
Corporate Notes/Bonds
      38,770        91        —          38,861  
  
 
 
     
 
 
     
 
 
     
 
 
  
   $ 116,245      $ 136      $ (8 )     $ 116,373  
  
 
 
     
 
 
     
 
 
     
 
 
  
The Company has classified all of its investment securities as
available-for-sale,
including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2020, and December 31, 2019, the Company held $197.3 million and $3.0 million, respectively, of
available-for-sale
investment securities with contractual maturity dates more than one year and less than two years.
The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect.
The aggregate related fair value of investments with unrealized losses as of September 30, 2020 was $192.8 million, which consisted of $110.4 million from U.S. government agency securities, $10.0 million of commercial paper, and $72.4 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2020 was approximately $163,000, which consisted of $32,000 from U.S. government agency securities, $2,000 from commercial paper, and $129,000 from corporate notes/bonds. The $192.8 million aggregate fair value of investments with unrealized losses as of September 30, 2020 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2019, the Company had approximately $29.6 million of investments with a continuous unrealized loss for 12 months or longer of which approximately $12.5 million had been held in a continuous loss position for 12 months or longer.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant.
Fair Value Measurements
The Company applies the fair value method under ASC Topic 820,
Fair Value Measurements and Disclosures
. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
 
 
•
 
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
 
 
•
 
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
 
 
•
 
Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy.
The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2020 or December 31, 2019. The carrying value of cash held in money market funds of approximately $224.2 million as of September 30, 2020 and $49.9 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of certificates of deposit of approximately
$
47.6 million as of December 31, 2019 is also included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs. The carrying value of commercial paper of approximately $3.0 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs.
The fair value measurements of the Company’s cash equivalents and
available-for-sale
investment securities are identified in the following tables (in thousands):
 
           
Fair Value Measurements at
Reporting Date Using
  
    
September 30,
2020
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 224,239      $ 224,239      $ —      $ —  
U.S. Government Agency Securities
      159,217        —          159,217        —    
Certificates of Deposit
      10,500        —          10,500        —    
Commercial Paper
      78,924        —          78,924        —    
Corporate Notes/Bonds
      172,318        —          172,318        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
  
$
645,198
 
   
$
224,239
 
   
$
420,959
 
   
$
—  
  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
           
Fair Value Measurements at
Reporting Date Using
  
    
December 31,
2019
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 49,882      $ 49,882      $ —      $ —  
U.S. Government Agency Securities
      35,494        —          35,494        —    
Certificates of Deposit
      50,622        —          50,622        —    
Commercial Paper
      42,015        —          42,015        —    
Corporate Notes/Bonds
      38,861        —          38,861        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
  
$
216,874
 
   
$
49,882
 
   
$
166,992
 
   
$
—  
  
  
 
 
     
 
 
     
 
 
     
 
 
  
Financial Instruments
The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2020 and December 31, 2019. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing.
Restricted Cash
Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU
No. 2016-18,
“Restricted Cash” (“ASU
2016-18”)
and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows.
Accounts Receivable, net
The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees.
The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. For the three and nine months ended September 30, 2020, 96% of sales were generated from three major industry wholesalers, respectively.
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine months ended September 30, 2020, all of the Company’s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 90 days. Three individual customers accounted for approximately 39%, 29%, and 28% of product sales for the three months ended September 30, 2020 as well as accounted for approximately 41%, 27% and 27% of product sales for the nine months ended September 30, 2020. As of September 30, 2020, the Company believes that such customers are of high credit quality.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
Inventory
The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a
first-in,
first-out
(“FIFO”) basis. The
Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales.
The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed.
Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs.
Property and Equipment
Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred.
When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360,
Property, Plant and Equipment
. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date.
Revenue Recognition
Effective January 1, 2018, the Company adopted FASB ASC Topic 606,
 Revenue from Contracts with Customers
(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact in the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine months ended September 30, 2020 reflect the application of ASC Topic 606.
To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see
Product Sales, net
(below).
To date, the Company’s only source of product sales has been from sales of CAPLYTA in the U.S., which the Company began shipping to customers in March 2020.
Product Sales, net
The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the
 
Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue.
Reserves for Variable Consideration
Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product.
These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include estimates that take into consideration a range of possible outcomes which are either considered more likely or probability-weighted in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA and historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, historical information related to similar products in their initial launch stages. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts after considering whether revenue should be constrained under ASC 606.
The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2020 and, therefore, the transaction price was not reduced further during the three and nine months ended September 30, 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known.
Trade Discounts and Allowances
— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of net sales within the condensed consolidated statements of operations through September 30, 2020, as well as a reduction to trade receivables, net on the condensed consolidated balance sheets.
Product Returns
— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any returns to date.
Provider Chargebacks and Discounts
— Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivables, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting
period-end
that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine months ended September 30, 2020, these amounts were not significant.
Government Rebates
— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.
Payer Rebates
— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Other Incentives
— Other incentives which the Company offers include voluntary patient assistance programs, such as the
co-pay
assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug
co-payments
required by payers. The calculation of the accrual for
co-pay
assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company estimates the number of claims through vouchers for product that is in the distribution channel inventories and reduces recognized revenue accordingly.
The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Cost of Product Sales
Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs).
For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations.
Prior to FDA approval of CAPLYTA, the Company
expensed all
costs associated with the manufacturing of lumateperone as part of research and development expenses
.
 From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production and no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the nine months ended September 30, 2020 are lower than incurred because of previously expensed inventory.
Research and Development, Including Clinical Trial Expenses
Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees.
Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be.
 
As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the nine-months ended September 30, 2020, the Company recorded a change in estimate of approximately $3.3 million of accrued expenses for clinical trials related to the first and second quarter of 2020 which resulted in an increase of clinical trial expense in the nine month period ending September 30, 2020. For the three and nine months ended September 30, 2020 and 2019, there were no material adjustments to the Company’s prior year estimates of accrued expenses for clinical trials.
 
Income Taxes
Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.
 109
). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not
threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.
The Company’s effective tax rate for the three and nine months ended September 30, 2020 and 2019 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit.
On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (CARES) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the three and nine months ended September 30, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020.
Comprehensive Income (Loss)
All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are incurred. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive income (loss) for each period.
 
Share-Based Compensation
Share-based payments are accounted for in accordance with the provisions of ASC Topic 718,
Compensation—Stock Compensation
. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.
For all awards granted with time based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the three and nine months ended September 30, 2020 and 2019 accounts for forfeitures as they occur.
The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. In the fourth quarter of 2019, expected volatility rates are based entirely on the historical volatility of the Company’s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term.
The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant.
A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company.
In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. In the first quarter of 2017, the Company granted performance-based RSUs, which vest based on the achievement of certain milestones that include (i) the submission of a new drug application (“NDA”) to the FDA for lumateperone for the treatment of schizophrenia, (ii) the approval of the NDA by the FDA (together, the “Milestone RSUs”) and (iii) the achievement of certain comparative shareholder returns against the Company’s peers (the “TSR RSUs”). The Milestone RSUs related to the NDA submission were fully amortized on December 31, 2018. The NDA submission milestone was achieved in the third quarter of 2018, so the Milestone RSUs related to the NDA submission vested on December 31, 2018. The Milestone RSU’s related to the NDA approval was achieved in the fourth quarter of 2019, so the RSU’s vested on December 31, 2019. The Milestone RSUs related to the approval of the NDA were fully amortized on December 31, 2019. The TSR RSUs were valued using the Monte Carlo Simulation method and were amortized over the life of the RSUs based on the agreements which vested on January 24, 2020.
In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements.
Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740,
Income Taxes
. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance.
 
Since the Company has losses and also maintains a full valuation allowance to cover its deferred tax assets as of September 30, 2020 and 2019, excess tax benefits, if any, recognized for the tax deductions related to share-based awards will add to the Company’s net operating loss deferred tax asset and covered by valuation allowances.
Equity instruments issued to
non-employees
for services are accounted for under the provisions of ASC Topic 718 and ASC Topic
505-50,
Equity/Equity-Based Payments to
Non-Employees
. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period.
In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants.
In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2020, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan.
 
Loss Per Share
Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs.
The following awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2020 and 2019:
 
    
Three and Nine Months Ended

September 30,
  
    
2020
     
2019
  
Stock options
      5,964,135        6,330,914  
RSUs
      1,702,538        1,425,459  
TSR RSUs
      43,022        134,170  
Recently Issued Accounting Standards
In June 2016, the FASB issued ASU
No. 2016-13,
“Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU
2016-13”).
This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For
available-for-sale
debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and
held-to-maturity
debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January 1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January 1, 2020 and for the three and nine month period ended September 30, 2020.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory
 9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Inventory
3. Inventory
Inventory consists of the following:
 
    
September 30,
2020
  
Raw materials
   
$
—  
  
Work in process
   
 
1,597,413
 
Finished goods
   
 
1,349,725
 
  
 
 
  
  
$
2,947,138
 
  
 
 
  
Inventory acquired prior to receipt of the FDA approval on December 20, 2019 for CAPLYTA was expensed as research and development expense as incurred. No inventory was produced from the FDA approval date through the end of 2019; therefore, no inventory was capitalized on the consolidated balance sheet as of December 31, 2019.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment
 9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
Property and Equipment
4. Property and Equipment
Property and equipment consist of the following:
 
    
September 30,
2020
     
December 31,
2019
  
Computer equipment
   
$
243,532
 
    $ 243,532  
Furniture and fixtures
   
 
423,097
 
      423,097  
Scientific equipment
   
 
4,053,185
 
      3,861,227  
Leasehold improvements
   
 
1,240,315
 
      1,240,315  
  
 
 
     
 
 
  
  
 
5,960,129
 
      5,768,171  
Less accumulated depreciation
   
 
(3,910,577
) 
      (3,508,431 ) 
  
 
 
     
 
 
  
  
$
2,049,552
 
    $ 2,259,740  
  
 
 
     
 
 
  
Depreciation expense for the three and nine months ended September 30, 2020 was $121,044 and $402,146, respectively, as compared to approximately $129,052 and $335,461, respectively, for the three and nine months ended September 30, 2019.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Right of Use Assets and Lease Liabilities
 9 Months Ended
Sep. 30, 2020
Leases [Abstract]  
Right of Use Assets and Lease Liabilities
5. Right of Use Assets and Lease Liabilities
Real Estate Leases
In 2014, the Company entered into a long-term lease with a related party which, as amended, provides for a lease of useable laboratory and office space located in New York, New York. A member of the Company’s board of directors is the Executive Chairman of the parent company to the landlord under this lease. Concurrent with this lease, the Company entered into a license agreement to occupy certain vivarium related space in the same facility for the same term and rent escalation provisions as the lease. This license has the primary characteristics of a lease and is characterized as a lease in accordance with ASU
2016-02
for accounting purposes. In September 2018, the Company further amended the lease to obtain additional office space beginning October 1, 2018 and to extend the term of the lease for previously acquired space. The lease, as amended, has a term of 14.3 years ending in May 2029. In February 2019, the Company entered into a long-term lease for office space in Towson, Maryland beginning March 1, 2019. The lease has a term of 3.2 years ending in April 2022 and includes limited rent abatement and escalation provisions.
In adopting ASU
2016-02
as of January 1, 2019, the Company elected the package of practical expedients, which permit the Company not to reassess under the new standard the historical lease classification. The Company made an accounting policy election to keep leases with an initial term of 12 months or less off of the condensed consolidated balance sheets. The Company also elected the lessee component election, allowing the Company to account for the lease and
non-lease
components as a single lease component. In determining whether a contract contains a lease, asset and service agreements are assessed at onset and upon modification for criteria of specifically identified assets, control and economic benefit. The Company recognized those lease payments in the consolidated statements of operations on a straight-line basis over the lease term. The Company uses the rate implicit in the contract whenever possible when determining the applicable discount rate. As the majority of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the
present value of lease payments. On the lease commencement dates, the Company estimated the lease liabilities and the right of use assets at present value using its applicable incremental borrowing rates of its two long-term leases of 7.2% for the Company’s Maryland lease of 3.2 years and 9.1% for the Company’s New York leases of 14.3 years. On January 1, 2019, upon adoption of ASU
2016-02,
the Company recorded right of use assets of approximately $20.2 million, lease liabilities of $23.4 million and eliminated deferred rent of $3.2 million. At the execution of the Maryland lease in 2019, the Company recorded a right of use asset and a lease liability of $0.2 million, which represented a
non-cash
transaction.
M
aturity analysis under the lease agreements are as follows:
 
Three months ending December 31, 2020
    $ 845,566  
Year ending December 31, 2021
      3,448,323  
Year ending December 31, 2022
      3,491,166  
Year ending December 31, 2023
      3,566,466  
Year ending December 31, 2024
      3,675,196  
Thereafter
      17,627,040  
  
 
 
  
Total
      32,653,757  
Less: Present value discount
      (10,463,196 ) 
  
 
 
  
Total Lease liability
      22,190,561  
  
 
 
  
Less: Current portion
      (3,259,966 ) 
  
 
 
  
Long-term lease liabilities
    $ 18,930,595  
  
 
 
  
Lease expense for the three and nine months ended September 30, 2020 was approximately $0.8 million and $2.5 million, respectively, as compared to approximately $0.8 million and $2.5
 million
, respectively, for the three and nine months ended September 30, 2019.
Vehicle Fleet Lease
On May 17, 2019, the Company entered into an agreement (the “Vehicle Lease”) with a company (the “Lessor”) to acquire motor vehicles for certain employees. The Vehicle Lease provides for individual leases for the vehicles, which at each lease commencement was determined to qualify for operating lease treatment. The Company began leasing vehicles under the Vehicle Lease in March 2020.
The contractual period of each lease is 12 months, followed by
month-to-month
renewal periods. The Company estimates the lease term for each vehicle to be 30 months based on industry standards. The lease permits either party to terminate the lease at any time via written notice to the other party. The Company neither acquires ownership of, nor has the option to purchase the vehicles at any time. The Company is required to maintain an irrevocable $1.4 million letter of credit that the Lessor may draw upon in the event the Company defaults on the Vehicle Lease. The $1.4 million is recorded as restricted cash on the condensed consolidated balance sheet.
The nature of the lease is one commonly referred to as “TRAC” lease, as it contains a terminal rental adjustment clause, or “TRAC” clause.” The TRAC clause limits lessee
exposure, or likelihood of having a variable lease payment
due at lease termination. This variable lease payment amount would be any difference between the vehicle stipulated (capitalized) cost and the sum of the reserve and net proceeds from disposal as described in the Vehicle Lease. Further, the Lessor guarantees that the net proceeds will not be less than 20% of the vehicle capitalized cost in the first 12 months, and 30% of the vehicle capitalized cost at the beginning of subsequent
12-month
period increments.
Right of use asset and lease liability for the vehicle fleet lease were approximately $6.9 million and $6.9 million, respectively, as of September 30, 2020. The vehicle leases entered into since March 2020 represent
non-cash
transactions. The total operating lease cost for the nine months ended September 30, 2020 was $585,490. The operating cash outflows related to vehicle fleet operating lease obligations for the nine months ended September 30, 2020 were $585,490.
The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2020:
 
Lease Assets and Liabilities – Fleet
   
Classification
     
September 30, 2020
  
Assets
      
Right of use assets, net
      Operating lease right of use assets      $ 6,946,254  
     
 
 
  
      $ 6,946,254  
     
 
 
  
Liabilities
      
Current
      
Lease liabilities, short-term
      Operating lease liabilities      $ 2,007,292  
Non-Current
      
Lease liabilities
     
Non-current operating lease liabilities
        4,938,962  
     
 
 
  
Total lease liabilities
       $ 6,946,254  
     
 
 
  
Weighted average remaining lease term
         2.2 years  
Weighted average discount rate
         1.85 % 
The following table presents the maturity of the Company’s fleet lease liability as of
September
 30, 2020:
 
Time
Period
 
Three months ending December 31, 2020
    $ 530,799  
Year ending December 31, 2021
      2,112,506  
Year ending December 31, 2022
      3,207,898  
Year ending December 31, 2023
     
1,273,867
  
Thereafter
      —    
  
 
 
  
Total
      7,125,070  
Less: Present value discount
      (178,816 ) 
  
 
 
  
Total operating lease liabilities
      6,946,254  
  
 
 
  
Less: Current portion
      (2,007,292 ) 
  
 
 
  
Long-term lease liabilities
    $ 4,938,962  
  
 
 
  
Right of use assets and lease liabilities for
all
operating leases were approximately $24.3 million and $29.1 million, respectively, as of September 30, 2020.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation
 9 Months Ended
Sep. 30, 2020
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-Based Compensation
6. Share-Based Compensation
On June 18, 2018, the Company’s stockholders approved the 2018 Equity Incentive Plan (the “2018 Plan”). The 2018 Plan provided for the granting of share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. On May 27, 2020, the Company’s stockholders approved the Amended and Restated 2018 Equity Incentive Plan (the “Amended 2018 Plan”), which amended and restated the 2018 Plan. The Amended 2018 Plan provides for the granting of up to 
6,500,000
additional share-based awards, such as stock options, restricted common stock, RSUs and stock appreciation rights to employees, directors and consultants as determined by the Board of Directors. In December 2019, the Company adopted the 2019 Inducement Award Plan (the “2019 Inducement Plan”) for the grant of equity awards of up to 
1,000,000 shares of common stock to newly hired employees.
As of December 31, 2019, the total number of shares reserved under all equity plans was 11,287,390 and the Company had 2,208,317 shares available for future issuance under the Amended 2018 Plan and the 2019 Inducement Plan. Stock options granted under the 2018 Plan and the 2019 Inducement Plan may be either incentive stock options (“ISOs”) as defined by the
Internal Revenue Code of 1986, as amended
, or
non-qualified
stock options. The Board of Directors determines who will receive options, the vesting periods (which are generally one to three years) and the exercise prices of such options. Options have a maximum term of 10 years. The exercise price of
stock options
 granted under the Amended 2018 Plan and the 2019 Inducement Plan must be at least equal to the fair market value of the common stock on the date of grant.
Total
share
-based compensation expense related to all of the Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2020 and 2019, was comprised of the following:
 
    
Three Months Ended September 30,
     
Nine Months Ended September 30,
  
    
2020
     
2019
     
2020
     
2019
  
Inventoriable costs
   
$
345,460
 
    $ —     
$
996,802
 
    $ —  
Research and development
   
 
2,402,865
 
      2,023,700     
 
6,792,498
 
    $ 6,785,280  
General and administrative
   
 
4,152,394
 
      2,783,068     
 
11,562,850
 
      8,064,129  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total share-based compensation expense
   
$
6,900,719
 
    $ 4,806,768     
$
19,352,150
 
    $ 14,849,409  
  
 
 
     
 
 
     
 
 
     
 
 
  
The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2020 and 2019:
 
    
2020
  
2019
Dividend yield
   
0%
   0%
Expected volatility
   
91.6%-92.7%
  
83.7%-85.7%
Weighted-average risk-free interest rate
   
1.31%
   2.32%
Expected term (in years)
   
6.0
   6.0
Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      —        $ —     
Options granted in 2020
      39,728      $ 17.18        9.5 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      39,728      $ 17.18        9.5 years  
  
 
 
     
 
 
     
Vested or expected to vest at September 30, 2020
      39,728      $ 17.18     
  
 
 
     
 
 
     
Exercisable at September 30, 2020
      —        $ —     
  
 
 
     
 
 
     
Information regarding RSU awards under the 2019 Inducement Plan during the nine month period ended September 30, 2020 are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Grant
 
Date

Fair
 
Value
 
Per
 
Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      —        $ —     
Time based RSUs granted in 2020
      274,410      $ 16.01        2.6 years  
Time based RSUs cancelled in 2020
      (15,064 )     $ 15.81        2.5 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      259,346      $ 16.01        2.6 years  
  
 
 
     
 
 
     
Vested or expected to vest at September 30, 2020
      259,346      $ 16.01     
  
 
 
     
 
 
     
Exercisable at September 30, 2020
      —        $ —     
  
 
 
     
 
 
     
As of September 30, 2020, the Company issued options and time based RSUs totaling 314,138 shares in the 2019 Inducement Plan. The Company does not intend to issue any additional equity awards under the 2019 Inducement Plan.
Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      6,039,945      $ 16.81        7.0 years  
Options granted
      742,509      $ 23.85        9.4 years  
Options exercised
      (696,936 )     $ 12.79        4.8 years  
Options canceled or expired
      (161,111 )     $ 21.70        7.9 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      5,924,407      $ 18.03        6.8 years  
  
 
 
     
 
 
     
Vested or expected to vest at September 30, 2020
      5,924,407      $ 18.03     
  
 
 
     
 
 
     
Exercisable at September 30, 2020
      3,620,984      $ 18.85        5.7 years  
  
 
 
     
 
 
     
The fair value of the time based RSUs and the Milestone RSUs is based on the closing price of the Company’s common stock on the date of grant.
The fair value of the TSR RSUs was determined using the Monte Carlo simulation method. Information
regarding the time based RSU activity and changes during the nine month period ended September 30, 2020 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      1,268,679      $ 13.60        1.7 years  
Time based RSUs granted in 2020
      728,596      $ 23.05        2.7 years  
Time based RSUs vested in 2020
      (506,546 )     $ 13.78        0.9 years  
Time based RSUs cancelled in 2020
      (90,559 )     $ 17.03        1.5 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      1,400,170      $ 18.69        1.9 years  
  
 
 
     
 
 
     
 
 
  
Information related to the Company’s Milestone RSUs and TSR RSUs during the nine month period ended September 30, 2020 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      67,080      $ 17.08        0.2 years  
Milestone RSUs and TSR RSUs granted in 2020
      86,044      $ 32.56        2.4 years  
Milestone RSUs and TSR RSUs vested in 2020
      (67,080 )     $ 17.08        0.2 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      86,044      $ 32.56        2.4 years  
  
 
 
     
 
 
     
 
 
  
The weighted average estimated fair value per share of the TSR RSUs granted in 2017 was $17.08, which was derived from a Monte Carlo simulation. Significant assumptions utilized in estimating the value of the awards granted include an expected dividend yield of 0%, a risk free rate of 1.6%, and expected volatility of 95.4%. The TSR RSUs granted in 2017 entitled the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ended and vested on December 31, 2019, provided the grantee remained in the service of the Company on the settlement date. The Company expensed the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs was settled was a percentage of shares for which the award was targeted and depended on the Company’s total shareholder return (as defined below), expressed as a percentile ranking of the Company’s total shareholder return as compared to the Company’s peer group (as defined below). The number of shares for which the TSR RSUs were settled varied depending on the level of achievement of the goal. Total shareholder return was determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding January 1, 2020 by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2017, with a deemed reinvestment of any dividends declared during the performance period.
The Company’s peer group originally included 223 companies that comprised the Nasdaq Biotechnology Index at December 31, 2018, which was selected by the Compensation Committee of the Company’s Board of Directors and included a range of biotechnology companies operating in several business segments.
The weighted average estimated fair value per share of the TSR RSUs granted in 2020 was $32.56, which was derived from a Monte Carlo simulation. Significant assumptions utilized in estimating the value of the awards granted include an expected dividend yield of 0%, a risk free rate of 1.4%, and expected volatility of 91.3%. The TSR RSUs granted in 2020 will entitle the grantee to receive a number of shares of the Company’s common stock determined over a three-year performance period ending and vesting on December 31, 2022, provided the grantee remained in the service of the Company on the settlement date. The Company is expensing the cost of these awards ratably over the requisite service period. The number of shares for which the TSR RSUs will be settled is a percentage of shares for which the award is targeted and depends on the Company’s total shareholder return, expressed as a percentile ranking of the Company’s total shareholder return as compared to the Company’s peer group, which is consistent with the TSR RSUs granted in 2017. The number of shares for which the TSR RSUs will be settled will vary depending on the level of achievement of the goal. Total shareholder return will be determined by dividing the average share value of the Company’s common stock over the 30 trading days preceding January 1, 2023 by the average share value of the Company’s common stock over the 30 trading days beginning on January 1, 2020, with a deemed reinvestment of any dividends declared during the performance period.
The Company’s peer group included companies that compromised the Nasdaq Biotechnology Index at December 31, 2019.
The Company recognized
non-cash
s
hare
-based compensation expense related to time based RSU’s for the three and nine months ended September 30, 2020 of approximately $3.2 million and $8.9 million, respectively, as compared to $1.7 million and $5.6 million for the three and nine months ended September 30, 2019, respectively. Total expense for all RSUs, including the time based
and performance based RSUs, is $3.4 million and $9.2 million for the three and nine months ended September 30, 2020, respectively, as
compared to $1.9 million and $6.1 million for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, there was $21.6 million of unrecognized compensation costs related to unvested time based RSUs. As of September 30, 2020, there was $1.0 million and $1.1 million of unrecognized compensation costs related to unvested Milestone RSUs and TSR RSUs, respectively.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborations and License Agreements
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaborations and License Agreements
7. Collaborations and License Agreements
The Bristol-Myers Squibb License Agreement
On May 31, 2005, the Company entered into a worldwide, exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company holds a license to certain patents and
know-how
of BMS relating to lumateperone and other specified compounds. The agreement was amended on November 3, 2010. The licensed rights are exclusive, except BMS retains rights in specified compounds in the fields of obesity, diabetes, metabolic syndrome and cardiovascular disease. However, BMS has no right to use, develop or commercialize lumateperone and other specified compounds in any field of use. The Company has the right to grant sublicenses of the rights conveyed by BMS. The Company is obliged under the agreement to use commercially reasonable efforts to develop and commercialize the licensed technology. The Company is also prohibited from engaging in the clinical development or commercialization of specified competitive compounds.
Under the agreement, the Company made an upfront payment of $1.0 million to BMS
 in 2005
, a milestone payment of $1.25 million in December 2013, and a milestone payment of $1.5 million in December 2014 following the initiation of the Company’s first Phase 3 clinical trial for lumateperone for patients with exacerbated schizophrenia. Upon FDA acceptance of an NDA filing for lumateperone, the Company was obligated to pay BMS a $2.0 million milestone payment, which was paid in January 2019. The FDA approved the NDA filing on December 23, 2019 and as a result the Company accrued an additional milestone liability of $5.0 million in the fourth quarter of 2019 which was paid in January 2020. Possible milestone payments remaining total $5.0 million. Under the agreement, the Company may be obliged to make other milestone payments to BMS for each licensed product of up to an aggregate of approximately $14.75 million. The Company is also obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The Company is obliged to pay to BMS a percentage of
non-royalty
payments made in consideration of any sublicense.
The agreement extends, and royalties are payable, on a
country-by-country
and
product-by-product
basis, through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product, its method of manufacture or use, or the expiration of other government grants providing market exclusivity, subject to certain rights of the parties to terminate the agreement on the occurrence of certain events. On termination of the agreement, the Company may be obliged to convey to BMS rights in developments relating to a licensed compound or licensed product, including regulatory filings, research results and other intellectual property rights.
In September 2016, the Company transferred certain of its rights under the BMS agreement to its wholly owned subsidiary, ITI Limited. In connection with the transfer, the Company guaranteed ITI Limited’s performance of its obligations under the BMS agreement. With the initial recognition of product sales revenue in the nine months ended September 30, 2020, the Company
expensed
approximately $506,000 in
cost of product sales
to satisfy its obligation under the BMS agreement.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements of Intra-Cellular Therapies, Inc. and its wholly own subsidiaries have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP set forth in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in one operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in one segment, which is discovering, developing and commercializing drugs for the treatment of neurological and psychiatric disorders.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers all highly liquid investments with a maturity of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of checking accounts, money market accounts, money market mutual funds, and certificates of deposit with a maturity date of three months or less. The carrying values of cash and cash equivalents approximate the fair market value. Certificates of deposit, commercial paper, corporate notes and corporate bonds with a maturity date of more than three months are classified separately on the condensed consolidated balance sheets.
Investment Securities, available-for-sale
Investment Securities
Investment securities consisted of the following (in thousands):
 
    
September 30, 2020
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
    
(Unaudited)
  
U.S. Government Agency Securities
    $ 159,237      $ 12      $ (32 )     $ 159,217  
Certificates of Deposit
      10,500        —          —          10,500  
Commercial Paper
      78,788        138        (2 )       78,924  
Corporate Notes/Bonds
      171,665        782        (129 )       172,318  
  
 
 
     
 
 
     
 
 
     
 
 
  
   $ 420,190      $ 932      $ (163 )     $ 420,959  
  
 
 
     
 
 
     
 
 
     
 
 
  
    
December 31, 2019
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
U.S. Government Agency Securities
    $ 35,462      $ 35      $ (3 )     $ 35,494  
Certificates of Deposit
      3,000        —          —          3,000  
Commercial Paper
      39,013        10        (5 )       39,018  
Corporate Notes/Bonds
      38,770        91        —          38,861  
  
 
 
     
 
 
     
 
 
     
 
 
  
   $ 116,245      $ 136      $ (8 )     $ 116,373  
  
 
 
     
 
 
     
 
 
     
 
 
  
The Company has classified all of its investment securities as
available-for-sale,
including those with maturities beyond one year, as current assets on the condensed consolidated balance sheets based on the highly liquid nature of the investment securities and because these investment securities are considered available for use in current operations. As of September 30, 2020, and December 31, 2019, the Company held $197.3 million and $3.0 million, respectively, of
available-for-sale
investment securities with contractual maturity dates more than one year and less than two years.
The Company monitors its investment portfolio for overall risk, specifically credit risk loss, quarterly or more frequently if circumstances warrant. The Company would estimate the expected credit loss over the lifetime of the asset and record an allowance for the portion of the amortized cost basis of the financial asset that the Company does not expect to collect.
The aggregate related fair value of investments with unrealized losses as of September 30, 2020 was $192.8 million, which consisted of $110.4 million from U.S. government agency securities, $10.0 million of commercial paper, and $72.4 million of corporate notes/bonds. The aggregate amount of unrealized losses as of September 30, 2020 was approximately $163,000, which consisted of $32,000 from U.S. government agency securities, $2,000 from commercial paper, and $129,000 from corporate notes/bonds. The $192.8 million aggregate fair value of investments with unrealized losses as of September 30, 2020 has been held in a continuous unrealized loss position for less than 12 months. As of December 31, 2019, the Company had approximately $29.6 million of investments with a continuous unrealized loss for 12 months or longer of which approximately $12.5 million had been held in a continuous loss position for 12 months or longer.
The Company reviewed all of the investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. The Company has analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant.
Fair Value Measurements
Fair Value Measurements
The Company applies the fair value method under ASC Topic 820,
Fair Value Measurements and Disclosures
. ASC Topic 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value and requires expanded disclosures about fair value measurements. The ASC Topic 820 hierarchy ranks the quality and reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following categories based on the lowest level input used that is significant to a particular fair value measurement:
 
 
•
 
Level 1—Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.
 
 
•
 
Level 2—Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.
 
 
•
 
Level 3—Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity—e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.
The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC Topic 820 hierarchy.
The Company has no assets or liabilities that were measured using quoted prices for significant unobservable inputs (Level 3 assets and liabilities) as of September 30, 2020 or December 31, 2019. The carrying value of cash held in money market funds of approximately $224.2 million as of September 30, 2020 and $49.9 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 1 inputs. The carrying value of certificates of deposit of approximately
$
47.6 million as of December 31, 2019 is also included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs. The carrying value of commercial paper of approximately $3.0 million as of December 31, 2019 is included in cash and cash equivalents on the condensed consolidated balance sheet and approximates market value based on quoted market prices or Level 2 inputs.
The fair value measurements of the Company’s cash equivalents and
available-for-sale
investment securities are identified in the following tables (in thousands):
 
           
Fair Value Measurements at
Reporting Date Using
  
    
September 30,
2020
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 224,239      $ 224,239      $ —      $ —  
U.S. Government Agency Securities
      159,217        —          159,217        —    
Certificates of Deposit
      10,500        —          10,500        —    
Commercial Paper
      78,924        —          78,924        —    
Corporate Notes/Bonds
      172,318        —          172,318        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
  
$
645,198
 
   
$
224,239
 
   
$
420,959
 
   
$
—  
  
  
 
 
     
 
 
     
 
 
     
 
 
  
 
           
Fair Value Measurements at
Reporting Date Using
  
    
December 31,
2019
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 49,882      $ 49,882      $ —      $ —  
U.S. Government Agency Securities
      35,494        —          35,494        —    
Certificates of Deposit
      50,622        —          50,622        —    
Commercial Paper
      42,015        —          42,015        —    
Corporate Notes/Bonds
      38,861        —          38,861        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
  
$
216,874
 
   
$
49,882
 
   
$
166,992
 
   
$
—  
  
  
 
 
     
 
 
     
 
 
     
 
 
  
Financial Instruments
Financial Instruments
The Company considers the recorded costs of its financial assets and liabilities, which consist of cash equivalents, restricted cash, accounts receivable, prepaid expenses, other assets, accounts payable, accrued liabilities, accrued employee benefits and lease liabilities, short-term, to approximate their fair value because of their relatively short maturities at September 30, 2020 and December 31, 2019. Management believes that the risks associated with its financial instruments are minimal as the counterparties are various corporations, financial institutions and government agencies of high credit standing.
Restricted Cash
Restricted Cash
Restricted cash is collateral used under the letter of credit arrangement for the vehicle lease agreement. The Company adopted ASU
No. 2016-18,
“Restricted Cash” (“ASU
2016-18”)
and now includes restricted cash balances within the cash, cash equivalents and restricted cash balance on the statement of cash flows.
Accounts Receivable, net
Accounts Receivable, net
The Company’s accounts receivable, net, primarily arise from product sales. They are generally stated at the invoiced amount and do not bear interest. Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from chargebacks, prompt pay discounts, and distribution fees.
The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in the customers’ credit profiles. For the three and nine months ended September 30, 2020, 96% of sales were generated from three major industry wholesalers, respectively.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments which potentially subject the Company to concentrations of credit risk consist of accounts receivable, net from customers and cash, cash equivalent and investments held at financial institutions. For the nine months ended September 30, 2020, all of the Company’s accounts receivable, net arose from product sales in the U.S. and all customers have standard payment terms which generally require payment within 90 days. Three individual customers accounted for approximately 39%, 29%, and 28% of product sales for the three months ended September 30, 2020 as well as accounted for approximately 41%, 27% and 27% of product sales for the nine months ended September 30, 2020. As of September 30, 2020, the Company believes that such customers are of high credit quality.
Cash equivalents are held with major financial institutions in the United States. Certificates of deposit, cash and cash equivalents held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and, therefore, bear minimal risk.
Inventory
Inventory
The Company values its inventories at the lower of cost or estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a
first-in,
first-out
(“FIFO”) basis. The
Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated net realizable value in the period in which the impairment is first identified. Such impairment charges, if they occur, are recorded within cost of product sales.
The Company capitalizes inventory costs associated with the Company’s products after regulatory approval when, based on management’s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Inventory acquired and manufactured prior to receipt of regulatory approval of a product candidate is expensed as research and development expense as incurred. Inventory that can be used in either the production of clinical or commercial product is expensed as research and development expense when selected for use in a clinical manufacturing campaign. Inventory that is used in the production of sample product is reclassified to prepaid and other current assets and is then expensed to selling, general and administrative expenses when the sample product is distributed.
Shipping and handling costs for product shipments to customers are recorded as incurred in cost of product sales along with costs associated with manufacturing the product, and any inventory write-downs.
Property and Equipment
Property and Equipment
Property and equipment is stated at cost and depreciated on a straight-line basis over estimated useful lives ranging from three to five years. Leasehold improvements are amortized using the straight-line method over the shorter of the estimated useful life of the assets or the term of the related lease. Expenditures for maintenance and repairs are charged to operations as incurred.
When indicators of possible impairment are identified, the Company evaluates the recoverability of the carrying value of its long-lived assets based on the criteria established in ASC Topic 360,
Property, Plant and Equipment
. The Company considers historical performance and anticipated future results in its evaluation of potential impairment. The Company evaluates the carrying value of those assets in relation to the operating performance of the business and undiscounted cash flows expected to result from the use of those assets. Impairment losses are recognized when carrying value exceeds the undiscounted cash flows, in which case management must determine the fair value of the underlying asset. No such impairment losses have been recognized to date.
Revenue Recognition
Revenue Recognition
Effective January 1, 2018, the Company adopted FASB ASC Topic 606,
 Revenue from Contracts with Customers
(“ASC Topic 606”). The Company did not generate any product related revenue prior to January 1, 2020, and therefore the adoption of ASC Topic 606 did not have an impact in the Company’s financial statements for any prior periods. In accordance with ASC Topic 606, the Company recognizes revenue when the customer obtains control of a promised good or service, in an amount that reflects the consideration that the Company expects to receive in exchange for the good or service. The reported results for the three and nine months ended September 30, 2020 reflect the application of ASC Topic 606.
To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the definition of a contract under ASC Topic 606, including when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC Topic 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. For additional discussion of accounting for product sales, see
Product Sales, net
(below).
To date, the Company’s only source of product sales has been from sales of CAPLYTA in the U.S., which the Company began shipping to customers in March 2020.
Product Sales, net
The Company sells CAPLYTA to a limited number of customers which include a number of national and select regional distributors. These customers subsequently resell the Company’s products to specialty pharmacy providers, as well as other retail pharmacies and certain medical centers or hospitals. In addition to distribution agreements with customers, the Company enters into arrangements with health care providers and payers that provide for government mandated and/or privately negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. The Company recognizes revenue on product sales when the
 
Customer obtains control of the Company’s product, which occurs at a point in time (upon delivery). Product revenues are recorded net of applicable reserves for variable consideration, including rebates, discounts and allowances, among others. If taxes should be collected from customers relating to product sales and remitted to governmental authorities, they will be excluded from revenue.
Reserves for Variable Consideration
Revenues are calculated based on the wholesale acquisition cost that the Company charges to distributors for CAPLYTA less variable consideration for which reserves are established. Components of variable consideration may include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payer rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payers, and other indirect customers relating to the Company’s sales of its product.
These reserves, as detailed below, are based on the amounts earned, or to be claimed on the related sales, include estimates that take into consideration a range of possible outcomes which are either considered more likely or probability-weighted in accordance with the expected value method in ASC Topic 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, forecasted customer buying and payment patterns. The Company’s estimates regarding the payer mix for CAPLYTA and historical industry information regarding the payer mix for comparable pharmaceutical products and product portfolios, in particular, historical information related to similar products in their initial launch stages. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts after considering whether revenue should be constrained under ASC 606.
The amount of variable consideration which is included in the transaction price may be constrained, and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined a material reversal of revenue would not occur in a future period for the estimates detailed below as of September 30, 2020 and, therefore, the transaction price was not reduced further during the three and nine months ended September 30, 2020. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product sales and earnings in the period such variances become known.
Trade Discounts and Allowances
— The Company generally provides customers with discounts which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company compensates (through trade discounts and allowances) its customers for sales order management, data, and distribution services. However, the Company has determined such services received to date are not distinct from the Company’s sale of products to the Customer and, therefore, these payments have been recorded as a reduction of net sales within the condensed consolidated statements of operations through September 30, 2020, as well as a reduction to trade receivables, net on the condensed consolidated balance sheets.
Product Returns
— Consistent with industry practice, the Company generally offers customers a limited right of return for product that has been purchased from the Company based on the product’s expiration date, which lapses upon shipment to a patient. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as accrued expenses and other current liabilities on the condensed consolidated balance sheets. The Company currently estimates product return liabilities using available industry data and its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has not received any returns to date.
Provider Chargebacks and Discounts
— Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and accounts receivables, net. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Reserves for chargebacks consist of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting
period-end
that the Company expects will be sold to qualified healthcare providers, and chargebacks that customers have claimed, but for which the Company has not yet issued a credit. For the three and nine months ended September 30, 2020, these amounts were not significant.
 
Government Rebates
— The Company is subject to discount obligations under state Medicaid and Medicare programs. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included in accrued expenses and other current liabilities on the condensed consolidated balance sheets. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel inventories at the end of each reporting period.
Payer Rebates
— The Company contracts with certain private payer organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its product. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability recorded as an accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Other Incentives
— Other incentives which the Company offers include voluntary patient assistance programs, such as the
co-pay
assistance program, which are intended to provide financial assistance to qualified commercially-insured patients with prescription drug
co-payments
required by payers. The calculation of the accrual for
co-pay
assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue but remains in the distribution channel inventories at the end of each reporting period. The Company also has a voucher program whereby a patient can receive a prescription at no cost and whereby the Company reimburses the pharmacy for 100% of the sales price of the prescription. The Company estimates the number of claims through vouchers for product that is in the distribution channel inventories and reduces recognized revenue accordingly.
The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability which is included as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Chargebacks, discounts, fees, and returns are recorded as reductions of trade receivables, net on the condensed consolidated balance sheets. Government and other rebates are recorded as a component of accrued expenses and other current liabilities on the condensed consolidated balance sheets.
Cost of Product Sales
Cost of Product Sales
Our cost of product sales relates to sales of CAPLYTA. Cost of product sales primarily includes product royalty fees, overhead, and direct costs (inclusive of material, shipping, and manufacturing costs).
For the product royalty fees, the Company entered into an exclusive License Agreement with Bristol-Myers Squibb Company (“BMS”), for which the Company is obliged to make tiered single digit percentage royalty payments ranging between 5 – 9% on sales of licensed products. The related royalties are recorded within cost of product sales on the statement of operations.
Prior to FDA approval of CAPLYTA, the Company
expensed all
costs associated with the manufacturing of lumateperone as part of research and development expenses
.
 From December 20, 2019, the date of approval of CAPLYTA, through December 31, 2019 there was no production and no inventory costs were incurred. Therefore, at December 31, 2019, no inventory costs had been capitalized. The cost of product sales in the nine months ended September 30, 2020 are lower than incurred because of previously expensed inventory.
Research and Development, including Clinical trial expenses
Research and Development, Including Clinical Trial Expenses
Except for payments made in advance of services, the Company expenses its research and development costs as incurred. For payments made in advance, the Company recognizes research and development expense as the services are rendered. Research and development costs primarily consist of salaries and related expenses for personnel and resources and the costs of clinical trials. Other research and development expenses include preclinical analytical testing, manufacturing of drug product for use in clinical and nonclinical trials, outside services, providers, materials and consulting fees.
Costs for certain development activities, such as clinical trials, are recognized based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or information provided to the Company by its vendors with respect to their actual costs incurred, among other factors. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as the case may be.
As part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by matching those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the clinical trial as measured by subject progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account various clinical information provided by vendors and discussion with applicable personnel and external service providers as to the progress or state of consummation of trials, or the services completed. During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company’s clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations, clinical sites and other third-party vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular period. For the nine-months ended September 30, 2020, the Company recorded a change in estimate of approximately $3.3 million of accrued expenses for clinical trials related to the first and second quarter of 2020 which resulted in an increase of clinical trial expense in the nine month period ending September 30, 2020. For the three and nine months ended September 30, 2020 and 2019, there were no material adjustments to the Company’s prior year estimates of accrued expenses for clinical trials.
 
Income Taxes
Income Taxes
Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.
The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established when necessary to reduce net deferred tax assets to the amount expected to be realized. Income tax expense is the tax payable for the period and the change during the period in deferred tax assets and liabilities. The Company accounts for uncertain tax positions pursuant to ASC Topic 740 (previously included in FASB Interpretation No. 48,
Accounting for Uncertainty in Income Taxes—an Interpretation of FASB Statement No.
 109
). Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a
more-likely-than-not
threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the tax benefit having the highest likelihood of being realized upon ultimate settlement with the taxing authority. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in the provision for income taxes.
The Company’s effective tax rate for the three and nine months ended September 30, 2020 and 2019 was approximately 0%. This effective tax rate is substantially lower than the U.S. statutory rate of 21% due to valuation allowances recorded on current year losses where the Company is not more-likely than not to recognize a future tax benefit.
On March 27, 2020, the United States enacted The Coronavirus Aid, Relief and Economic Security (CARES) Act which includes several significant business tax provisions, of which the immediate relevance to the Company is the acceleration of refunds of previously generated corporate Alternative Minimum Tax (“AMT”) credits. The CARES Act also adds an employee retention credit to encourage employers to maintain headcounts even if employees cannot report to work because of issues related to the coronavirus, a temporary provision allowing companies to defer remitting to the government the employee share of some payroll taxes, among other things. The Company reviewed the provisions and there was not a material tax impact on its financial statements for the three and nine months ended September 30, 2020. The Company did reclassify its deferred tax asset related to the AMT tax credit carryforward of $265,000 to a current tax receivable in the first quarter of 2020 upon the filing of its tax return for year ended December 31, 2019 and received the refund in July 2020.
Comprehensive Income (Loss)
Comprehensive Income (Loss)
All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are incurred. Comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from
non-owner
sources. In accordance with accounting guidance, the Company presents the impact of any unrealized gains or (losses) on its investment securities in a separate statement of comprehensive income (loss) for each period.
Share-Based Compensation
Share-Based Compensation
Share-based payments are accounted for in accordance with the provisions of ASC Topic 718,
Compensation—Stock Compensation
. The fair value of share-based payments is estimated, on the date of grant, using the Black-Scholes-Merton option-pricing model (the “Black-Scholes model”). The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.
For all awards granted with time based vesting conditions, expense is amortized using the straight-line attribution method. Share-based compensation expense recognized in the statements of operations for the three and nine months ended September 30, 2020 and 2019 accounts for forfeitures as they occur.
The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of subjective assumptions, and changes in the assumptions used can materially affect the grant date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.
Expected volatility rates for quarterly periods prior to December 31, 2019 were based on a combination of the historical volatility of the common stock of comparable publicly traded entities and the limited historical information about the Company’s common stock. In the fourth quarter of 2019, expected volatility rates are based entirely on the historical volatility of the Company’s common stock. The expected life of stock options is the period of time for which the stock options are expected to be outstanding. Given the limited historical exercise data, the expected life is determined using the “simplified method,” which defines expected life as the midpoint between the vesting date and the end of the contractual term.
The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception and does not plan to pay cash dividends in the foreseeable future. Therefore, the Company has assumed an expected dividend rate of zero. For stock options granted, the exercise price was determined by using the closing market price of the Company’s common stock on the date of grant.
A restricted stock unit (“RSU”) is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the fair market value of the Company’s common stock on the date of grant. The Company has granted RSUs that vest in three equal annual installments provided that the employee remains employed with the Company.
In the first quarter of each fiscal year beginning in 2016, the Company granted time based RSUs that vest in three equal annual installments. In the first quarter of 2017, the Company granted performance-based RSUs, which vest based on the achievement of certain milestones that include (i) the submission of a new drug application (“NDA”) to the FDA for lumateperone for the treatment of schizophrenia, (ii) the approval of the NDA by the FDA (together, the “Milestone RSUs”) and (iii) the achievement of certain comparative shareholder returns against the Company’s peers (the “TSR RSUs”). The Milestone RSUs related to the NDA submission were fully amortized on December 31, 2018. The NDA submission milestone was achieved in the third quarter of 2018, so the Milestone RSUs related to the NDA submission vested on December 31, 2018. The Milestone RSU’s related to the NDA approval was achieved in the fourth quarter of 2019, so the RSU’s vested on December 31, 2019. The Milestone RSUs related to the approval of the NDA were fully amortized on December 31, 2019. The TSR RSUs were valued using the Monte Carlo Simulation method and were amortized over the life of the RSUs based on the agreements which vested on January 24, 2020.
In the first quarter of 2020, the Company granted performance-based RSUs for 86,000 shares of common stock, which vest based on the achievement of certain milestones that include (i) the approval of a planned NDA by the FDA and (ii) the achievement of certain comparative shareholder returns against the Company’s peers (the “2020 TSR RSUs”). The 2020 TSR RSUs were valued using the Monte Carlo Simulation method and will be amortized over the life of the RSUs based on the agreements.
Under ASC Topic 718, the cumulative amount of compensation cost recognized for instruments classified as equity that ordinarily would result in a future tax deduction under existing tax law is considered to be a deductible difference in applying ASC Topic 740,
Income Taxes
. The deductible temporary difference is based on the compensation cost recognized for financial reporting purposes; however, these provisions currently do not impact the Company, as all the deferred tax assets have a full valuation allowance.
 
Since the Company has losses and also maintains a full valuation allowance to cover its deferred tax assets as of September 30, 2020 and 2019, excess tax benefits, if any, recognized for the tax deductions related to share-based awards will add to the Company’s net operating loss deferred tax asset and covered by valuation allowances.
Equity instruments issued to
non-employees
for services are accounted for under the provisions of ASC Topic 718 and ASC Topic
505-50,
Equity/Equity-Based Payments to
Non-Employees
. Accordingly, the estimated fair value of the equity instrument is recorded on the earlier of the performance commitment date or the date the required services are completed and are marked to market during the service period.
In June 2018, the Company’s stockholders approved the Company’s 2018 Equity Incentive Plan pursuant to which 4,750,000 additional shares of common stock were reserved for future equity grants. In May 2020, the Company’s stockholders approved the Company’s 2018 Amended and Restated Equity Incentive Plan pursuant to which 6,500,000 additional shares of common stock were reserved for future equity grants.
In December 2019, the Company adopted the Intra-Cellular Therapies, Inc. 2019 Inducement Award Plan (the “2019 Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Pursuant to the 2019 Inducement Plan, the Company may grant stock options, RSUs, stock awards and other share-based awards for up to a total of 1,000,000 shares of common stock to new employees of the Company. As of September 30, 2020, stock options and RSUs for 314,138 shares have been granted under the 2019 Inducement Plan. The Company does not intend to make additional grants under the 2019 Inducement Plan.
 
Loss Per Share
Loss Per Share
Basic net loss per common share is determined by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock option grants and RSUs.
The following awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2020 and 2019:
 
    
Three and Nine Months Ended

September 30,
  
    
2020
     
2019
  
Stock options
      5,964,135        6,330,914  
RSUs
      1,702,538        1,425,459  
TSR RSUs
      43,022        134,170  
Recently Issued Accounting Standards
Recently Issued Accounting Standards
In June 2016, the FASB issued ASU
No. 2016-13,
“Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU
2016-13”).
This guidance applies to all entities and impacts how entities account for credit losses for most financial assets and other instruments. For
available-for-sale
debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction to the carrying value of the asset. For trade receivables, loans and
held-to-maturity
debt securities, entities will be required to estimate lifetime expected credit losses. The Company adopted this standard on January 1, 2020. The Company evaluated the implications of the new standard, inclusive of the applicable financial statement disclosures required, as well as to its internal controls, business processes, and accounting policies, noting there was no significant impact to the financial statements as of January 1, 2020 and for the three and nine month period ended September 30, 2020.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2020
Accounting Policies [Abstract]  
Schedule of Investment Securities
Investment Securities
Investment securities consisted of the following (in thousands):
 
    
September 30, 2020
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
    
(Unaudited)
  
U.S. Government Agency Securities
    $ 159,237      $ 12      $ (32 )     $ 159,217  
Certificates of Deposit
      10,500        —          —          10,500  
Commercial Paper
      78,788        138        (2 )       78,924  
Corporate Notes/Bonds
      171,665        782        (129 )       172,318  
  
 
 
     
 
 
     
 
 
     
 
 
  
   $ 420,190      $ 932      $ (163 )     $ 420,959  
  
 
 
     
 
 
     
 
 
     
 
 
  
    
December 31, 2019
  
    
Amortized
Cost
     
Unrealized
Gains
     
Unrealized
(Losses)
     
Estimated
Fair
Value
  
U.S. Government Agency Securities
    $ 35,462      $ 35      $ (3 )     $ 35,494  
Certificates of Deposit
      3,000        —          —          3,000  
Commercial Paper
      39,013        10        (5 )       39,018  
Corporate Notes/Bonds
      38,770        91        —          38,861  
  
 
 
     
 
 
     
 
 
     
 
 
  
   $ 116,245      $ 136      $ (8 )     $ 116,373  
  
 
 
     
 
 
     
 
 
     
 
 
  
Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities
The fair value measurements of the Company’s cash equivalents and
available-for-sale
investment securities are identified in the following tables (in thousands):
 
           
Fair Value Measurements at
Reporting Date Using
  
    
September 30,
2020
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 224,239      $ 224,239      $ —      $ —  
U.S. Government Agency Securities
      159,217        —          159,217        —    
Certificates of Deposit
      10,500        —          10,500        —    
Commercial Paper
      78,924        —          78,924        —    
Corporate Notes/Bonds
      172,318        —          172,318        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
  
$
645,198
 
   
$
224,239
 
   
$
420,959
 
   
$
—  
  
  
 
 
     
 
 
     
 
 
     
 
 
  
           
Fair Value Measurements at
Reporting Date Using
  
    
December 31,
2019
     
Quoted Prices
in Active
Markets for
Identical
Assets
(Level 1)
     
Significant
Other
Observable
Inputs
(Level 2)
     
Significant
Unobservable
Inputs
(Level 3)
  
Money Market Funds
    $ 49,882      $ 49,882      $ —      $ —  
U.S. Government Agency Securities
      35,494        —          35,494        —    
Certificates of Deposit
      50,622        —          50,622        —    
Commercial Paper
      42,015        —          42,015        —    
Corporate Notes/Bonds
      38,861        —          38,861        —    
  
 
 
     
 
 
     
 
 
     
 
 
  
  
$
216,874
 
   
$
49,882
 
   
$
166,992
 
   
$
—  
  
  
 
 
     
 
 
     
 
 
     
 
 
  
Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share
The following awards were excluded in the calculation of diluted loss per share because their effect could be anti-dilutive as applied to the loss from operations for the three and nine months ended September 30, 2020 and 2019:
 
    
Three and Nine Months Ended

September 30,
  
    
2020
     
2019
  
Stock options
      5,964,135        6,330,914  
RSUs
      1,702,538        1,425,459  
TSR RSUs
      43,022        134,170  
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory (Tables)
 9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventory, Current
Inventory consists of the following:
 
    
September 30,
2020
  
Raw materials
   
$
—  
  
Work in process
   
 
1,597,413
 
Finished goods
   
 
1,349,725
 
  
 
 
  
  
$
2,947,138
 
  
 
 
  
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment (Tables)
 9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]  
Property and Equipment
Property and equipment consist of the following:
 
    
September 30,
2020
     
December 31,
2019
  
Computer equipment
   
$
243,532
 
    $ 243,532  
Furniture and fixtures
   
 
423,097
 
      423,097  
Scientific equipment
   
 
4,053,185
 
      3,861,227  
Leasehold improvements
   
 
1,240,315
 
      1,240,315  
  
 
 
     
 
 
  
  
 
5,960,129
 
      5,768,171  
Less accumulated depreciation
   
 
(3,910,577
) 
      (3,508,431 ) 
  
 
 
     
 
 
  
  
$
2,049,552
 
    $ 2,259,740  
  
 
 
     
 
 
  
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Right of Use Assets and Lease Liabilities (Tables)
 9 Months Ended
Sep. 30, 2020
Schedule Of Maturity Analysis Under Lease Agreements
M
aturity analysis under the lease agreements are as follows:
 
Three months ending December 31, 2020
    $ 845,566  
Year ending December 31, 2021
      3,448,323  
Year ending December 31, 2022
      3,491,166  
Year ending December 31, 2023
      3,566,466  
Year ending December 31, 2024
      3,675,196  
Thereafter
      17,627,040  
  
 
 
  
Total
      32,653,757  
Less: Present value discount
      (10,463,196 ) 
  
 
 
  
Total Lease liability
      22,190,561  
  
 
 
  
Less: Current portion
      (3,259,966 ) 
  
 
 
  
Long-term lease liabilities
    $ 18,930,595  
  
 
 
  
Vehicle Fleet Lease [Member]  
Schedule Of Quantitative Information About Operating Leases
The following table presents the Vehicle Lease balances within the condensed consolidated balance sheet, weighted average remaining fleet lease term, and the weighted average discount rates related to the Vehicle Lease as of September 30, 2020:
 
Lease Assets and Liabilities – Fleet
   
Classification
     
September 30, 2020
  
Assets
      
Right of use assets, net
      Operating lease right of use assets      $ 6,946,254  
     
 
 
  
      $ 6,946,254  
     
 
 
  
Liabilities
      
Current
      
Lease liabilities, short-term
      Operating lease liabilities      $ 2,007,292  
Non-Current
      
Lease liabilities
     
Non-current operating lease liabilities
        4,938,962  
     
 
 
  
Total lease liabilities
       $ 6,946,254  
     
 
 
  
Weighted average remaining lease term
         2.2 years  
Weighted average discount rate
         1.85 % 
Schedule Of Maturity Analysis Under Lease Agreements
The following table presents the maturity of the Company’s fleet lease liability as of
September
 30, 2020:
 
Time
Period
 
Three months ending December 31, 2020
    $ 530,799  
Year ending December 31, 2021
      2,112,506  
Year ending December 31, 2022
      3,207,898  
Year ending December 31, 2023
     
1,273,867
  
Thereafter
      —    
  
 
 
  
Total
      7,125,070  
Less: Present value discount
      (178,816 ) 
  
 
 
  
Total operating lease liabilities
      6,946,254  
  
 
 
  
Less: Current portion
      (2,007,292 ) 
  
 
 
  
Long-term lease liabilities
    $ 4,938,962  
  
 
 
  
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2020
Total Stock-Based Compensation Expense
Total
share
-based compensation expense related to all of the Company’s share-based awards, including stock options and RSUs to employees, directors and consultants, recognized during the three and nine months ended September 30, 2020 and 2019, was comprised of the following:
 
    
Three Months Ended September 30,
     
Nine Months Ended September 30,
  
    
2020
     
2019
     
2020
     
2019
  
Inventoriable costs
   
$
345,460
 
    $ —     
$
996,802
 
    $ —  
Research and development
   
 
2,402,865
 
      2,023,700     
 
6,792,498
 
    $ 6,785,280  
General and administrative
   
 
4,152,394
 
      2,783,068     
 
11,562,850
 
      8,064,129  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total share-based compensation expense
   
$
6,900,719
 
    $ 4,806,768     
$
19,352,150
 
    $ 14,849,409  
  
 
 
     
 
 
     
 
 
     
 
 
  
Assumptions Used for Calculating Value of Options Granted
The following table describes the weighted-average assumptions used for calculating the value of options granted during the nine months ended September 30, 2020 and 2019:
 
    
2020
  
2019
Dividend yield
   
0%
   0%
Expected volatility
   
91.6%-92.7%
  
83.7%-85.7%
Weighted-average risk-free interest rate
   
1.31%
   2.32%
Expected term (in years)
   
6.0
   6.0
Stock Option Activity
Information regarding the stock options activity, including with respect to grants to employees, directors and consultants as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      6,039,945      $ 16.81        7.0 years  
Options granted
      742,509      $ 23.85        9.4 years  
Options exercised
      (696,936 )     $ 12.79        4.8 years  
Options canceled or expired
      (161,111 )     $ 21.70        7.9 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      5,924,407      $ 18.03        6.8 years  
  
 
 
     
 
 
     
Vested or expected to vest at September 30, 2020
      5,924,407      $ 18.03     
  
 
 
     
 
 
     
Exercisable at September 30, 2020
      3,620,984      $ 18.85        5.7 years  
  
 
 
     
 
 
     
Time Based Restricted Stock Units [Member]  
Summary of Information Regarding RSU Activity
The fair value of the TSR RSUs was determined using the Monte Carlo simulation method. Information
regarding the time based RSU activity and changes during the nine month period ended September 30, 2020 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      1,268,679      $ 13.60        1.7 years  
Time based RSUs granted in 2020
      728,596      $ 23.05        2.7 years  
Time based RSUs vested in 2020
      (506,546 )     $ 13.78        0.9 years  
Time based RSUs cancelled in 2020
      (90,559 )     $ 17.03        1.5 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      1,400,170      $ 18.69        1.9 years  
  
 
 
     
 
 
     
 
 
  
Milestone and Total Shareholder Return Restricted Stock Units [Member]  
Summary of Information Regarding RSU Activity
Information related to the Company’s Milestone RSUs and TSR RSUs during the nine month period ended September 30, 2020 are summarized as follows:
 
    
Number of
Shares
     
Weighted-Average
Grant Date
Fair Value Per Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      67,080      $ 17.08        0.2 years  
Milestone RSUs and TSR RSUs granted in 2020
      86,044      $ 32.56        2.4 years  
Milestone RSUs and TSR RSUs vested in 2020
      (67,080 )     $ 17.08        0.2 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      86,044      $ 32.56        2.4 years  
  
 
 
     
 
 
     
 
 
  
Inducement Award Plan [Member]  
Stock Option Activity
Information regarding stock option awards under the 2019 Inducement Plan, including with respect to grants to employees as of September 30, 2020, and changes during the nine month period then ended, are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Exercise
Price
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      —        $ —     
Options granted in 2020
      39,728      $ 17.18        9.5 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      39,728      $ 17.18        9.5 years  
  
 
 
     
 
 
     
Vested or expected to vest at September 30, 2020
      39,728      $ 17.18     
  
 
 
     
 
 
     
Exercisable at September 30, 2020
      —        $ —     
  
 
 
     
 
 
     
Summary of Information Regarding RSU Activity
Information regarding RSU awards under the 2019 Inducement Plan during the nine month period ended September 30, 2020 are summarized as follows:
 
    
Number of
Shares
     
Weighted-
Average
Grant
 
Date

Fair
 
Value
 
Per
 
Share
     
Weighted-
Average
Contractual
Life
  
Outstanding at December 31, 2019
      —        $ —     
Time based RSUs granted in 2020
      274,410      $ 16.01        2.6 years  
Time based RSUs cancelled in 2020
      (15,064 )     $ 15.81        2.5 years  
  
 
 
     
 
 
     
 
 
  
Outstanding at September 30, 2020
      259,346      $ 16.01        2.6 years  
  
 
 
     
 
 
     
Vested or expected to vest at September 30, 2020
      259,346      $ 16.01     
  
 
 
     
 
 
     
Exercisable at September 30, 2020
      —        $ —     
  
 
 
     
 
 
     
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Organization - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 15, 2020
Sep. 10, 2020
Jan. 10, 2020
Sep. 12, 2019
Sep. 30, 2020
Sep. 30, 2020
Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Initial public offering, Number of shares 12,666,667   10,000,000        
Initial public offering, Price per share $ 30.00   $ 29.50        
Net proceeds from the sale of common stock   $ 17,900,000       $ 652,712,011  
Common stock issued, shares   742,791     80,142,797 80,142,797 55,507,497
Common Stock [Member]              
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Initial public offering, Number of shares         13,179,458 23,409,458  
IPO [Member]              
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Initial public offering, Gross proceeds $ 380,000,000.0   $ 295,000,000.0        
Initial public offering, Net proceeds $ 357,800,000   $ 277,000,000.0        
Maximum [Member]              
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Universal shelf registration statement, effective date value       $ 350,000,000      
Net proceeds from the sale of common stock       75,000,000      
Maximum [Member] | Common Stock [Member]              
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]              
Universal shelf registration statement, effective date value       $ 75,000,000      
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies - Additional Information (Detail)
 3 Months Ended 9 Months Ended
Mar. 31, 2020
shares
Dec. 31, 2019
USD ($)
shares
Sep. 30, 2020
USD ($)
Customers
shares
Sep. 30, 2020
USD ($)
Segment
Customers
shares
Sep. 30, 2019
May 31, 2020
shares
Mar. 27, 2020
USD ($)
Jun. 30, 2018
shares
Significant Accounting Policies [Line Items]                
Number of operating segments | Segment       1        
Maturity of highly liquid investments       3 months        
Maturity of certificates of deposit, commercial paper, corporate notes and corporate bonds       more than three months        
Investment securities, available-for-sale   $ 116,373,335 $ 420,958,509 $ 420,958,509        
Aggregate related fair value of investments with unrealized losses   29,600,000 192,800,000 192,800,000        
Investment securities aggregate amount of unrealized loss     163,000 163,000        
Investment securities, held in continuous unrealized loss position for 12 months or longer   12,500,000            
Carrying value of cash held in money market funds   49,900,000 $ 224,200,000 224,200,000        
Impairment losses recognized       $ 0        
Manufacturing Costs   0            
Inventory Costs   0            
Effective tax rate       0.00%        
US statutory rate       21.00%        
Assumed expected dividend rate       0.00% 0.00%      
Commercial Paper [Member]                
Significant Accounting Policies [Line Items]                
Carrying value of commercial paper   3,000,000.0            
AMT Tax Credit [Member]                
Significant Accounting Policies [Line Items]                
Deferred Tax Assets, Gross             $ 265,000  
Accounts Receivable [Member]                
Significant Accounting Policies [Line Items]                
Concentration Risk, Percentage       96.00%        
Accounts Receivable [Member] | Customer one [Member]                
Significant Accounting Policies [Line Items]                
Concentration Risk, Percentage     39.00% 41.00%        
Accounts Receivable [Member] | Customer two [Member]                
Significant Accounting Policies [Line Items]                
Concentration Risk, Percentage     29.00% 27.00%        
Accounts Receivable [Member] | Customer three [Member]                
Significant Accounting Policies [Line Items]                
Concentration Risk, Percentage     28.00% 27.00%        
Accounts Receivable [Member] | Customer Concentration Risk [Member]                
Significant Accounting Policies [Line Items]                
Number of customers | Customers     3 3        
U.S. Government Agency Securities [Member]                
Significant Accounting Policies [Line Items]                
Investment securities, available-for-sale   35,494,000 $ 159,217,000 $ 159,217,000        
Aggregate related fair value of investments with unrealized losses     110,400,000 110,400,000        
Investment securities aggregate amount of unrealized loss     32,000 32,000        
Commercial Paper [Member]                
Significant Accounting Policies [Line Items]                
Investment securities, available-for-sale   39,018,000 78,924,000 78,924,000        
Aggregate related fair value of investments with unrealized losses     10,000,000.0 10,000,000.0        
Investment securities aggregate amount of unrealized loss     2,000 2,000        
Corporate Notes/Bonds [Member]                
Significant Accounting Policies [Line Items]                
Investment securities, available-for-sale   38,861,000 172,318,000 172,318,000        
Aggregate related fair value of investments with unrealized losses     72,400,000 72,400,000        
Investment securities aggregate amount of unrealized loss     129,000 129,000        
Cash and Cash Equivalents [Member]                
Significant Accounting Policies [Line Items]                
Carrying value of cash held in certificates of deposit   47,600,000            
Significant Unobservable Inputs (Level 3) [Member]                
Significant Accounting Policies [Line Items]                
Assets measured using quoted prices   0 0 0        
Liabilities measured using quoted prices   0 0 0        
Contractual Maturity Dates More Than One Year and Less Than Two Years [Member]                
Significant Accounting Policies [Line Items]                
Investment securities, available-for-sale   $ 3,000,000.0 $ 197,300,000 $ 197,300,000        
2018 Equity Incentive Plan [Member]                
Significant Accounting Policies [Line Items]                
Additional shares of common stock reserved for future equity grants | shares           6,500,000   4,750,000
ITCI Inducement Award Plan [Member]                
Significant Accounting Policies [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | shares     314,138 314,138        
Performance Based Restricted Stock Units [Member]                
Significant Accounting Policies [Line Items]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares 86,000              
Minimum [Member]                
Significant Accounting Policies [Line Items]                
Property and equipment, estimated useful life       3 years        
Minimum [Member] | Product [Member] | Bristol-Myers Squibb Company [Member]                
Significant Accounting Policies [Line Items]                
Royalty payment, percentage       5.00%        
Maximum [Member]                
Significant Accounting Policies [Line Items]                
Property and equipment, estimated useful life       5 years        
Maximum [Member] | Product [Member] | Bristol-Myers Squibb Company [Member]                
Significant Accounting Policies [Line Items]                
Royalty payment, percentage       9.00%        
Maximum [Member] | ITCI Inducement Award Plan [Member]                
Significant Accounting Policies [Line Items]                
Issuance of shares, Inducement Award Plan | shares   1,000,000            
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost $ 420,190,000 $ 116,245,000
Unrealized Gains 932,000 136,000
Unrealized (Losses) (163,000) (8,000)
Estimated Fair Value 420,958,509 116,373,335
U.S. Government Agency Securities [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 159,237,000 35,462,000
Unrealized Gains 12,000 35,000
Unrealized (Losses) (32,000) (3,000)
Estimated Fair Value 159,217,000 35,494,000
Certificates of Deposit [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 10,500,000 3,000,000
Estimated Fair Value 10,500,000 3,000,000
Commercial Paper [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 78,788,000 39,013,000
Unrealized Gains 138,000 10,000
Unrealized (Losses) (2,000) (5,000)
Estimated Fair Value 78,924,000 39,018,000
Corporate Notes/Bonds [Member]    
Schedule of Available-for-sale Securities [Line Items]    
Amortized Cost 171,665,000 38,770,000
Unrealized Gains 782,000 91,000
Unrealized (Losses) (129,000)  
Estimated Fair Value $ 172,318,000 $ 38,861,000
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail) - Fair Value, Measurements, Recurring [Member] - USD ($)
$ in Thousands
Sep. 30, 2020
Dec. 31, 2019
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities $ 645,198 $ 216,874
Money Market Funds [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 224,239 49,882
U.S. Government Agency Securities [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 159,217 35,494
Certificates of Deposit [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 10,500 50,622
Commercial Paper [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 78,924 42,015
Corporate Notes/Bonds [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 172,318 38,861
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 224,239 49,882
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member] | Money Market Funds [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 224,239 49,882
Significant Other Observable Inputs (Level 2) [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 420,959 166,992
Significant Other Observable Inputs (Level 2) [Member] | U.S. Government Agency Securities [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 159,217 35,494
Significant Other Observable Inputs (Level 2) [Member] | Certificates of Deposit [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 10,500 50,622
Significant Other Observable Inputs (Level 2) [Member] | Commercial Paper [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities 78,924 42,015
Significant Other Observable Inputs (Level 2) [Member] | Corporate Notes/Bonds [Member]    
Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]    
Available-for-sale investment securities $ 172,318 $ 38,861
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) - shares
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Stock options [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Number of anti-dilutive securities excluded from computation of earnings per share 5,964,135 6,330,914
RSUs [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Number of anti-dilutive securities excluded from computation of earnings per share 1,702,538 1,425,459
Total Shareholder Return Restricted Stock Units [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Number of anti-dilutive securities excluded from computation of earnings per share 43,022 134,170
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Inventory - Schedule of Inventory, Current (Detail)
Sep. 30, 2020
USD ($)
Inventory Disclosure [Abstract]  
Raw materials $ 0
Work in process 1,597,413
Finished goods 1,349,725
Total inventories $ 2,947,138
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment - Property and Equipment (Detail) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross $ 5,960,129 $ 5,768,171
Less accumulated depreciation (3,910,577) (3,508,431)
Property Plant and Equipment Net 2,049,552 2,259,740
Computer Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross 243,532 243,532
Furniture and Fixtures [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross 423,097 423,097
Scientific Equipment [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross 4,053,185 3,861,227
Leasehold Improvements [Member]    
Property, Plant and Equipment [Line Items]    
Property plant and equipment, gross $ 1,240,315 $ 1,240,315
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Property and Equipment - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Property, Plant and Equipment [Abstract]        
Depreciation $ 121,044 $ 129,052 $ 402,146 $ 335,461
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Right of Use Assets and Lease Liabilities - Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Feb. 28, 2019
Jan. 01, 2019
Sep. 30, 2018
Right of use assets, net $ 24,292,167   $ 24,292,167   $ 18,252,074      
Net lease liabilities 29,100,000   29,100,000          
Operating lease expense $ 800,000 $ 800,000 2,500,000 $ 2,500,000        
Right of use assets obtained in exchange for operating lease liability         $ 200,000      
Operating Lease, Cost     $ 585,490          
Vehicle Fleet Lease [Member]                
Operating lease discount rate 1.85%   1.85%          
Right of use assets, net $ 6,946,254   $ 6,946,254          
Net lease liabilities $ 6,946,254   $ 6,946,254          
Term of long term lease 12 months   12 months          
Operating Lease, Weighted Average Remaining Lease Term 2 years 2 months 12 days   2 years 2 months 12 days          
Operating lease cash outflows     $ 585,490          
Restricted Cash $ 1,400,000   $ 1,400,000          
Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months     20.00%          
Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months     30.00%          
Vehicle Fleet Lease [Member] | Financial Standby Letter of Credit [Member]                
Guarantee Obligations $ 1,400,000   $ 1,400,000          
Accounting Standards Update 2016-02 [Member]                
Right of use assets, net             $ 20,200,000  
Net lease liabilities             23,400,000  
Eliminated deferred rent             $ 3,200,000  
NEW YORK                
Term of long term lease               14 years 3 months 18 days
NEW YORK | Accounting Standards Update 2016-02 [Member]                
Operating lease discount rate             7.20%  
Operating Lease, Weighted Average Remaining Lease Term             3 years 2 months 12 days  
MARYLAND                
Term of long term lease           3 years 2 months 12 days    
MARYLAND | Accounting Standards Update 2016-02 [Member]                
Operating lease discount rate             9.10%  
Operating Lease, Weighted Average Remaining Lease Term             14 years 3 months 18 days  
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Total Lease liability $ 29,100,000  
Less: current portion (5,267,258) $ (3,187,435)
Long-term lease liabilities 23,869,557 $ 19,955,186
Real Estates Lease [Member]    
Three months ending December 31, 2020 845,566  
Year ending December 31, 2021 3,448,323  
Year ending December 31, 2022 3,491,166  
Year ending December 31, 2023 3,566,466  
Year ending December 31, 2024 3,675,196  
Thereafter 17,627,040  
Total 32,653,757  
Less: Present value discount (10,463,196)  
Total Lease liability 22,190,561  
Less: current portion (3,259,966)  
Long-term lease liabilities $ 18,930,595  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Lessee, Lease, Description [Line Items]    
Right of use assets, net $ 24,292,167 $ 18,252,074
Lease liabilities, short-term 5,267,258 3,187,435
Lease liabilities 23,869,557 $ 19,955,186
Total Lease liability 29,100,000  
Vehicle Fleet Lease [Member]    
Lessee, Lease, Description [Line Items]    
Right of use assets, net 6,946,254  
Lease liabilities, short-term 2,007,292  
Lease liabilities 4,938,962  
Total Lease liability $ 6,946,254  
Weighted average remaining lease term 2 years 2 months 12 days  
Weighted average discount rate 1.85%  
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Lessee, Lease, Description [Line Items]    
Total operating lease liabilities $ 29,100,000  
Less: current portion (5,267,258) $ (3,187,435)
Long-term lease liabilities 23,869,557 $ 19,955,186
Vehicle Fleet Lease [Member]    
Lessee, Lease, Description [Line Items]    
Three months ending December 31, 2020 530,799  
Year ending December 31, 2021 2,112,506  
Year ending December 31, 2022 3,207,898  
Year ending December 31, 2023 1,273,867  
Thereafter 0  
Total 7,125,070  
Less: Present value discount (178,816)  
Total operating lease liabilities 6,946,254  
Less: current portion (2,007,292)  
Long-term lease liabilities $ 4,938,962  
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Mar. 31, 2017
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares of common stock reserved for issuance             11,287,390
Expected dividend yield         0.00% 0.00%  
Risk free interest rate         1.31% 2.32%  
2018 Equity Incentive Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Shares of common stock reserved for issuance             2,208,317
Additional Stock- based awards, grant         6,500,000    
Time Based Restricted Stock Units [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation costs related to unvested RSUs $ 21.6       $ 21.6    
Non-cash stock-based compensation expense recognized 3.2   $ 1.7   8.9 $ 5.6  
RSUs [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Non-cash stock-based compensation expense recognized 3.4   $ 1.9   $ 9.2 $ 6.1  
Weighted average grant date fair value of stock options granted         $ 23.05    
RSUs [Member] | Maximum [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Options, vesting term         3 years    
Milestone Restricted Stock Units [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Unrecognized compensation costs related to unvested RSUs $ 1.0       $ 1.0    
Stock Options [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Options, maximum term         10 years    
Inducement Award Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Issuance of shares, Inducement Award Plan 1,000,000       1,000,000    
Awards granted 314,138       314,138    
Weighted average grant date fair value of stock options granted         $ 16.01    
Total Shareholder Return Restricted Stock Units [Member]              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted average grant date fair value of stock options granted       $ 17.08      
Unrecognized compensation costs related to unvested RSUs $ 1.1       $ 1.1    
Expected dividend yield   0.00%   0.00%      
Risk free interest rate   1.40%   1.60%      
Expected volatility   91.30%   95.40%      
Weighted average grant date fair value of stock options granted         $ 32.56    
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense $ 6,900,719 $ 4,806,768 $ 19,352,150 $ 14,849,409
Inventoriable costs [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense 345,460   996,802  
Research and Development [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense 2,402,865 2,023,700 6,792,498 6,785,280
General and Administrative [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]        
Total share-based compensation expense $ 4,152,394 $ 2,783,068 $ 11,562,850 $ 8,064,129
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]    
Dividend yield 0.00% 0.00%
Expected volatility, minimum 91.60% 83.70%
Expected volatility, maximum 92.70% 85.70%
Weighted-average risk-free interest rate 1.31% 2.32%
Expected term (in years) 6 years 6 years
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail) - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of period, Number of Shares 6,039,945  
Options granted, Number of Shares 742,509  
Outstanding at end of period, Number of Shares 5,924,407 6,039,945
Vested or expected to vest at end of period, Number of Shares 5,924,407  
Exercisable at end of period, Number of Shares 3,620,984  
Outstanding at beginning of period, Weighted-Average Exercise Price $ 16.81  
Options granted, exercise price 23.85  
Outstanding at end of period, Weighted-Average Exercise Price 18.03 $ 16.81
Vested or expected to vest at end of period, Weighted-Average Exercise Price 18.03  
Exercisable at end of period, Weighted-Average Exercise Price $ 18.85  
Options granted, Weighted-Average Contractual Life 9 years 4 months 24 days  
Outstanding at end of period, Weighted-Average Contractual Life 6 years 9 months 18 days 7 years
Inducement Award Plan [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of period, Number of Shares 0  
Options granted, Number of Shares 39,728  
Outstanding at end of period, Number of Shares 39,728 0
Vested or expected to vest at end of period, Number of Shares 39,728  
Exercisable at end of period, Number of Shares 0  
Outstanding at beginning of period, Weighted-Average Exercise Price $ 0  
Options granted, exercise price 17.18  
Outstanding at end of period, Weighted-Average Exercise Price 17.18 $ 0
Vested or expected to vest at end of period, Weighted-Average Exercise Price 17.18  
Exercisable at end of period, Weighted-Average Exercise Price $ 0  
Options granted, Weighted-Average Contractual Life 9 years 6 months  
Outstanding at end of period, Weighted-Average Contractual Life 9 years 6 months  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail) - Inducement Award Plan [Member]
 9 Months Ended
Sep. 30, 2020
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Outstanding at beginning of year, Number of Shares | shares 0
Time based RSU's granted, Number of Shares | shares 274,410
Time based RSU's cancelled, Number of Shares | shares (15,064)
Outstanding at end of year, Number of Shares | shares 259,346
Vested or expected to vest, Number of Shares | shares 259,346
Exercisable, Number of Shares | shares 0
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value | $ / shares $ 0
Time based RSU's granted, Weighted-Average Grant Date Fair Value | $ / shares 16.01
Time based RSU's cancelled, Weighted-Average Grant Date Fair Value | $ / shares 15.81
Outstanding at end of year, Weighted-Average Grant Date Fair Value | $ / shares 16.01
Vested or expected to vest, Weighted- Average Exercise Price | $ / shares 16.01
Exercisable, Weighted- Average Exercise Price | $ / shares $ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 2 years 6 months
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms 2 years 7 months 6 days
Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited 2 years 7 months 6 days
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation - Stock Options Activity (Detail) - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]    
Outstanding at beginning of period, Number of Shares 6,039,945  
Options granted, Number of Shares 742,509  
Options exercised, Number of Shares (696,936)  
Options canceled or expired, Number of Shares (161,111)  
Outstanding at end of period, Number of Shares 5,924,407 6,039,945
Vested or expected to vest at end of period, Number of Shares 5,924,407  
Exercisable at end of period, Number of Shares 3,620,984  
Outstanding at beginning of period, Weighted-Average Exercise Price $ 16.81  
Options granted, Weighted-Average Exercise Price 23.85  
Options exercised, Weighted-Average Exercise Price 12.79  
Options canceled or expired, Weighted-Average Exercise Price 21.70  
Outstanding at end of period, Weighted-Average Exercise Price 18.03 $ 16.81
Vested or expected to vest at end of period, Weighted-Average Exercise Price 18.03  
Exercisable at end of period, Weighted-Average Exercise Price $ 18.85  
Options granted, Weighted-Average Contractual Life 9 years 4 months 24 days  
Options exercised, Weighted-Average Contractual Life 4 years 9 months 18 days  
Options canceled or expired, Weighted-Average Contractual Life 7 years 10 months 24 days  
Outstanding at end of period, Weighted-Average Contractual Life 6 years 9 months 18 days 7 years
Exercisable at end of period, Weighted-Average Contractual Life 5 years 8 months 12 days  
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) - RSUs [Member] - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of year, Number of Shares 1,268,679  
Time based RSU's granted, Number of Shares 728,596  
Time based RSU's vested, Number of Shares (506,546)  
Time based RSU's cancelled, Number of Shares (90,559)  
Outstanding at end of year, Number of Shares 1,400,170 1,268,679
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value $ 13.60  
Time based RSU's granted, Weighted-Average Grant Date Fair Value 23.05  
Time based RSU's vested, Weighted-Average Grant Date Fair Value 13.78  
Time based RSU's cancelled, Weighted-Average Grant Date Fair Value 17.03  
Outstanding at end of year, Weighted-Average Grant Date Fair Value $ 18.69 $ 13.60
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 1 year 10 months 24 days 1 year 8 months 12 days
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms 2 years 8 months 12 days  
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms 10 months 24 days  
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms 1 year 6 months  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail) - Milestone and Total Shareholder Return Restricted Stock Units [Member] - $ / shares
 9 Months Ended 12 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Outstanding at beginning of year, Number of Shares 67,080  
Milestone RSUs and TSR RSUs granted, Number of Shares 86,044  
Time based RSU's vested, Number of Shares (67,080)  
Outstanding at end of year, Number of Shares 86,044 67,080
Outstanding at beginning of year, Weighted-Average Grant Date Fair Value $ 17.08  
Milestone RSUs and TSR RSUs granted, Weighted- Average Grant Date Fair Value 32.56  
Time based RSU's vested, Weighted-Average Grant Date Fair Value 17.08  
Outstanding at end of year, Weighted-Average Grant Date Fair Value $ 32.56 $ 17.08
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 2 years 4 months 24 days 2 months 12 days
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms 2 months 12 days  
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms 2 years 4 months 24 days  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborations and License Agreements - Additional Information (Detail) - Product [Member] - Bristol-Myers Squibb Company [Member] - USD ($)
 1 Months Ended 9 Months Ended
Dec. 23, 2019
May 31, 2005
Dec. 31, 2014
Dec. 31, 2013
Sep. 30, 2020
Jan. 31, 2019
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]            
Company made an upfront payment   $ 1,000,000.0        
Company made milestone payment     $ 1,500,000 $ 1,250,000    
Obliged to make milestone payments         $ 14,750,000 $ 2,000,000.0
License expiration period         through the later of 10 years after first commercial sale of a licensed product in such country, expiration of the last licensed patent covering a licensed product  
Accrued Royalties         $ 506,000  
Minimum [Member]            
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]            
Royalty payment, percentage         5.00%  
Maximum [Member]            
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]            
Royalty payment, percentage         9.00%  
National Democratic Alliance [Member]            
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]            
Company remaining milestone payment $ 5,000,000.0          
ITCI National Democratic Alliance Member [Member]            
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]            
Payment of milestone amount         $ 5,000,000.0  
EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 196 320 1 false 58 0 false 8 false false R1.htm 1001 - Document - Cover Page Sheet http://www.intracellulartherapies.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited Condensed Consolidated Statements of Comprehensive Loss (Unaudited) Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 1007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 1008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Statements 8 false false R9.htm 1009 - Disclosure - Organization Sheet http://www.intracellulartherapies.com/role/Organization Organization Notes 9 false false R10.htm 1010 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 10 false false R11.htm 1011 - Disclosure - Inventory Sheet http://www.intracellulartherapies.com/role/Inventory Inventory Notes 11 false false R12.htm 1012 - Disclosure - Property and Equipment Sheet http://www.intracellulartherapies.com/role/PropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 1013 - Disclosure - Right of Use Assets and Lease Liabilities Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities Right of Use Assets and Lease Liabilities Notes 13 false false R14.htm 1014 - Disclosure - Share-Based Compensation Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensation Share-Based Compensation Notes 14 false false R15.htm 1015 - Disclosure - Collaborations and License Agreements Sheet http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreements Collaborations and License Agreements Notes 15 false false R16.htm 1016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 1017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 1018 - Disclosure - Inventory (Tables) Sheet http://www.intracellulartherapies.com/role/InventoryTables Inventory (Tables) Tables http://www.intracellulartherapies.com/role/Inventory 18 false false R19.htm 1019 - Disclosure - Property and Equipment (Tables) Sheet http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.intracellulartherapies.com/role/PropertyAndEquipment 19 false false R20.htm 1020 - Disclosure - Right of Use Assets and Lease Liabilities (Tables) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables Right of Use Assets and Lease Liabilities (Tables) Tables http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities 20 false false R21.htm 1021 - Disclosure - Share-Based Compensation (Tables) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://www.intracellulartherapies.com/role/ShareBasedCompensation 21 false false R22.htm 1022 - Disclosure - Organization - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail Organization - Additional Information (Detail) Details 22 false false R23.htm 1023 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 23 false false R24.htm 1024 - Disclosure - Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail) Details 24 false false R25.htm 1025 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail) Details 25 false false R26.htm 1026 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Sheet http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail) Details 26 false false R27.htm 1027 - Disclosure - Inventory - Schedule of Inventory, Current (Detail) Sheet http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail Inventory - Schedule of Inventory, Current (Detail) Details 27 false false R28.htm 1028 - Disclosure - Property and Equipment - Property and Equipment (Detail) Sheet http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail Property and Equipment - Property and Equipment (Detail) Details 28 false false R29.htm 1029 - Disclosure - Property and Equipment - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail Property and Equipment - Additional Information (Detail) Details 29 false false R30.htm 1030 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail Right of Use Assets and Lease Liabilities - Additional Information (Detail) Details 30 false false R31.htm 1031 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail) Details 31 false false R32.htm 1032 - Disclosure - Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail) Details 32 false false R33.htm 1033 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail) Sheet http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail) Details 33 false false R34.htm 1034 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 34 false false R35.htm 1035 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail Share-Based Compensation - Total Stock-Based Compensation Expense (Detail) Details 35 false false R36.htm 1036 - Disclosure - Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail) Details 36 false false R37.htm 1037 - Disclosure - Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail) Details 37 false false R38.htm 1038 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail) Details 38 false false R39.htm 1039 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail Share-Based Compensation - Stock Options Activity (Detail) Details 39 false false R40.htm 1040 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail) Details 40 false false R41.htm 1041 - Disclosure - Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail) Sheet http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail) Details 41 false false R42.htm 1042 - Disclosure - Collaborations and License Agreements - Additional Information (Detail) Sheet http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail Collaborations and License Agreements - Additional Information (Detail) Details 42 false false All Reports Book All Reports d18633d10q.htm d18633dex101.htm d18633dex311.htm d18633dex312.htm d18633dex32.htm itci-20200930.xsd itci-20200930_cal.xml itci-20200930_def.xml itci-20200930_lab.xml itci-20200930_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/stpr/2018-01-31 http://fasb.org/srt/2020-01-31 true true JSON 60 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d18633d10q.htm": { "axisCustom": 1, "axisStandard": 25, "contextCount": 196, "dts": { "calculationLink": { "local": [ "itci-20200930_cal.xml" ] }, "definitionLink": { "local": [ "itci-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "d18633d10q.htm" ] }, "labelLink": { "local": [ "itci-20200930_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "itci-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "itci-20200930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 432, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 1, "http://xbrl.sec.gov/dei/2020-01-31": 6, "total": 7 }, "keyCustom": 30, "keyStandard": 290, "memberCustom": 20, "memberStandard": 33, "nsprefix": "itci", "nsuri": "http://www.intracellulartherapies.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "1001 - Document - Cover Page", "role": "http://www.intracellulartherapies.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1010 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1011 - Disclosure - Inventory", "role": "http://www.intracellulartherapies.com/role/Inventory", "shortName": "Inventory", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1012 - Disclosure - Property and Equipment", "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1013 - Disclosure - Right of Use Assets and Lease Liabilities", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities", "shortName": "Right of Use Assets and Lease Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1014 - Disclosure - Share-Based Compensation", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1015 - Disclosure - Collaborations and License Agreements", "role": "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreements", "shortName": "Collaborations and License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1016 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1017 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1018 - Disclosure - Inventory (Tables)", "role": "http://www.intracellulartherapies.com/role/InventoryTables", "shortName": "Inventory (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1019 - Disclosure - Property and Equipment (Tables)", "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1020 - Disclosure - Right of Use Assets and Lease Liabilities (Tables)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables", "shortName": "Right of Use Assets and Lease Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1021 - Disclosure - Share-Based Compensation (Tables)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P09_15_2020To09_15_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1022 - Disclosure - Organization - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "shortName": "Organization - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P09_15_2020To09_15_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1023 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "Unit_Segment", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:AvailableForSaleSecuritiesTextBlock", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1024 - Disclosure - Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Investment Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:AvailableForSaleSecuritiesTextBlock", "us-gaap:InvestmentPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1025 - Disclosure - Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "shortName": "Summary of Significant Accounting Policies - Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020_FairValueMeasurementsRecurringMemberusgaapFairValueByMeasurementFrequencyAxis", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1026 - Disclosure - Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "role": "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail", "shortName": "Summary of Significant Accounting Policies - Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1027 - Disclosure - Inventory - Schedule of Inventory, Current (Detail)", "role": "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail", "shortName": "Inventory - Schedule of Inventory, Current (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1028 - Disclosure - Property and Equipment - Property and Equipment (Detail)", "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail", "shortName": "Property and Equipment - Property and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1029 - Disclosure - Property and Equipment - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail", "shortName": "Property and Equipment - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_USD_per_Share", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1030 - Disclosure - Right of Use Assets and Lease Liabilities - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "shortName": "Right of Use Assets and Lease Liabilities - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "-5", "lang": null, "name": "us-gaap:OperatingLeaseExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1031 - Disclosure - Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "shortName": "Right of Use Assets and Lease Liabilities - Maturity analysis under the lease agreements (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020_RealEstatesLeaseMemberusgaapLeaseContractualTermAxis", "decimals": "0", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1032 - Disclosure - Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "shortName": "Right Of Use Assets and Lease Liabilities - Schedule Of Quantitative Information About Operating Leases (Detail)", "subGroupType": "details", "uniqueAnchor": null }, "R33": { "firstAnchor": { "ancestors": [ "div", "div", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseLiability", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1033 - Disclosure - Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail)", "role": "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "shortName": "Right Of Use Assets and Lease Liabilities - Maturity analysis of the Company's fleet lease liability (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020_VehicleFleetLeaseMemberusgaapLeaseContractualTermAxis", "decimals": "0", "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1034 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "shortName": "Share-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1035 - Disclosure - Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "shortName": "Share-Based Compensation - Total Stock-Based Compensation Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "Unit_pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1036 - Disclosure - Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail", "shortName": "Share-Based Compensation - Assumptions Used for Calculating Value of Options Granted (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "3", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Unit_pure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1037 - Disclosure - Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "shortName": "Share-Based Compensation - Stock Options Activity of Inducement Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020_InducementAwardPlanMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1038 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail", "shortName": "Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes Under the Inducement Plan (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2019_InducementAwardPlanMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2019", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1039 - Disclosure - Share-Based Compensation - Stock Options Activity (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "shortName": "Share-Based Compensation - Stock Options Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2019_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1040 - Disclosure - Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "shortName": "Share-Based Compensation - Summary of Information Regarding the Time Based RSU Activity and Changes (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2019_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unitRef": "Unit_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1041 - Disclosure - Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail)", "role": "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "shortName": "Share-Based Compensation - Summary of Information Regarding Milestone RSU grants and TSR RSU grants (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMemberusgaapAwardTypeAxis", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "Unit_shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P05_31_2005To05_31_2005_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis", "decimals": "INF", "first": true, "lang": null, "name": "itci:CollaborativeAgreementUpfrontPayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1042 - Disclosure - Collaborations and License Agreements - Additional Information (Detail)", "role": "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "shortName": "Collaborations and License Agreements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P05_31_2005To05_31_2005_BristolMyersSquibbCompanyMembersrtCounterpartyNameAxis_ProductMembersrtProductOrServiceAxis", "decimals": "INF", "first": true, "lang": null, "name": "itci:CollaborativeAgreementUpfrontPayments", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005 - Statement - Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P07_01_2020To09_30_2020", "decimals": "0", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2018", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn12_31_2018", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1007 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2020", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "Unit_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1008 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "role": "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "PAsOn09_30_2019", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "1009 - Disclosure - Organization", "role": "http://www.intracellulartherapies.com/role/Organization", "shortName": "Organization", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "div", "body", "html" ], "baseRef": "d18633d10q.htm", "contextRef": "P01_01_2020To09_30_2020", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 58, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r441" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r442" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r444" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r443" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r439" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r440" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "itci_AmtTaxCreditMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AMT tax credit.", "label": "AMT Tax Credit [Member]" } } }, "localname": "AmtTaxCreditMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_AvailableForSaleSecuritiesMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Available For Sale Securities Maturity Period", "label": "Available For Sale Securities Maturity Period", "terseLabel": "Maturity of certificates of deposit, commercial paper, corporate notes and corporate bonds" } } }, "localname": "AvailableForSaleSecuritiesMaturityPeriod", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationStringItemType" }, "itci_BristolMyersSquibbCompanyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bristol Myers Squibb company.", "label": "Bristol Myers Squibb Company [Member]", "terseLabel": "Bristol-Myers Squibb Company [Member]" } } }, "localname": "BristolMyersSquibbCompanyMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CashAndCashEquivalentMaximumMaturityPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cash And Cash Equivalent Maximum Maturity Period", "label": "Cash And Cash Equivalent Maximum Maturity Period", "terseLabel": "Maturity of highly liquid investments" } } }, "localname": "CashAndCashEquivalentMaximumMaturityPeriod", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "itci_CollaborativeAgreementUpfrontPayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative Agreement Upfront Payments", "label": "Collaborative Agreement Upfront Payments", "terseLabel": "Company made an upfront payment" } } }, "localname": "CollaborativeAgreementUpfrontPayments", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_CollaborativeArrangementAmountPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement amount payable.", "label": "Collaborative Arrangement Amount Payable", "terseLabel": "Obliged to make milestone payments" } } }, "localname": "CollaborativeArrangementAmountPayable", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_CollaborativeArrangementLicenseExpirationDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement license expiration description.", "label": "Collaborative Arrangement License Expiration Description", "terseLabel": "License expiration period" } } }, "localname": "CollaborativeArrangementLicenseExpirationDescription", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_CollaborativeArrangementMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement Milestone Payments", "label": "Collaborative Arrangement Milestone Payments", "terseLabel": "Company made milestone payment" } } }, "localname": "CollaborativeArrangementMilestonePayments", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_CollaborativeArrangementRemainingPotentialMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement remaining potential milestone payments.", "label": "Collaborative Arrangement Remaining Potential Milestone Payments", "terseLabel": "Company remaining milestone payment" } } }, "localname": "CollaborativeArrangementRemainingPotentialMilestonePayments", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Contractual Maturity More Than One Year And Less Than Two Years [Member]", "label": "Contractual Maturity More Than One Year And Less Than Two Years [Member]", "terseLabel": "Contractual Maturity Dates More Than One Year and Less Than Two Years [Member]" } } }, "localname": "ContractualMaturityMoreThanOneYearAndLessThanTwoYearsMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CostOfProductSales": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost of product sales.", "label": "Cost Of Product Sales", "terseLabel": "Cost of product sales" } } }, "localname": "CostOfProductSales", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "itci_CustomerOneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer one.", "label": "Customer One [Member]", "terseLabel": "Customer one [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CustomerThreeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer three.", "label": "Customer Three [Member]", "terseLabel": "Customer three [Member]" } } }, "localname": "CustomerThreeMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_CustomerTwoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer two.", "label": "Customer Two [Member]", "terseLabel": "Customer two [Member]" } } }, "localname": "CustomerTwoMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]", "label": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]", "terseLabel": "Fair Value Of Assets And Liabilities Measured On Non Recurring Basis [Line Items]" } } }, "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnNonRecurringBasisLineItems", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "itci_ITCINationalDemocraticAllianceMemberMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ITCI national democratic alliance [member].", "label": "ITCI National Democratic Alliance Member [Member]", "terseLabel": "ITCI National Democratic Alliance Member [Member]" } } }, "localname": "ITCINationalDemocraticAllianceMemberMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_IncreaseDecreaseInOperatingLeaseLiabilititesCurrent": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase decrease in operating lease liabilitites, current.", "label": "Increase Decrease In Operating Lease Liabilitites Current", "terseLabel": "Lease liabilities, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilititesCurrent", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "itci_InducementAwardPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inducement Award Plan [Member]", "terseLabel": "Inducement Award Plan [Member]" } } }, "localname": "InducementAwardPlanMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "itci_InventoriableCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventoriable costs.", "label": "Inventoriable costs [Member]", "terseLabel": "Inventoriable costs [Member]" } } }, "localname": "InventoriableCostsMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "itci_InventoryCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventory costs.", "label": "Inventory Costs", "terseLabel": "Inventory Costs" } } }, "localname": "InventoryCosts", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_Investment1Axis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment1 [Axis]", "terseLabel": "Investment [Axis]" } } }, "localname": "Investment1Axis", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_Investment1Domain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investment1 [Domain]", "terseLabel": "Investment [Domain]" } } }, "localname": "Investment1Domain", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_ItciInducementAwardPlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ITCI inducement award plan.", "label": "ITCI Inducement Award Plan [Member]", "terseLabel": "ITCI Inducement Award Plan [Member]" } } }, "localname": "ItciInducementAwardPlanMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_LesseeOperatingLeaseLiabilityPaymentsDueInRollingAfterYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Lessee operating lease liability payments due in rolling after year four.", "label": "Lessee Operating Lease Liability Payments Due In Rolling After Year Four", "terseLabel": "Thereafter", "verboseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingAfterYearFour", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "itci_MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone and total shareholder return restricted stock units.", "label": "Milestone And Total Shareholder Return Restricted Stock Units [Member]", "terseLabel": "Milestone and Total Shareholder Return Restricted Stock Units [Member]" } } }, "localname": "MilestoneAndTotalShareholderReturnRestrictedStockUnitsMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "itci_MilestoneRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Milestone Restricted Stock Units [Member]", "label": "Milestone Restricted Stock Units [Member]", "terseLabel": "Milestone Restricted Stock Units [Member]" } } }, "localname": "MilestoneRestrictedStockUnitsMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_NationalDemocraticAllianceMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "National Democratic Alliance.", "label": "National Democratic Alliance [Member]", "terseLabel": "National Democratic Alliance [Member]" } } }, "localname": "NationalDemocraticAllianceMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_NumberOfCustomers": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of customers.", "label": "Number Of Customers", "terseLabel": "Number of customers" } } }, "localname": "NumberOfCustomers", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Organization consolidation and presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureLineItems", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Organization consolidation and presentation of financial statements disclosure.", "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_PaymentOfMilestoneAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Payment of milestone amount.", "label": "Payment Of Milestone Amount", "terseLabel": "Payment of milestone amount" } } }, "localname": "PaymentOfMilestoneAmount", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of minimum net proceeds of capitalized costs in first twelve months.", "label": "Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months", "terseLabel": "Percentage Of Minimum Net Proceeds Of Capitalized Costs In First Twelve Months" } } }, "localname": "PercentageOfMinimumNetProceedsOfCapitalizedCostsInFirstTwelveMonths", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "itci_PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of minimum net proceeds of capitalized costs later than twelve months.", "label": "Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months", "terseLabel": "Percentage Of Minimum Net Proceeds Of Capitalized Costs Later Than Twelve Months" } } }, "localname": "PercentageOfMinimumNetProceedsOfCapitalizedCostsLaterThanTwelveMonths", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "itci_PerformanceBasedRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Performance Based Restricted Stock Units [member]", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance Based Restricted Stock Units [Member]" } } }, "localname": "PerformanceBasedRestrictedStockUnitsMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_RealEstateLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Real estate lease.", "label": "Real Estate Lease [Member]", "terseLabel": "Real Estate Lease [Member]" } } }, "localname": "RealEstateLeaseMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "itci_RealEstatesLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Real Estates Lease [Member]" } } }, "localname": "RealEstatesLeaseMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "domainItemType" }, "itci_RoyaltyPaymentPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty Payment Percentage", "label": "Royalty Payment Percentage", "terseLabel": "Royalty payment, percentage" } } }, "localname": "RoyaltyPaymentPercentage", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "itci_ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of quantitative information about operating leases.", "label": "Schedule Of Quantitative Information About Operating Leases [Table Text Block]", "terseLabel": "Schedule Of Quantitative Information About Operating Leases" } } }, "localname": "ScheduleOfQuantitativeInformationAboutOperatingLeasesTableTextBlock", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "itci_SecuritiesAuthorizedAmountForIssuance": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Securities Authorized Amount For Issuance", "label": "Securities Authorized Amount For Issuance", "terseLabel": "Universal shelf registration statement, effective date value" } } }, "localname": "SecuritiesAuthorizedAmountForIssuance", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options forfeited average remaining contractual terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedAverageRemainingContractualTerms", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options granted average remaining contractual terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Granted Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedAverageRemainingContractualTerms", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options grants in period remaining contractual terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodRemainingContractualTerms", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, equity instruments other than options, vested and expected to vest, outstanding, number.", "label": "Share based Compensation Arrangement by Share based Payment Award Equity Instruments Other than Options Vested and Expected to Vest Outstanding Number", "terseLabel": "Vested or expected to vest, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested average remaining contractual terms.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms", "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRemainingContractualTerms", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Remaining Contractual Term", "terseLabel": "Options canceled or expired, Weighted-Average Contractual Life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award options grants in period weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Remaining Contractual Term 2", "terseLabel": "Options granted, Weighted-Average Contractual Life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageRemainingContractualTerm2", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based compensation arrangements by share-based payment award options exercises in period weighted average remaining contractual term.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Remaining Contractual Term", "terseLabel": "Options exercised, Weighted-Average Contractual Life" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageRemainingContractualTerm", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "durationItemType" }, "itci_ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share based compensation by share based payment arrangement other than options weighted average contractual term of instruments forfeited.", "label": "Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited", "terseLabel": "Share Based Compensation By Share Based Payment Arrangement Other Than Options Weighted Average Contractual Term Of Instruments Forefeited" } } }, "localname": "ShareBasedCompensationByShareBasedPaymentArrangementOtherThanOptionsWeightedAverageContractualTermOfInstrumentsForefeited", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "durationItemType" }, "itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Number.", "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Exercisable Number", "terseLabel": "Exercisable, Number of Shares" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableNumber", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercisable Weighted Average Exercise Price.", "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Exercisable Weighted Average Exercise Price", "terseLabel": "Exercisable, Weighted- Average Exercise Price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "itci_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested and Expected to Vest, Outstanding Weighted Average Exercise Price.", "label": "Sharebased Compensation Arrangement by Sharebased Payment Award Equity Instruments Other than Options Vested and Expected to Vest Outstanding Weighted Average Exercise Price", "terseLabel": "Vested or expected to vest, Weighted- Average Exercise Price" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "itci_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "itci_TimeBasedRestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Time based restricted stock units.", "label": "Time Based Restricted Stock Units R S U [Member]", "terseLabel": "Time Based Restricted Stock Units [Member]" } } }, "localname": "TimeBasedRestrictedStockUnitsRSUMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "itci_TotalShareholderReturnRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Total shareholder return restricted stock units.", "label": "Total Shareholder Return Restricted Stock Units [Member]", "terseLabel": "Total Shareholder Return Restricted Stock Units [Member]", "verboseLabel": "Total Shareholder Return Restricted Stock Units [Member]" } } }, "localname": "TotalShareholderReturnRestrictedStockUnitsMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "domainItemType" }, "itci_TwoThousandEighteenEquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two Thousand Eighteen Equity Incentive Plan [Member]", "label": "Two Thousand Eighteen Equity Incentive Plan [Member]", "terseLabel": "2018 Equity Incentive Plan [Member]" } } }, "localname": "TwoThousandEighteenEquityIncentivePlanMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "itci_VehicleFleetLeaseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vehicle fleet lease.", "label": "Vehicle Fleet Lease [Member]", "terseLabel": "Vehicle Fleet Lease [Member]" } } }, "localname": "VehicleFleetLeaseMember", "nsuri": "http://www.intracellulartherapies.com/20200930", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r291", "r292", "r297", "r298", "r437" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r291", "r292", "r297", "r298" ], "lang": { "en-US": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r45", "r86" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r146", "r199", "r201", "r394" ], "lang": { "en-US": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r212", "r214", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r392", "r395" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r212", "r214", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r392", "r395" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r146", "r199", "r201", "r394" ], "lang": { "en-US": { "role": { "label": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r144", "r199", "r200", "r357", "r391", "r393" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r144", "r199", "r200", "r357", "r391", "r393" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r203", "r212", "r214", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r392", "r395" ], "lang": { "en-US": { "role": { "label": "Range [Axis]", "terseLabel": "Range [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r203", "r212", "r214", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r392", "r395" ], "lang": { "en-US": { "role": { "label": "Range [Domain]", "terseLabel": "Range [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436" ], "lang": { "en-US": { "role": { "label": "Name of Property [Axis]" } } }, "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "auth_ref": [ "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436" ], "lang": { "en-US": { "role": { "label": "Name of Property [Domain]" } } }, "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r213" ], "lang": { "en-US": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r189", "r213", "r346" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r147", "r344" ], "lang": { "en-US": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Relationship to Entity [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "stpr_MD": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "MARYLAND" } } }, "localname": "MD", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "stpr_NY": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "NEW YORK" } } }, "localname": "NY", "nsuri": "http://xbrl.sec.gov/stpr/2018-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201602Member": { "auth_ref": [ "r330" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).", "label": "Accounting Standards Update 2016-02 [Member]" } } }, "localname": "AccountingStandardsUpdate201602Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r36" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r16", "r148", "r149" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "terseLabel": "Accounts receivable, net" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r76" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of premiums and discounts on investment securities, net" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedEmployeeBenefitsCurrent": { "auth_ref": [ "r7", "r8", "r38" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 22.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Employee Benefits, Current", "terseLabel": "Accrued employee benefits" } } }, "localname": "AccruedEmployeeBenefitsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 21.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.", "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "auth_ref": [ "r367", "r384" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.", "label": "Accrued Royalties", "terseLabel": "Accrued Royalties" } } }, "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r34", "r184" ], "calculation": { "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r47", "r48", "r49", "r380", "r403", "r407" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r46", "r49", "r50", "r88", "r89", "r90", "r296", "r398", "r399" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated Comprehensive Income (Loss) [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r17" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r88", "r89", "r90", "r255", "r256", "r257" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r91", "r92", "r93", "r94", "r164", "r165", "r166", "r167", "r168", "r169", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r278", "r279", "r280", "r281", "r359", "r360", "r361", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407" ], "lang": { "en-US": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature": { "auth_ref": [ "r196", "r197", "r277" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.", "label": "Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature", "terseLabel": "Common shares receivable collected" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r215", "r217", "r261", "r262" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Share-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r217", "r247", "r260" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share-based Compensation Expense", "terseLabel": "Non-cash stock-based compensation expense recognized" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Number of anti-dilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r84", "r133", "r136", "r142", "r163", "r291", "r297", "r317", "r365", "r378" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r5", "r6", "r44", "r84", "r163", "r291", "r297", "r317" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r304" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets measured using quoted prices", "verboseLabel": "Available-for-sale investment securities" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r155" ], "calculation": { "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.", "label": "Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Unrealized (Losses)" } } }, "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesAmortizedCost": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.", "label": "Available-for-sale Securities, Amortized Cost Basis", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleSecuritiesAmortizedCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale that have been in a continuous loss position for twelve months or longer.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "terseLabel": "Investment securities, held in continuous unrealized loss position for 12 months or longer" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss": { "auth_ref": [ "r159" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated unrealized loss on investments in debt and equity securities classified as available-for-sale in a continuous loss position.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss", "terseLabel": "Investment securities aggregate amount of unrealized loss" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This item represents the aggregate fair value of investments in debt and equity securities in an unrealized loss position which are categorized neither as held-to-maturity nor trading securities.", "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value", "terseLabel": "Aggregate related fair value of investments with unrealized losses" } } }, "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleSecuritiesAmortizedCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.", "label": "Available-for-sale Securities, Current", "terseLabel": "Estimated Fair Value", "verboseLabel": "Investment securities, available-for-sale" } } }, "localname": "AvailableForSaleSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of Investment Securities" } } }, "localname": "AvailableForSaleSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r218", "r249" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r302", "r303" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r31", "r77" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Member]", "terseLabel": "Cash and Cash Equivalents [Member]" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r10", "r78", "r80" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r10", "r78", "r80", "r364" ], "lang": { "en-US": { "role": { "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash" } } }, "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r72", "r77", "r79" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r72", "r318" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "auth_ref": [ "r31" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Certificates of Deposit, at Carrying Value", "terseLabel": "Carrying value of cash held in certificates of deposit" } } }, "localname": "CertificatesOfDepositAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositMember": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.", "label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of Deposit [Member]" } } }, "localname": "CertificatesOfDepositMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ChangeInAccountingEstimateByTypeAxis": { "auth_ref": [ "r98", "r111" ], "lang": { "en-US": { "role": { "documentation": "Information by type of change in accounting estimate.", "label": "Change in Accounting Estimate by Type [Axis]" } } }, "localname": "ChangeInAccountingEstimateByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingEstimateTypeDomain": { "auth_ref": [ "r98", "r111" ], "lang": { "en-US": { "role": { "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.", "label": "Change in Accounting Estimate, Type [Domain]" } } }, "localname": "ChangeInAccountingEstimateTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r83", "r84", "r102", "r103", "r104", "r106", "r108", "r114", "r115", "r116", "r163", "r317" ], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r285", "r286", "r288" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborations and License Agreements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommercialPaperAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Commercial Paper, at Carrying Value", "verboseLabel": "Carrying value of commercial paper" } } }, "localname": "CommercialPaperAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r195" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial Paper [Member]" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r40" ], "lang": { "en-US": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Additional shares of common stock reserved for future equity grants" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r88", "r89" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Common stock issued, shares" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r196" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.0001 par value: 100,000,000 shares authorized; 80,142,797 and 55,507,497 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r53", "r55", "r56", "r62", "r371", "r387" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer Equipment [Member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r123", "r124", "r146", "r315", "r316" ], "lang": { "en-US": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r123", "r124", "r146", "r315", "r316", "r409" ], "lang": { "en-US": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r123", "r124", "r146", "r315", "r316", "r409" ], "lang": { "en-US": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r119", "r377" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r123", "r124", "r146", "r315", "r316" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r123", "r124", "r146", "r315", "r316" ], "lang": { "en-US": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r204", "r211", "r408" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate Notes/Bonds [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfSalesPolicyTextBlock": { "auth_ref": [ "r202" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.", "label": "Cost of Goods and Service [Policy Text Block]", "terseLabel": "Cost of Product Sales" } } }, "localname": "CostOfSalesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r122", "r146" ], "lang": { "en-US": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of common shares reserved for future issuance related to deferred compensation arrangements with individuals.", "label": "Deferred Compensation Arrangement with Individual, Common Stock Reserved for Future Issuance", "terseLabel": "Shares of common stock reserved for issuance" } } }, "localname": "DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_DeferredIncomeTaxAssetsNet": { "auth_ref": [ "r267", "r268" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.", "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred tax asset, net" } } }, "localname": "DeferredIncomeTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRentCredit": { "auth_ref": [ "r327" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.", "label": "Deferred Rent Credit", "terseLabel": "Eliminated deferred rent" } } }, "localname": "DeferredRentCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r273" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Gross", "terseLabel": "Deferred Tax Assets, Gross" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r75", "r182" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/PropertyAndEquipmentAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r263" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r107" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Basic & Diluted" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r80", "r109", "r110" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r270" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r270", "r283" ], "lang": { "en-US": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "US statutory rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r248" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options", "terseLabel": "Unrecognized compensation costs related to unvested RSUs" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Stock Options [Member]", "verboseLabel": "Stock options [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Scientific Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r88", "r89", "r90", "r92", "r99", "r101", "r113", "r167", "r196", "r197", "r255", "r256", "r257", "r280", "r281", "r319", "r320", "r321", "r322", "r323", "r325", "r398", "r399", "r400" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r304", "r305", "r306", "r311" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r304", "r305" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets measured at fair value measured on a recurring or nonrecurring basis. Includes, but is not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2.", "label": "Fair Value, Assets Measured on Recurring and Nonrecurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurements of Cash Equivalents and Available-for-Sale Investment Securities" } } }, "localname": "FairValueAssetsMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r305", "r347", "r348", "r349" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r304", "r305", "r308", "r309", "r312" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r204", "r205", "r210", "r211", "r305", "r347" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r204", "r205", "r210", "r211", "r305", "r348" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2) [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r305", "r349" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3) [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Fair Value, Measurement Frequency [Domain]", "terseLabel": "Fair Value, Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r347", "r348", "r349" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r310", "r312" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Measurements, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r80", "r313", "r314" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialStandbyLetterOfCreditMember": { "auth_ref": [ "r190", "r194" ], "lang": { "en-US": { "role": { "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation if defined events occur or fail to occur.", "label": "Financial Standby Letter of Credit [Member]", "terseLabel": "Financial Standby Letter of Credit [Member]" } } }, "localname": "FinancialStandbyLetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r174", "r176", "r178", "r180", "r358", "r362" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r174", "r177" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r63" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and Administrative [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_GrantMember": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Award of money not required to be repaid.", "label": "Grant [Member]", "terseLabel": "Grant revenue [Member]" } } }, "localname": "GrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_GuaranteeObligationsByNatureAxis": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Information by nature of guarantee.", "label": "Guarantor Obligations, Nature [Axis]" } } }, "localname": "GuaranteeObligationsByNatureAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_GuaranteeObligationsCurrentCarryingValue": { "auth_ref": [ "r192" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The current carrying amount of the liability for the freestanding or embedded guarantor's obligations under the guarantee or each group of similar guarantees.", "label": "Guarantor Obligations, Current Carrying Value", "terseLabel": "Guarantee Obligations" } } }, "localname": "GuaranteeObligationsCurrentCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteeObligationsNatureDomain": { "auth_ref": [ "r191" ], "lang": { "en-US": { "role": { "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees.", "label": "Guarantor Obligations, Nature [Domain]" } } }, "localname": "GuaranteeObligationsNatureDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "IPO [Member]", "terseLabel": "IPO [Member]" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r75", "r181", "r186" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment of Long-Lived Assets Held-for-use", "terseLabel": "Impairment losses recognized" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r59", "r133", "r135", "r138", "r141", "r143", "r363", "r368", "r372", "r389" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before provision for income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r187" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r85", "r100", "r101", "r132", "r269", "r282", "r284", "r390" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r57", "r80", "r265", "r266", "r271", "r272", "r274", "r276", "r425" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r74" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r74" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r74" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued liabilities and other" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "auth_ref": [ "r74" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.", "label": "Increase (Decrease) in Deferred Income Taxes", "negatedLabel": "Long term deferred tax asset, net" } } }, "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r74" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r74" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r175", "r179" ], "lang": { "en-US": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-lived Intangible Assets [Axis]", "terseLabel": "Indefinite-lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r175", "r179" ], "lang": { "en-US": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r173" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/Inventory" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r23", "r172" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r42" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventory", "verboseLabel": "Total inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r9", "r43", "r80", "r112", "r170", "r171", "r173" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r25", "r172" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r24", "r172" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work in process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryScheduleOfInventoryCurrentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r66", "r131" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 9.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r162", "r388" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investment Securities, available-for-sale" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-US": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]", "terseLabel": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424" ], "lang": { "en-US": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]", "terseLabel": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r75" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Stock issued for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r183" ], "lang": { "en-US": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LeasesOfLesseeDisclosureTextBlock": { "auth_ref": [ "r329" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.", "label": "Leases of Lessee Disclosure [Text Block]", "terseLabel": "Right of Use Assets and Lease Liabilities" } } }, "localname": "LeasesOfLesseeDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r336" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r342" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule Of Maturity Analysis Under Lease Agreements" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r342" ], "calculation": { "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Total", "totalLabel": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four", "verboseLabel": "Year ending December 31, 2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three", "terseLabel": "Year ending December\u00a031, 2023", "verboseLabel": "Year ending December 31, 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two", "terseLabel": "Year ending December\u00a031, 2022", "verboseLabel": "Year ending December 31, 2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months", "terseLabel": "Year ending December\u00a031, 2021", "verboseLabel": "Year ending December 31, 2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "verboseLabel": "Three months ending December 31, 2020" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r342" ], "calculation": { "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: Present value discount" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r335" ], "lang": { "en-US": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of long term lease" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r37", "r84", "r137", "r163", "r292", "r297", "r298", "r317" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r84", "r163", "r317", "r366", "r382" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r39", "r84", "r163", "r292", "r297", "r298", "r317" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r304" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities measured using quoted prices" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ManufacturingCosts": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred in the production of goods for sale.", "label": "Manufacturing Costs" } } }, "localname": "ManufacturingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, at Carrying Value", "terseLabel": "Carrying value of cash held in money market funds" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r204" ], "lang": { "en-US": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r72", "r73", "r76" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r51", "r54", "r60", "r76", "r84", "r91", "r95", "r96", "r97", "r98", "r100", "r101", "r105", "r133", "r135", "r138", "r141", "r143", "r163", "r317", "r369", "r385" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Non-cash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r128" ], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r133", "r135", "r138", "r141", "r143" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r337", "r343" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating Lease, Cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r333" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Operating lease expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Lease Liabilities, Payments Due [Abstract]" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r332" ], "calculation": { "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Net lease liabilities", "totalLabel": "Total operating lease liabilities", "verboseLabel": "Total Lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r332" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 23.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "negatedLabel": "Less: current portion", "terseLabel": "Lease liabilities, short-term", "verboseLabel": "Lease liabilities, short-term" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r332" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "definitionGuidance": "Lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Long-term lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisOfTheCompanySFleetLeaseLiabilityDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePaymentsUse": { "auth_ref": [ "r334", "r338" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments, Use", "verboseLabel": "Operating lease cash outflows" } } }, "localname": "OperatingLeasePaymentsUse", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r331" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "definitionGuidance": "Right of use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "verboseLabel": "Right of use assets, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r341", "r343" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease discount rate", "verboseLabel": "Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r340", "r343" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesScheduleOfQuantitativeInformationAboutOperatingLeasesDetail" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r301" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Organization" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/Organization" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r35" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r289", "r290", "r295" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "verboseLabel": "Unrealized gain (loss) on investment securities" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r52", "r55", "r58", "r61", "r196", "r319", "r324", "r325", "r370", "r386" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive gain (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r69" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r68" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r218", "r249" ], "lang": { "en-US": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r5", "r29", "r30" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Initial public offering, Net proceeds" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r70" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds of public offering, net", "verboseLabel": "Net proceeds from the sale of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r67" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Maturities of investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r70", "r250" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductMember": { "auth_ref": [ "r200" ], "lang": { "en-US": { "role": { "documentation": "Article or substance produced by nature, labor or machinery.", "label": "Product [Member]", "terseLabel": "Product [Member]", "verboseLabel": "Product sales, net [Member]" } } }, "localname": "ProductMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r0", "r51", "r54", "r71", "r84", "r91", "r100", "r101", "r133", "r135", "r138", "r141", "r143", "r163", "r289", "r293", "r294", "r299", "r300", "r317", "r372" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r34", "r185" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Type [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r188", "r426", "r427", "r428" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r33", "r183" ], "calculation": { "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r185", "r383" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property Plant and Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r32", "r80", "r185", "r426", "r427" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r185" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r183" ], "lang": { "en-US": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property, Plant and Equipment, Type [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, Plant and Equipment, Useful Life", "terseLabel": "Property and equipment, estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "Information by property that could be leased or is available for lease.", "label": "Property Subject to or Available for Operating Lease [Axis]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain": { "auth_ref": [ "r328" ], "lang": { "en-US": { "role": { "documentation": "A descriptive title of whether the property is subject to or available for operating lease.", "label": "Property Subject to or Available for Operating Lease [Domain]" } } }, "localname": "PropertySubjectToOrAvailableForOperatingLeaseDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r80", "r150", "r152", "r153", "r154" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivables, Policy [Policy Text Block]", "terseLabel": "Accounts Receivable, net" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RegulatoryAgencyAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of regulatory agency.", "label": "Regulatory Agency [Axis]" } } }, "localname": "RegulatoryAgencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RegulatoryAgencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Organization that establishes and ensures compliance with rules or regulations.", "label": "Regulatory Agency [Domain]" } } }, "localname": "RegulatoryAgencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r264", "r438" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and Development [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r80", "r264" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development, including Clinical trial expenses" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCash": { "auth_ref": [ "r79", "r364", "r379" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash", "terseLabel": "Restricted Cash" } } }, "localname": "RestrictedCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r2", "r10", "r79" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnauditedParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "RSUs [Member]" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r197", "r258", "r381", "r402", "r407" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r88", "r89", "r90", "r92", "r99", "r101", "r167", "r255", "r256", "r257", "r280", "r281", "r398", "r400" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r129", "r130", "r134", "r139", "r140", "r144", "r145", "r146", "r198", "r199", "r357" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "verboseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]", "terseLabel": "Revenue Recognition, Multiple-deliverable Arrangements [Line Items]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionMultipleDeliverableArrangementsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the recognition of revenue arrangements under which the entity does or will perform multiple revenue-generating activities, categorized by type of arrangement, including certain revenue arrangements that include software elements. This item does not include multiple-deliverable arrangements for industries that prepare disclosures under specific requirements (for instance, construction-type and production-type contracts) otherwise provided for in the taxonomy.", "label": "Revenue Recognition, Multiple-deliverable Arrangements [Table]" } } }, "localname": "RevenueRecognitionMultipleDeliverableArrangementsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r81", "r82" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r339", "r343" ], "crdr": "debit", "lang": { "en-US": { "role": { "definitionGuidance": "Right of use assets under operating", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right of use assets obtained in exchange for operating lease liability" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Initial public offering, Gross proceeds" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesCommonStockEquivalentsExcludedInCalculationOfDilutedLossPerShareDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r109" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Common Stock Equivalents Excluded in Calculation of Diluted Loss Per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Schedule of Available-for-sale Securities [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": { "auth_ref": [ "r156", "r157", "r158", "r159", "r160", "r161", "r374", "r375" ], "lang": { "en-US": { "role": { "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.", "label": "Schedule of Available-for-sale Securities [Table]", "terseLabel": "Schedule of Available-for-sale Securities [Table]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r217", "r246", "r260" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]", "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r217", "r246", "r260" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Total Stock-Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r9", "r26", "r27", "r28" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory, Current" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/InventoryTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r34", "r185" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/PropertyAndEquipmentPropertyAndEquipmentDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r218", "r249" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r224", "r236", "r238" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r240" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions Used for Calculating Value of Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.", "label": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]", "terseLabel": "Summary of Information Regarding RSU Activity" } } }, "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r65" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r74" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Compensation", "terseLabel": "Share-based compensation", "verboseLabel": "Total share-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTotalStockBasedCompensationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r219" ], "lang": { "en-US": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Options, vesting term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r230" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Time based RSU's cancelled, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Time based RSU's cancelled, Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "definitionGuidance": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Time based RSU's granted, Number of Shares", "verboseLabel": "Milestone RSUs and TSR RSUs granted, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r233" ], "lang": { "en-US": { "role": { "definitionGuidance": "Milestone RSUs and TSR RSUs granted, Weighted- Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "positiveLabel": "Weighted average grant date fair value of stock options granted", "terseLabel": "Time based RSU's granted, Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Outstanding at end of year, Number of Shares", "periodStartLabel": "Outstanding at beginning of year, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r232" ], "lang": { "en-US": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Outstanding at end of year, Weighted-Average Grant Date Fair Value", "periodStartLabel": "Outstanding at beginning of year, Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Time based RSU's vested, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r234" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Time based RSU's vested, Weighted-Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r243" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "positiveLabel": "Expected dividend yield", "terseLabel": "Assumed expected dividend rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r242" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "terseLabel": "Expected volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum", "terseLabel": "Expected volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk free interest rate", "verboseLabel": "Weighted-average risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r221" ], "lang": { "en-US": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Issuance of shares, Inducement Award Plan", "verboseLabel": "Issuance of shares, Inducement Award Plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Awards granted", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r227" ], "lang": { "en-US": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of period, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Options canceled or expired, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r231" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Options canceled or expired, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r228" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options granted, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Additional Stock- based awards, grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r237" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of stock options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r226", "r249" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period, Number of Shares", "periodStartLabel": "Outstanding at beginning of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period, Weighted-Average Exercise Price", "periodStartLabel": "Outstanding at beginning of period, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Vested or expected to vest at end of period, Number of Shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Vested or expected to vest at end of period, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r216", "r222" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingMilestoneRsuGrantsAndTsrRsuGrantsDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationSummaryOfInformationRegardingTheTimeBasedRsuActivityAndChangesUnderTheInducementPlanDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Options exercised, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Options granted, exercise price", "verboseLabel": "Options granted, Weighted-Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r80", "r218", "r223" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]", "terseLabel": "Share-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Initial public offering, Price per share" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r220" ], "lang": { "en-US": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Options, maximum term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r241", "r259" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationAssumptionsUsedForCalculatingValueOfOptionsGrantedDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at end of period, Weighted-Average Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at end of period, Weighted-Average Contractual Life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail", "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityOfInducementPlanDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r13", "r14", "r15", "r83", "r84", "r102", "r103", "r104", "r106", "r108", "r114", "r115", "r116", "r163", "r196", "r317" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r41", "r88", "r89", "r90", "r92", "r99", "r101", "r113", "r167", "r196", "r197", "r255", "r256", "r257", "r280", "r281", "r319", "r320", "r321", "r322", "r323", "r325", "r398", "r399", "r400" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r88", "r89", "r90", "r113", "r357" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesMaturityAnalysisUnderTheLeaseAgreementsDetail", "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesTables", "http://www.intracellulartherapies.com/role/ShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Stock issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r14", "r15", "r196", "r197" ], "lang": { "en-US": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Common shares issued, shares", "verboseLabel": "Initial public offering, Number of shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r14", "r15", "r196", "r197" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Exercise of stock options and issuances of restricted stock (Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r196", "r197", "r229" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised, Number of Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/ShareBasedCompensationStockOptionsActivityDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Stock issued for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r14", "r15", "r196", "r197" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Common shares issued" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r196", "r197" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Exercise of stock options and issuances of restricted stock (Value)" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r20", "r21", "r84", "r151", "r163", "r317" ], "calculation": { "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets", "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r326", "r345" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r326", "r345" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited", "http://www.intracellulartherapies.com/role/OrganizationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardAxis": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "Information by specific tax credit related to an unused tax credit.", "label": "Tax Credit Carryforward [Axis]", "terseLabel": "Tax Credit Carryforward [Axis]" } } }, "localname": "TaxCreditCarryforwardAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_TaxCreditCarryforwardNameDomain": { "auth_ref": [ "r275" ], "lang": { "en-US": { "role": { "documentation": "The name of the tax credit carryforward.", "label": "Tax Credit Carryforward, Name [Domain]", "terseLabel": "Tax Credit Carryforward, Name [Domain]" } } }, "localname": "TaxCreditCarryforwardNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r91", "r92", "r93", "r94", "r164", "r165", "r166", "r167", "r168", "r169", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r278", "r279", "r280", "r281", "r359", "r360", "r361", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407" ], "lang": { "en-US": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/RightOfUseAssetsAndLeaseLiabilitiesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r287" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CollaborationsAndLicenseAgreementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r204", "r373" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government Agency Securities [Member]" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfFairValueMeasurementsOfCashEquivalentsAndAvailableForSaleInvestmentSecuritiesDetail", "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInvestmentSecuritiesDetail" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r117", "r118", "r120", "r121", "r125", "r126", "r127" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Basic & Diluted" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted average number of common shares:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.intracellulartherapies.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited" ], "xbrltype": "stringItemType" } }, "unitCount": 8 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r188": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121548805&loc=d3e10037-110241" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12069-110248" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e12803-110250" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r202": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "705", "URI": "http://asc.fasb.org/topic&trid=2122478" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)-(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "51", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121610041&loc=d3e34017-109320" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r288": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121549951&loc=d3e39896-112707" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=121578510&loc=d3e41551-112718" }, "r329": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "840", "URI": "http://asc.fasb.org/topic&trid=2208923" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121329987&loc=SL77916155-209984" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r439": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r441": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r442": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r443": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r444": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" } }, "version": "2.1" } ZIP 61 0001193125-20-288507-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-288507-xbrl.zip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

WL=G[9^/QQNI@TZ 6KUS!O))),Z.%@//W$[A=_SB:7C;7TL[#_S_8[F308 MC^0RN6Q$(LCLJL%=-2WF>BF35J;2?C?-+ECY[*HL4W$Q%*@D:QGY7]'O[9X# M'LMHTU_(6!AV(]9LKF*.DZYFTP\WEPTMER&.&EP/)X^A=&7&R#(VZ%P/!YT[ M,NT0@M[Y3X3@69\TAJ/)?#%]/QU=+::W-_?L/S?CR9S=3T;TR-YTSQD!.NR1 MGX)G.'78?9M=QC23,6(]$S5:W;BLQF)\(0Q7(-RA54QIB58#BB^T S^]T)FS[H:#GV$3]O_AY\QU^! MD @>0+W<&.R ' MT_%:[[V728!XY9G$/C+QHMS'GG#JGG4.")$4XRE\0GP2SU&TY:M>*WUEGIR- MH/ E[>R0-_,($\"2@BOM><8"\K@)61"IM:DHU&(I#;(!)W$:+( #IK/'A*G0 M/(/[-Y#QMDT)NP?\MU]Z;_]Q84IOE]I%H:6"0.+QS#2M45/&M;"A!G=(-Q)D M)A,@S8VD"6D%38N16I1>].Q+XT7*Y%A'2:=55/@QU

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end